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ABSTRACT 
Pneumonia and ventilator associated pneumonia (VAP) are a frequent cause for admission to 
Intensive Care and complication of ventilation respectively. VAP occurs in 10-40% of patients 
requiring mechanical ventilation and is associated with increased mortality, morbidity and 
healthcare costs. Diagnosis can be difficult due to poor predictive value of clinical features and low 
specificity of radiological changes. Bronchoscopic techniques are often invasive, may not be suitable 
for all patients and are not without complications. New tests are required to improve the diagnosis 
of these conditions allowing early, appropriate antibiotic treatment. 
In this study several techniques were used to explore the value of profiling of a range of biofluids 
obtained from ventilated patients as an aid to diagnosis of pneumonia. Patients were recruited from 
Intensive Care with either a diagnosis of pneumonia or brain injury. Those with brain injuries were 
tracked to identify patients who developed VAP. Serum, urine and exhaled breath condensate (EBC) 
were collected from all patients.  
Metabonomics, an approach that identifies changes in metabolic profiles associated with disease, 
was applied using proton nuclear magnetic resonance spectroscopy to both blood and urine and 
with mass spectrometry (MS) to exhaled breath condensate. Following from the metabonomic work 
a panel of inflammatory mediators, including cytokines and eicosanoids were measured in serum 
using MS and flow cytometry to explore the inflammatory changes in these patients. 
Overall metabolic and inflammatory profiling of serum showed potential as an adjunct to clinical 
diagnosis especially when combined with clinical data. Analysis of urine and EBC proved more 
challenging due the number of drug metabolites and low concentration of metabolites they 
respectively contained. In summary this study has added to the field by demonstrating the potential 
for profiling techniques of serum from critically ill patients to assist in the diagnosis of both 
pneumonia and VAP. 
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ANOVA - Analysis of Variance  
APACHE II - Acute Physiology and Chronic Health Evaluation II  
ARDS - Acute Respiratory Distress Syndrome  
AUROC  - Area Under the Receiver Operating Characteristic Curve  
BAL - Broncheoalveolar Lavage 
BALF - Broncheoalveolar Lavage Fluid 
BI - Brain Injury  
BSA - N,O-Bis(trimethylsilyl)Acetamide 
CAP - Community Acquired Pneumonia  
CFU - Colony Forming Units 
COPD - Chronic Obstructive Pulmonary Disease 
COSY - Correlation Spectroscopy 
CPIS - Clinical Pulmonary Infection Score  
CPMG - Carr-Purcell-Meiboom-Gill  
CRP - C-Reactive Protein  
CVA - Cerebrovascular Accident  
D2O - Deuterium Oxide 
DGLA - Dihomo-γ-Linolenic Acid 
DHA - Docosahexaenoic Acid 
EBC - Exhaled Breath Condensate   
EPA - Eicosapentaenoic Acid 
FID - Free Induction Decay 
FS - Forward Scatter 
GC-MS - Gas Chromatography - Mass Spectrometry 
G-CSF - Granulocyte Colony-Stimulating Factor 
HDL - High Density Lipoprotein 
HME - Heat and Moisture Exchanger 
ICAM-1 - Intercellular Adhesion Molecule 1 
ICU - Intensive Care Unit  
IFNα - Interferon Alpha 
IFN γ - Interferon Gamma 
IL-10 - Interleukin 10 
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IL12p70 - Interleukin 12 p70 Subunit 
IL-13 - Interleukin 13 
IL-17A - Interleukin 17A 
IL-1β - Interleukin 1ß 
IL-1α - Interleukin 1α 
IL-4 - Interleukin 4 
IL-6 - Interleukin 6   
IL-8 - Interleukin 8 
IP-10 - Interferon Gamma-Induced Protein 10 
IS - Internal Standards 
LA - Linolaeic Acid 
LAP - Latency-Associated Protein 
LC-MS - Liquid Chromatography – Mass Spectrometry 
LC-MS/MS - Liquid Chromatography Tandem Mass Spectrometry 
LDL - Low Density Lipoprotein 
LTB4 - Leukotriene B4 
LTC4 - Leukotriene C4 
LTD4 - Leukotriene D4 
LTE4 - Leukotriene E4 
MAP - Mean Arterial Pressure  
MCP-1 - Monocyte Chemotactic Protein 1 
MFI - Mean Fluorescence Intensity 
MIP1α - Macrophage Inflammatory Protein 1 α 
MIP1 β - Macrophage Inflammatory Protein 1ß 
MS - Mass Spectrometry  
MV - Mechanical Ventilation 
NMR - Nuclear Magnetic Resonance Spectroscopy  
NOESY - Nuclear Overhauser Effect Spectroscopy  
OPLS-DA - Orthogonal Partial Least Squared Discriminant Analysis 
PBS - Phosphate Buffered Saline 
PCA - Principle Component Analysis  
PE - Phycoerythrin 
PGD2 - Prostaglandin D2 
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PGE2 - Prostaglandin E2 
PGF2α - Prostaglandin F2α 
PLS - Partial Least Squares 
PLS-DA - Partial Least Squared Discriminant Analysis 
ppm - Parts Per Million  
PSB - Protected Specimen Brushings 
ROC - Receiver Operating Characteristic  
SAH - Subarachnoid Haemorrhage  
SOFA - Sequential Organ Failure Assessment Score 
SPE - Solid Phase Extraction 
SS - Side Scatter 
STOCSY - Statistical Total Correlation Spectroscopy 
sTREM-1 - Soluble Triggering Receptor Expressed on Myeloid Cells 
TA - Tracheal Aspirate 
Tetranor-PGDM - Tetranor Prostaglandin D Metabolite 
Tetranor-PGEM - Tetranor Prostaglandin E Metabolite 
Tetranor-PGFM - Tetranor Prostaglandin F Metabolite 
TNFα - Tumour Necrosis Factor Alpha 
TOCSY - Total Correlation Spectroscopy 
TSP - 3-(Trimethyl-Silyl) Propionic Acid 
TXB2 - Thromboxane B2 
UPLC-MS/MS - Ultra Performance Liquid Chromatography Tandem Mass Spectrometry 
VAP - Ventilator Associated Pneumonia 
VIP - Variable Importance for the Projection 
VLDL - Very Low Density Lipoprotein 
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1. LITERATURE REVIEW 
1.1 Pneumonia  
1.1.1 Incidence  
Pneumonia is a common cause of admission to both hospital and the Intensive Care Unit (ICU). 
Pneumonia is defined as community acquired (CAP), in those patients without prior hospital contact, 
hospital acquired (HAP), in those hospitalised for at least 48-72h or aspiration pneumonia, following 
the aspiration of oro-gastric contents, for example in the context of impaired consciousness. 
Pneumonia is the commonest cause of death across all age groups from an infective cause and is the 
sixth leading cause of death in the USA and in the late 1990’s had an incidence of 1.3-3.9% 
depending on age group and geographical location (1). In 2012 pneumonia was the sixth leading 
cause of death in men, causing 4.6% of deaths, and the fourth leading cause in women, causing 5.8% 
of deaths, in the United Kingdom and in both groups was the leading cause of death associated with 
infection (2). Within the emergency department pneumonia is the leading cause of admission in 
patients presenting with sepsis (3) and every year in the UK 0.5%-1% of adults have CAP of which 22-
42% are admitted to hospital (4). 
1.1.2 Pathogenesis 
The common organisms causing CAP are dependent on the source of the patients in question, table 
1.1.  Pneumococcus is the most common organism causing CAP and its incidence increases with age 
(5). Certain organisms are more common in defined populations, for example S. Aureus may be more 
common in nursing home residents (5).  
The role of aspiration of oro-gastric contents in the development of pneumonia is controversial (6, 7) 
and may be a common cause of pneumonia in those over 80 years of age. Large aspirates of gastric 
contents lead to a chemical pneumonitis which may lead to the development of acute respiratory 
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distress syndrome (ARDS), however, many episodes of aspiration go unnoticed. The most classical 
syndrome associated with aspiration is an anaerobic pleuropneumonia, which is associated with a 
cough producing purulent secretions and a cavitating pneumonia, however, this is rarely seen and 
more commonly  aspiration pneumonia now refers to an acute lung infection developing after the 
aspiration of a large volume of oropharyngeal or upper gastrointestinal contents depositing a large 
bacterial load into the lungs (7). However, the diagnosis of aspiration in the community may be 
unclear where the events preceding the features of a respiratory tract infection are uncertain. 
Although aspiration pneumonia is classically associated with anaerobic organisms, over time the 
predominance of anaerobes seems to have diminished and aerobes and gram negative organisms 
seem to be more common. In those patients who aspirate whilst in hospital the organisms causing 
pneumonia appear similar to those causing other cases of hospital acquired infection with an 
abundance of S. Aureus (7). 
 
Table 1.1 Most Common causes of community acquired pneumonia from the 2007 American Thoracic 
Society Consensus Guidelines (5). Organisms listed in decreasing order of frequency. 
 
Patient Type Aetiology 
Outpatient Streptococcus pneumonia 
Mycoplasma pneumoniae 
Haemophilus influenzae 
Chlamydophila pneumoniae 
Respiratory viruses 
Inpatient (non-ICU) Streptococcus pneumonia 
Mycoplasma pneumoniae 
Chlamydophila pneumoniae 
Haemophilus influenzae 
Legionella species 
Aspiration 
Respiratory viruses 
Inpatient (ICU) Streptococcus pneumonia 
Staphylococcus Aureus 
Legionella species 
Gram-negative bacilli 
Haemophilus influenza 
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1.1.3 Outcome 
Admission to hospital in the UK with CAP is associated with a mean length of stay of 30 days with a 
median stay of 7 days (8). CAP is associated with a mortality of around 5-14% (4) which rises to 16.1-
19.3% in those admitted depending on the route of admission to hospital (9). 1.2-10% of patients 
admitted to hospital will be managed in ICU and in this group mortality may reach 30% (4). Similarly 
an episode of hospital acquired pneumonia increases the length of stay by about 8 days and has a 
mortality of 30-70% (4). 
Not only is pneumonia associated with a significant mortality, a recent study found that an 
admission with pneumonia was estimated to cost a median of €3,899 in the Netherlands with 
nursing care in ICU accounting for the second largest portion of spending (10). Cost to the UK from 
pneumonia in 1995/6 was estimated at £480 million with the majority of the cost being accounted 
for by inpatient care with each inpatient episode costing £1700-£5100 (8).  
1.1.4 Diagnosis 
1.1.4.1 Clinical Features 
Although often perceived as a straight forward diagnosis there is no gold standard by which to make 
the diagnosis. The clinical features of CAP have been stated to be non-specific (11) and have limited 
value in making a diagnosis. There is limited evidence in the literature to quantify their usefulness. 
The use of clinical diagnostic criteria in a paediatric population to predict radiologically confirmed 
pneumonia had a sensitivity of 0.45, specificity of 0.66 and positive and negative predictive values of 
0.25 and 0.82 respectively (12) with similar patterns being reproduced in other groups of children 
(13). In adults abnormal vital signs have a high degree of sensitivity (14) but lack specificity for 
pneumonia. With advancing age the presence of symptoms with pneumonia becomes less common  
(15) and some features, such as respiratory rate, may be sensitive but not specific (16) limiting their 
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usefulness in older patients.  Decision aids have been evaluated in adult patients that use clinical 
features to determine the likelihood of radiological findings, on chest radiographs, consistent with 
pneumonia (17). In one study clinicians’ judgement was found to have sensitivity of  0.74, a 
specificity of 0.84, a positive predictive value of 0.27 and a negative predictive value of 0.97 for 
radiological diagnosis in a primary care setting (18) and in a large study performed in general 
practice across Europe clinical diagnosis of pneumonia had a sensitivity of 0.29, a specificity of 0.99, 
positive predictive value of 0.57 and a negative predictive value of 0.96 (19). However, clinical 
features did not perform similarly in all patient groups such as the elderly and nursing home 
residents (20) and the initial Emergency Department  diagnoses of pneumonia often turned out to 
be incorrect after further investigations (21).  
1.1.4.2 Biomarkers 
Biomarkers have been used in an attempt to improve the recognition of pneumonia, the most 
studied being C-reactive protein (CRP) and procalcitonin (PCT). In studies of CRP with and without 
clinical features of pneumonia sensitivity varied between 0.36-1.0 and specificity 0.52-0.96 for 
detecting radiographic pneumonia depending on the cut off of CRP used (22-24). If an infiltrate was 
present on the radiograph then these values changed to sensitivity 0.36-0.89 and specificity 0.17-
0.91 (24). In another primary care study a CRP >20mg/l had a sensitivity of 0.73, specificity of 0.65, 
positive predictive value of 0.24 and negative predictive value of 0.94 to diagnose pneumonia in 
patients already suspected of having lower respiratory tract infections (25). Studies of PCT to 
diagnose pneumonia in primary care have shown sensitivities of 0.17-0.90, specificities of 0.59-1.0, 
positive predictive values of 0.24-1.0 and negative predictive values of 0.89-0.94 in the absence of 
radiology depending on the cut off levels used. If an infiltrate was already present on the CXR then 
these values changed to sensitivity 0.43-0.90 and specificity 0.39-0.87. In comparison blood cultures 
only had a sensitivity of 0.11 (24, 25). 
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1.1.4.3 Radiology 
Many of these studies used radiological findings as confirmation of pneumonia, however, depending 
on the frequency of bacterial infection infiltrates on chest radiograph have been found to have a 
positive predictive value of only 0.46-0.85 (26) and lack sensitivity, with around 21% of radiographs 
being negative initially (27).   
1.2 Ventilator Associated Pneumonia 
Ventilator associated pneumonia (VAP) is defined as pneumonia occurring at least 48-72h after 
endotracheal intubation (28). It is associated with inflammation of the lung parenchyma secondary 
to infectious agents not present at the time of initiation of mechanical ventilation (MV)(29). VAP is a 
common nosocomial infection and causes a significant mortality and morbidity. 
1.2.1 Pathology 
The act of invasive ventilation, either as part of anaesthesia for surgery or for respiratory support, 
circumvents many of a patient’s natural mechanisms of protecting the lungs from colonisation and 
infection. The endotracheal tube bypasses the vocal cords and the normal methods of gas 
humidification (30). Sedation leaves patients unable to cough and clear secretions and severe illness 
causes modulation in the immune system which can leave patients susceptible to infection.  
Pneumonia occurs when these barriers to infection are overcome and the normally sterile lungs 
become colonised with and inflamed secondary to pathogenic organisms. 
VAP is thought to be predominantly caused by micro-aspiration of contaminated oropharyngeal fluid 
into the lungs. Contamination of mucosal surfaces and secretions with pathogenic bacteria is 
common in critical illness and increases with severity of disease (31). Secretions may pool above the 
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endotracheal cuff and can then be transmitted into the lung. The endotracheal tube can also serve 
as a reservoir of micro-organisms with a biofilm forming within hours of intubation (32). Much less 
commonly pneumonia may be caused by haematogenous spread of micro-organisms from a site 
distant to the lungs, from contiguous spread of disease or by inhalation of an infective aerosol. 
1.2.2 Epidemiology 
MV increases the risk of pneumonia by 3-7 times (33, 34). However, the reported incidence of VAP is 
variable depending on the ICU, patient population, diagnostic method and rates of antibiotic use. 
VAP rates may vary between 6% and up to nearly 40% in different groups, table 1.2. 
Table 1.2. Reported frequencies of VAP in different ICU populations. 
Study Type of study ICU Frequency (%) Rate/1000 
Ventilator Days 
Langer, 1987 (35) Prospective Mixed 38.2 - 
Fagon, 1989 (36) Prospective Mixed 9 - 
Torres, 1990 (37) Prospective Mixed 24 - 
Baker, 1996 (38) Prospective Trauma 5.8  
Long, 1996 (39) Retrospective Medical - 11.5 
Long, 1996 (39) Retrospective Neurological - 19.4 
Sirvent, 1997 (40) Prospective Neurological 37  
Cook, 1998 (41) Prospective Mixed 17.5 14.8 
Leal-Noval, 2000 (42) Prospective Cardiothoracic 6.5 - 
Rello, 2002 (43) Retrospective Mixed 9.3 - 
Bouza, 2003 (44) Prospective Cardiothoracic 7.9 34.5 
Rosenthal, 2003 (45) Prospective Mixed - 51 
Lizan-Garcia, 2006 (46) Prospective Surgical 17.7 21 
Joseph, 2009 (47) Prospective Mixed 18 22.9 
 
Incidence of VAP may also be influenced by concomitant disease, with VAP rates increasing in 
patients suffering from ARDS to 37 -60% (48-50).  
1.2.3 Risk Factors 
Although duration of mechanical ventilation is one of the most significant risk factors for 
development of VAP (37, 44, 51) evidence suggests that after ten days of ventilation the incidence of 
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VAP decreases (33). Numerous other factors, table 1.3 have also been implicated as risk factors for 
VAP as outlined below.  
Table 1.3. Risk Factors for VAP (29, 37, 41, 42, 44, 52-56) 
Patient Factors Intervention Factors 
Impaired airway reflexes Sedative agents 
High APACHE II score Cardiopulmonary resuscitation 
Large volume gastric aspiration Enteral nutrition 
Chronic Obstructive Pulmonary Disease Nasogatric tube 
Postoperative cardiac failure Transfusion of blood products 
Central nervous system dysfunction Aerosolized therapy 
Trauma Surgery 
Burns Re-intubation 
 Stress ulcer prophylaxis 
Supine positioning 
Patient transfer 
Neuromuscular blocking agents 
 
1.2.3.1 Surgery 
Patients who have undergone surgery appear to be at higher risk for pneumonia than equivalent 
medical patients (51). Within surgery some patients may be more at risk than others. Cardiothoracic 
(57) and both burns and trauma (41, 53) patients have been independently found to have higher 
rates of VAP.  
1.2.3.2 Stress Ulcer Prophylaxis and Positioning 
Alkalising gastric fluid has been shown to lead to gastric contamination with potentially pathogenic 
micro-organisms (58). A meta-analysis looking at H2 antagonists found an increase in VAP (59) and a 
randomised controlled trial comparing feeding in the supine versus semi-recumbent position 
confirmed a significantly increased rate of VAP in those fed in the supine position (60). 
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1.2.3.3 Intubation 
The presence of the endotracheal tube may act as a reservoir for pathogenic organisms and 
circumvent natural defence mechanisms. The need for re-intubation has been found to be an 
independent risk factor for VAP in a number of studies (37, 42, 61). Similarly transfer of patients out 
of the ICU, for example to the radiology department or to the operating theatre,  has been 
associated with increased VAP rates (54), however, this may be a surrogate for patients who are 
sicker and require more intervention. 
The role of tracheostomy in preventing VAP is unclear. Although both a randomised trial (62) and 
subsequent meta-analysis (63) found trends towards reduction in the rate of VAP neither proved 
statistically significant. 
1.2.3.4 Antibiotics 
The role of antibiotics in preventing VAP is unclear. A number of studies have found that prior 
administration of antibiotics to be an independent risk factor (42, 55) but in others antimicrobial 
agents have been found to have a protective effect (40, 52). In one study the previous use of 
antimicrobials proved to be a risk factor for mortality (64). 
1.2.4 Aetiological Agents 
The European Prevalence of Infection in Intensive Care Study found that on a single day nearly a 
third of ICU-acquired pneumonia was caused by Staphylococcus Aureus, closely followed by 
Pseudomonal species (65). Other organisms such as E.Coli, Acinetobacter, Enterococci and yeasts 
were much less common. Haemophilus Influenza has been found to cause VAP at around 10 days 
post onset of MV, commonly in those who have not received prior antimicrobial agents but is 
associated with a lower mortality than other causes (66). 
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Infection with resistant organisms is a significant problem. Vanhems et al found that risk factors for 
pneumonia  caused by resistant organisms were a medical diagnosis, transfer from another ward, 
the presence of a colonised central venous line and longer length of hospital stay (67). Patients with 
VAP caused by Methicillin Resistant Staphylococcus Aureus (MRSA) are likely to have been ventilated 
for longer, have received prior antibiotics and corticosteroids and are more likely to suffer from 
chronic obstructive pulmonary disease (COPD) than those with the sensitive strain (68). MRSA is also 
more likely to be associated with bacteraemia, septic shock and has a higher mortality than that 
caused by sensitive staphylococci (68). Patients with head trauma, neurosurgery, ARDS and large 
volume pulmonary aspirate are predisposed to infection with Acinetobacter species (69).  
1.2.5 Mortality, Morbidity and Health Care Costs 
Estimates of mortality associated with VAP have ranged from 34-70% (42, 44, 45, 56). However, due 
to differences in diagnostic criteria, heterogeneity of patient populations and associated pathology it 
has been difficult to determine to what extent VAP is the cause of death. Pneumonia is associated 
with significant increases in hospital and ICU stay. Hospital stay can be increased by 10-20 days for 
patients with VAP (51). 
Nosocomial pneumonia is recognised as one of the most costly hospital acquired infections (70, 71). 
Development of VAP significantly increases the cost of medical care by 1.5 (38) to 3 times (56) 
compared to patients who do not develop this complication.  
1.2.6 Diagnosis 
1.2.6.1 Clinical Features  
Fagon and co-workers found that using clinical features, such as temperature, oxygenation, 
radiology, laboratory results and change in endotracheal secretions, clinicians only correctly 
diagnosed VAP 62% of the time (72). Leukocytosis, fever and quality of respiratory secretions have 
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all performed poorly when compared to histological specimens with sensitivities ranging from 46-
77% and specificities of 42-58% (73). 
 A study examining post mortem specimens of lung tissue of patients with ARDS found a 29% 
misdiagnosis rate for pneumonia based on clinical parameters. Although fever, leucocytosis and 
growth of pathogens from sputum were more common in patients with pneumonia they were still 
present in 70-80% of those without. Response to antimicrobial therapy was misleading with more 
patients without pneumonia appearing to respond (74). 
1.2.6.2 Radiology 
Presence of infiltrates on the chest radiograph have a sensitivity of 92% but a specificity of only 33% 
(73) when compared to biopsy confirmed VAP. However, the presence of radiological infiltrates plus 
two of: leucocytosis, fever or purulent secretions had a sensitivity of 69% and a specificity of 75% 
(73). Comparison of specific radiographic findings with post mortem confirmation of VAP found that 
the presence of an air bronchogram had the best overall performance with a sensitivity of 83% and 
specificity of 58% (75) but alveolar infiltrates were the most sensitive finding (88%) and fissure 
abutment was the most specific (96%). However, no radiological finding had a positive predictive 
value of more than 68% for VAP. 
1.2.6.3 Microbiology  
A microbiological diagnosis of pneumonia is important in confirming clinical suspicion and in guiding 
antibiotic therapy. Specimens can be collected using a variety of techniques from tracheal aspirate 
(TA), bronchoalveolar lavage (BAL), protected specimen brushings (PSB) and mini-bronchoscopy. 
These methods have been found to have differing efficacies in the diagnosis of VAP. 
A comparison of various microbiological sampling techniques against pathological specimens gave 
TA, protected bronchoalveolar lavage, BAL and PSB  sensitivities of 69, 39, 77 and 62% respectively 
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and specificities of 92, 100, 58, 75% (73).  Using post mortem histology as a gold standard Marquette 
et al found that TA, PSB and BAL had sensitivities of 56, 58 and 47% and associated specificities of 
86, 89 and 100%. Use of staining to detect intracellular organisms from BAL samples was also 
associated with 100% specificity but a poor sensitivity of only 37% (76). 
TA is often felt to have poor specificity for the diagnosis of VAP due to a tendency to detect airway 
colonisation. However, in a study comparing PSB, BAL and TA, quantitative culture of TA with a cut 
off between 105 and 106 Colony Forming Units (CFU)/ml had a sensitivity and specificity of around 
70% (77, 78). However, BAL and PSB had greater specificities of 87 and 93%. TA was also found to 
have a better negative predictive value than PSB (72 vs 34%, p<0.05) (78). 
A randomised pilot study comparing BAL combined with PSB to TA to guide antibiotic decision 
making found no statistical difference in mortality or morbidity between the two methods. However, 
there was a trend towards higher mortality in the group undergoing invasive sampling (79). In 
another, non-randomised, trial invasive pulmonary investigation with BAL appeared to reduce 
mortality compared to a control group and the results of this investigation were found to 
significantly influence physician decision making (80). A meta-analysis of four randomised controlled 
trials found no overall difference in mortality between invasive and non-invasive diagnostic 
approaches but that invasive investigation consistently led to more frequent changes in antibiotic 
prescribing (81). 
All sampling techniques pose technical challenges. If samples are not collected and handled correctly 
the diagnostic yield may be reduced. It is therefore important that for microbiological investigations 
to remain valid, stringent sampling methods must be adhered to (82). 
1.2.6.4 Scoring Systems 
Pugin et al developed a Clinical Pulmonary Infection Score (CPIS) for the diagnosis of VAP based on 
six clinical parameters, table 1.4, which gave a score from 0-12 (83). They found that a score of 
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greater than six correlated with a bacterial index of greater than five on both guided and blind BAL. 
A randomized study Singh et al used the CPIS score to guide antibiotic prescribing. They found a 
significant reduction in antibiotic prescribing without increase in mortality or length of ICU stay (84). 
Table 1.4. Clinical Pulmonary Infection Score (83) 
Clinical Feature Score 
Temperature (oC) 
36.5-38.4 
38.5-38.9 
≥39 ≤36 
 
0 
1 
2 
White Cell Count (mm-3) 
4,000-11,000 
>11,000,  <4,000 
Band forms >500 
 
0 
1 
+1 
Radiology 
No infiltrate 
Diffuse (Patchy) Infiltrate 
Localised Infiltrate 
 
0 
1 
2 
Oxygenation (mmHg) 
PaO2/FiO2 > 240 or ARDS 
PaO2/FiO2 ≤240 
 
0 
2 
Secretions 
<14 of total secretions in 24h 
≥14 of total secretions 
Plus purulent secretions 
 
0 
1 
+1 
Microbiology 
Pathogenic bacteria cultured ≤ 1+ or no growth 
Pathogenic bacteria cultured ≥ 1+ 
Gram stain ≥ +1 with same pathogenic organism 
 
0 
1 
+1 
 
The use of the CPIS score as a diagnostic tool has been debated. Fartoukh et al found that a modified 
CPIS score at baseline was only slightly better at predicting VAP than a strong clinical suspicion but 
that it could be improved with the addition of the gram stain result from either protected telescopic 
catheter or BAL sampling (85). The CPIS score was originally developed in medical ICU patients and 
concern has been raised that it may not be applicable in other patient groups. In some instances, for 
example in burn and trauma patients, the area under the receiver operating curve for the CPIS score 
has been less than 0.5 (86).  
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1.2.6.5 Biomarkers 
Various biomarkers have been suggested to aid in the diagnosis of VAP including total bile acids, 
soluble triggering receptor expressed on myeloid cells (sTREM-1), C-reactive protein (CRP), 
procalcitonin (PCT), elastin fibres and endotoxin in BAL fluid. Of these, sTREM-1, CRP and PCT are 
probably best studied. sTREM-1 is a glycoprotein expressed on phagocytic cells which is up-regulated 
in bacterial infection. An initial study found sTREM-1 measured in BAL samples had a sensitivity of 
96% and a specificity of 90% for pneumonia. However, in subsequent studies it has performed less 
well than a CPIS<6 (87) and has been non-discriminative for VAP (88), possibly being influenced by 
prior antibiotic use.  It has proved possible to measure sTREM-1 in exhaled breath condensate, 
although at lower concentrations than in BAL fluid, presenting a non-invasive means of 
measurement (89). However, in this study BAL levels still performed poorly as a diagnostic tool. 
CRP, a protein manufactured in the liver that is elevated with inflammation, and PCT, a pro-hormone 
secreted into the serum from the C-cells of the thyroid in health and from other neuroendocrine 
tissues during inflammation, have both been measured in serum and BAL fluid as an aid to VAP 
diagnosis (90). In one study serum PCT performed better than CRP in separating VAP from non-VAP 
with a sensitivity of 100% (91). However, both CRP (92)and PCT are elevated in infection from any 
cause in the ICU limiting their specificity. 
 A randomised controlled trial using PCT to guide antibiotic therapy in lower respiratory tract 
infections found a reduction in antibiotic prescribing without an increase in adverse events (93) 
indicating a role in treatment decisions. However, as a diagnostic tool for VAP PCT is limited as it 
becomes elevated in a range of bacterial infections as well as non-bacterial inflammatory conditions 
(94).  
It is therefore apparent that pneumonia is a major healthcare problem and that better diagnostic 
methods are required to better manage patients. 
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1.3 Metabonomics 
Metabonomics is “the quantitative measurement over time of the metabolic responses of an 
individual or population to drug treatment or other intervention” such as a disease process (95). 
Spectroscopic techniques including nuclear magnetic resonance (NMR) spectroscopy and mass 
spectrometry (MS) have been used to determine the global metabolic profiles of numerous types of 
biological samples. Blood and urine are the most commonly analysed but any biological specimens 
such as tissue, cerebrospinal fluid or exhaled breath condensate (EBC) can be used (96-99). These 
methods have been used to evaluate numerous clinically significant conditions including trauma 
patients (100, 101), detection of acute kidney injury and monitoring of dialysis (102-104), diagnosis 
of subarachnoid haemorrhage (105), and acute lung injury (106).  
Metabonomic analysis is carried out using two broad analytical platforms, nuclear magnetic 
resonance spectroscopy and mass spectrometery. These two techniques each have their own 
strengths and weaknesses and together give complementary information. Data can be acquired that 
either provides global information collecting as much non-targeted metabolic information as 
possible, which is useful for initial biomarker discovery when there are no pre-conceived ideas 
regarding candidate markers, or can be targeted to obtain detailed information on a specific class of 
metabolites or metabolic processes. 
1.3.1  1H Nuclear Magnetic Resonance Spectroscopy 
NMR spectroscopy uses the magnetic properties of certain nuclei that possess spin, for example 1H 
and 13C. NMR spectrometers use superconductors to generate strong magnetic field, figure 1.1. A 
spinning charge placed in such a magnetic field produces two spin states – one up, aligned with the 
magnetic field, and one down, aligned against the magnetic field (107). The energy difference 
between the two spin states is proportional to the magnetic moment of the nuclei which is 
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In order to improve fragment separation mass spectrometry is often coupled to chromatographic 
techniques. Such techniques include gas chromatography-mass spectrometry (GC-MS), where a gas 
chromatogram is used to separate molecules in gaseous phase before they are fed into the ion 
source allowing ionisation and further separation. Liquid chromatography-mass spectrometry (LC-
MS) and high performance liquid chromatography-mass spectrometry (HPLC-MS) similarly separates 
molecules in a sample in a liquid mobile phase using a liquid chromatogram using a combination of 
organic solvents prior to ionisation.  
MS based platforms generally have the advantage of greater sensitivity compared to NMR, however, 
some substances such as sugars and amino acids are difficult to analyse with this method due to 
their polarity and lack of volatility (111). MS requires reasonably extensive sample preparation and, 
with long chromatographic times, can take longer to process than NMR. Also because of the need to 
vaporise and ionise the sample MS is a more destructive analytical technique than NMR. 
1.3.3 Data Analysis 
Analytical techniques used in metabonomics generate data sets that are unlike those produced in 
many other scientific areas. Whereas there would often be many more subjects than variables, 
metabonomics generally produces thousands of variables, several of which may correlate, and many 
may not be normally distributed. These features pose problems for regular statistical methods so 
analysis is generally performed using multivariate statistics. Many techniques exist within 
multivariate statistics but broadly speaking those used in chemometrics can be split into 
unsupervised tests, where no class information is given to the model. These are good at finding 
natural clustering within the data sets and at identifying outliers. Supervised tests, on the other 
hand, look for variation between predefined groups or classes and are able to build predictive 
models. 
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1.3.3.1 Principal Component Analysis 
Principal Component Analysis (PCA) is the predominant method of unsupervised multivariate 
analysis used in metabonomics. It is generally concerned with elucidating the covariance structure of 
the data set by representing the data along new axes based on the direction of the maximum 
variation, so called principal components. Mathematically this is done by splitting the data into a set 
of eigenvectors, essentially directions of variation, and for each eigenvector an associated 
eigenvalue describes the magnitude of this variation. The first principal component is the 
eigenvector associated with the greatest eigenvalue and the second principal component will be that 
with the second largest value that is orthogonal to the first, figure 1.7. This method of analysis allows 
data reduction. Although an eigenvector exists for each variable in a data set some of these will 
contain very little variation and eigenvectors with low eigenvalues, which contain little information, 
are discarded. The data can then be re-displayed using the principal components as a new set of 
axes, giving a PCA scores plot, figure 1.7. 
An approximation to the Student’s t-test called the Hotelling’s ellipse can be projected onto the PCA 
scores plot. This gives an indication of a 95% confidence interval within which 95% of observations 
should fall. Data points lying outside of this ellipse can be considered as strong outliers and can be 
examined in more detail. 
1.3.3.2 Supervised Analysis 
Supervised multivariate analysis is aimed at finding the variation in the data matrix that explains a 
predefined classification.  One of the underlying methods of supervised analysis is partial least 
squares analysis (PLS). PLS determines the underlying relationship between two data matrices, X 
which contains the sample data and a second data matrix Y, containing dependent information, 
using a latent variable approach finding the fewest variables that account for the differences in the Y  
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matrix. Overall the goal is to predict Y from X. Where the Y data matrix contains classification data 
the process is called Partial Least Squared Discriminant Analysis (PLS-DA). Extensions of PLS and PLS- 
DA occur with both orthogonal partial least squared (OPLS) and orthogonal partial least squared 
discriminant analysis (OPLS-DA). These two techniques work in a similar fashion to their PLS 
counterparts. However, in these methods the variation in the X matrix is divided into that which 
explains data in the Y matrix and that which is orthogonal to it and does not explain the Y data. The 
data can be represented as one component that explains the between group variation and one 
orthogonal to it that explains within group variation.  Although these extensions do not improve the 
predictively of the models they aid analysis by improving both visualisation and diagnostics of the 
models. 
In order to assess the predictive capacity of a model cross validation can be carried out. A number of 
methods exist to do this but a commonly utilized approach is to leave out every nth row in the data 
matrix and build a model based on the remaining data. The remaining data can then be predicted by 
the model and the results compared to the expected outcome. This process can then be repeated 
until all of the data has been left out once. After cross validation it is possible to derive two 
descriptive metrics for the models. The first is known as the R2Y which explains the amount of 
variation between the classification groups that is explained by the model. This value ranges from 0 
to 1.0 with values approaching 1.0 explaining almost all of the variation in the model and lower 
values suggesting that much of the variation in the data is irrelevant or noise. The second value is 
the Q2Y which describes the fraction of variation in the dependent variable, Y matrix, by the model. 
Again this can range from 0 to 1.0 and the higher the value the more predictive the model. The 
expected values of both R2Y and Q2Y are dependent on the type of data being analysed but in 
general should ideally be no more than 0.2 apart (112). For biological models a Q2Y of 0.4 would 
equate to a reasonable model. However, the ideal way to test a model is to challenge it with a 
complete new set of data from a validation cohort of samples that have not been used to generate 
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the model in the first instance. From this set of data model statistics such as sensitivity, specificity 
and predictive values can be obtained. 
In order to determine the variables that are important in separating two groups based on 
multivariate analysis the loading of each variable can be examined. The loading describes the 
correlation that a component has with the original variable, variables that are strongly correlated 
with the component have a loading close to 1.0 where as those that have an opposite effect have 
values closer to -1.0. Variables with loadings close to zero have no influence on the model. 
1.3.3.3 Pre-processing 
Prior to multivariate analysis data sets need to undergo several pre-processing steps. Mean centring 
is performed to ensure that the first component genuinely represents the direction of maximum 
variation as opposed to the mean vector. This is done by subtracting the mean from each variable 
and gives each variable a mean of zero. Multivariate analysis is very sensitive to scale. Variables that 
have a large magnitude tend to be associated with a large variance and would have a greater effect 
on the models than variables that are smaller with lower variance. Similarly if variables are 
measured in different units, for example heart rate in beats per minute and partial pressure of 
oxygen (PaO2) in kPa, then the models would look very different to the same data analysed using a 
different measurement scale, for example where the PaO2 is measured in mmHg. To alleviate these 
problems the data is often scaled so that each variable has the same unit variance.  
1.4 Metabonomics of Sepsis and Pneumonia 
A range of work has been carried out attempting to utilize metabonomic techniques to explore both 
sepsis and specific infections using cells, animals and human subjects with both NMR and MS, 
allowing over 500 metabolites and pathways to be implicated in infection. Work has been done 
using cell lines and culture media (113-119) allowing bacterial (114, 116, 117, 120) and Candida 
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species (119) to be identified with NMR. Specifically investigating cell lines infected with Chlamydia 
Pneumonia using several MS platforms found changes in amino acid and cholesterol synthesis (113) 
to be important in detecting the organism. 
Several animal models have been used in an attempt to further understand the metabonomics of 
infection. Mice (115, 121-126), rats (127-132), horses (133) and primates (134) have all been used as 
models of various infections allowing biofluids including blood (121, 130), broncheoalveolar fluid 
(BALF) (128) and lymph (132) to be analysed as well as tissue including lung (124, 128), liver (124, 
125), kidney (126) and spleen (124, 126). Infections as diffuse as cerebral malaria (126), peritonitis 
(128, 131) (127, 129), E.coli sepsis (134) and Gram positive and Gram negative infection (121) have 
been investigated. Metabolites including amino acids, those involved in energy and carbohydrate 
metabolism, fatty acids and those associated with mitochondrial dysfunction have all been identified 
in these animal models of infection. 
A range of infections have also been explored in human subjects. The majority of work in humans 
involves clinical samples from subjects with a number of infections, however, humans have also 
been used to explore metabolic changes over time of a lipopolysaccharide induced sepsis model 
(135) which found alterations in fatty acid, amino acid and protein metabolism over a 24 hour 
period. A great deal of work has been done to look at urinary tract infection using NMR of urine 
samples (136-140) for a range of organisms including E.coli (137, 139) and Gram positive and 
negative infections (138) with an attempt to identify specific causative bacteria (139).  
Several other specific infections have been studied including leprosy (141), cerebrospinal fluid 
analysis to distinguish various forms of meningitis and ventriculitis (142) and generic sepsis in both 
adults (143-146) and children (147, 148). 
 
51 
 
 
 
1.4.1 Pneumonia 
A small amount of work has been carried out investigating pneumonia using metabonomics. Animal 
studies have found elevated lipoproteins, triglycerides, unsaturated and polyunsaturated fatty acids, 
ω-3 fatty acids, lactate and 3-hydroxybutyrate and reduced glucose levels in the plasma of rats 
infected with Klebsiella Pneumoniae compared to controls (149). Mice with pneumonia caused by 
Staphylococcus Aureus or Streptococcus Pneumoniae can be separated from control animals based 
on urine metabolic profiling (150). Viral pneumonia caused by Influenza A has been studied using MS 
finding several metabolites that were altered in infected animals, including the amino acids, valine, 
ornithine, and taurine and the eicosanoids PGF2a and 20-ethyl-PGE2 (123). A specific form of 
pneumonia, tuberculosis, has been examined using a murine model taking serum and tissue samples 
to successfully categorise infected and non-infected animals (124).  
Work in humans has focused on community acquired pneumonia and tuberculosis. Studies in 
tuberculosis have found a combination of both classification metabolites and those associated with 
treatment (151, 152). A few studies exist examining more typical forms of pneumonia.  A study using 
MS of plasma from children with pneumonia from Gambia found elevated uric acid, hypoxanthine, 
glutamic acid and L-tryptophan but reduced adenosine diphosphate levels. In this study, clustering 
based on sex was noted in the pneumonia group that was not seen in the controls suggesting 
potential differences in inflammatory responses between boys and girls (153). A study looking 
specifically at patients with Streptococcus Pneumoniae pneumonia found numerous urinary 
metabolites to separate cases from controls including citrate, succinate, 1-methylnicotinamide, 
several amino acids, glucose, lactate, acetone, carnitine, acetylcarnitine, hypoxanthine and acetate 
(154). This study also aimed to address several potential confounding factors associated with this 
type of investigation by comparing cases to several control groups such as those with other types of 
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lung disease, those with other types of pneumonia and those with other acute illnesses. In most 
cases multivariate statistical models provided reasonable prediction accuracy.  
1.4.2 Critical Care 
Work within critical care has focussed on the outcomes of patients with community acquired 
pneumonia (CAP) and sepsis (155). MS analysis of plasma found higher levels of bile acids, steroid 
hormone metabolites, markers of oxidative stress and nucleic acid metabolites in non-survivors, 
however, the statistical models based on these differences had only modest sensitivity with an area 
under the receiver operating curve (AUROC) of 0.67.  
A common differential for VAP is acute lung injury (ALI) or ARDS and differentiation can be difficult. 
A metabonomic study of sepsis induced ALI and ARDS (106), in 13 patients with ALI or ARDS 
compared to 6 healthy controls, found differences in plasma levels of glutathione, adenosine, 
phosphatidylserine and sphingomyelin between case and controls and in another study using LC-MS 
of BALF several lipid metabolites increased and a component of surfactant decreased in BALF of 
those with ARDS (156). Other work in ICU patients has looked at predisposition to sepsis following 
trauma using NMR of plasma samples from 21 patients and identified valine, citrate, aspartate, 
allantoin and hydroxybutyrate as associated with the future development of sepsis (157).  Looking at 
septic shock in adults on ICU glycerophospholipids and acetylcarnitines were elevated in 33 patients 
with sepsis when compared to 30 other patients with SIRS (146). Further exploration of sepsis on ICU 
used NMR techniques to predict mortality (145) in 37 intensive care patients compared to 20 
controls and looked at sepsis in 137 children from different age groups admitted to critical care 
(148). In an attempt to explore ICU mortality (158) in adult ICU patients plasma samples were 
analysed with MS finding 31 metabolites associated with mortality most of which were elevated in 
those who died. These covered a range of metabolites including lipids, carbohydrates and amino 
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acids. Only six metabolites were greater in those who survived and these were all involved in the 
lipid synthesis pathway.  
To date no work has been published using metabonomic methods to specifically focus on VAP or 
looking at methods for differentiating patients with pneumonia from similar critically unwell patients 
without pneumonia. Current work has often used healthy volunteers as controls for pneumonia 
cases. This approach has several disadvantages as healthy volunteers may be expected to be 
metabolically quite different from pneumonia patients compared to similar severely ill patients. 
1.5 Oxylipins and Cytokines 
Oxylipins are a family of molecules formed from the oxidation of fatty acids and the most well 
known of these are the eicosanoids, signalling molecules formed from the oxidation of 20-carbon 
fatty acids. Eicosanoids play an important role in mediating both inflammation and immunity and are 
predominantly derived from three fatty acids, arachidonic acid (AA), eicosapentanoic acid (EPA) and 
linoleic acid (LA). The derived eicosanoids can be subclassified, for example, prostaglandin analogs, 
thromboxanes, lipoxins and leukotrienes, figure 1.8. The effects of these mediators are varied and 
depend on the organ involved and the balance of mediators released but can have effects including 
vasodilation and vasoconstriction, bronchodilation and bronchoconstriction and release of other 
inflammatory mediators. 
Cytokines are another broad range of small signalling proteins produced by a variety of cell types. 
They encompass interleukins (IL), interferons, tumour necrosis factor alpha (TNFα), colony 
stimulating factors and chemokines and are related to several of the adhesion molecules such as 
intracellular adhesion molecule 1 (ICAM-1). These mediators are generally produced from 
inflammatory cell lines including lymphocytes, monocytes, mast cells and natural killer cells and are  
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implicated in a range of pathology from infection and inflammation to malignancy. The interactions 
of cytokines and eicosanoids are complex and are interdependent and can have similar actions. 
Eicosanoids such as the leukotrienes, especially leukotriene B4 (LTB4), are thought to be important 
in protecting the lungs from infection with actions including chemoattraction and leukocyte 
activation. LTB4 may increase IL-6 levels (159) and has been associated with pulmonary 
complications following trauma (160).  Streptococcus Pneumonia has been shown to be capable of 
inducing COX-2 expression, an enzyme crucial to eicosanoid production, within lung tissue in models 
of lung infection (161). Eicosanoids not only act as pro-inflammatory mediators but, substances such 
as the lipoxins, have been implicated in the resolution of pulmonary inflammation. Lipoxin A4 can be 
generated in response to lung injury and has been found in the BALF of patients with pneumonia 
(162) and may inhibit LTB4 mediated chemoattraction. 
Cytokines are also known to play an important role in the pathology of pneumonia with circulating 
levels of pro-inflammatory cytokines, such as TNFα, interleukin-1 (IL-1), interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-12 (IL-12), and interferon gamma (IFNγ) having been found to be 
elevated in patients with pneumonia. A study looking at pneumonia (163) found higher levels of IL-6 
and interleukin-10 (IL-10) in non-survivors compared to survivors and higher IL-6, IL-10 and TNFα 
levels in those pneumonia patients with severe sepsis compared to those without. The inflammatory 
response to CAP may not be the same throughout life and may alter with age, for example, IL-8 has 
shown a trend to be elevated at admission in older patients with CAP compared to those younger 
than 50yrs (164). In children IL-6, IL-8 and IL-10 levels were found to be higher, not only in septic 
patients compared to controls, but also in those septic patients who went on to develop nosocomial 
infections (165). Specific micro-organisms have also shown similar patterns of cytokine response 
(166) with Interleukin 4 (IL-4), IL-6 and IL-10 being higher in mycoplasma pneumonia than in 
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controls. Many of these mediators are produced locally, for example, IL-8, LTB4, C4, D4, and E4 have 
been found at higher concentrations in the BALF of pneumonia patients compared to controls (167).  
The diagnostic potential of cytokines or eicosanoids in pneumonia has been examined in a few 
studies and a smaller body of work exists applying a panel approach to measuring an array of 
inflammatory mediators. For example, one study aimed to diagnose tuberculosis using a multiplex 
cytokine assay measuring cytokines produced from stimulated peripheral blood mononuclear cells 
with  IFNγ, interferon gamma inducible protein-10 (IP-10), monokine induced by interferon gamma 
(MIG), TNFα and IL-2 showing the most significant differences between patients with active 
pulmonary tuberculosis and healthy controls (168). In another study ARDS cases were separated into 
different phenotypic groups based on IL-6 and IL-8 levels combined with other biological and clinical 
data (169). No work exists combining a large profile of cytokines and eicosanoids into one model in 
an attempt to diagnose either pneumonia in patients admitted to critical care or VAP in those 
already ventilated on the ICU. 
1.6 Breath Analysis 
Formalised breath analysis is used widely in law enforcement and in some diagnostic clinical tests 
such as for Helicobacter pylori. Volatile organic compounds (VOCs) in breath give signatures that are 
familiar to us as odours associated with several diseases from the ketones associated with diabetic 
complications to the recognizable hepatic fetor.  
Online metabolic profiling of exhaled breath using selected ion flow tube mass spectrometry (SIFT-
MS) and gas chromatography mass spectrometry (GC-MS) (170-172) can be performed. Metabolites 
such as acetone, ammonia and methane have been quantified (173, 174) in healthy volunteers and 
the repeatability of the SIFT-MS technique has been demonstrated (175). Exhaled nitric oxide (NO) 
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has shown potential for detecting airway inflammation in asthma, COPD (176) and pneumonia (177) 
and carbon monoxide levels in breath have been found to increase in patients with sepsis (178).  
Headspace gas analysis from a range of cultures has shown potential to detect of a range of micro-
organisms (179-181) including cultures of BALF from patients with pneumonia (182). For example, 
Pseudomonas has been identified from cultures taken from patients with cystic fibrosis (183, 184) 
and breath from these patients has been analysed in an attempt to determine Pseudomonas 
colonisation status (185-187). Analysis of exhaled breath may therefore allow detection of specific 
causative organisms in pneumonia by differentiating metabolic profiles. Although some of the above 
work shows promise for breath analysis to be used to explore pneumonia no studies exist examining 
metabolic profiling of exhaled gaseous breath with regard to this disease. Specifically no work has 
been done regarding VAP.  
It is possible to condense and collect the water vapour contained in breath, known as exhaled breath 
condensate (EBC). EBC is 99% evaporated water but also contains droplets of fluid from the airway 
linings allowing non-volatile compounds to be measured. EBC contains a number of substances 
including interleukins (188), leukotrienes (189) and sTREM (89). Hydrogen peroxide is one of the 
most studied substances from EBC and is elevated in many inflammatory condition including ARDS 
(190), asthma (191) and may correlate with treatment response in patients with cystic fibrosis (192). 
Isoprostanes have been noted to be increased  in COPD (193), asthma (194) and ARDS (195) and EBC 
pH appears to decrease with lung inflammation in conditions such as bronchiectasis, COPD and lung 
injury (196, 197). In the field of pneumonia thiobarbituric acid and hydrogen peroxide have been 
seen to increase in CAP (198, 199). 
1.6.1 Metabonomics of Breath Condensate – 1H-NMR Spectroscopy 
Small scale studies with EBC have used NMR analysis to distinguish stable from unstable patients 
with cystic fibrosis (200), asthmatics from healthy controls (201-203), to investigate smoking related 
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diseases (204) and examine the potential of salivary and disinfectant contamination, from reusable 
collection equipment, of EBC (205). Studies have made attempts at metabolite assignment (99, 200, 
204, 205) identifying 26 compounds between them. As yet there is no experience of collecting EBC 
from ventilated patients for the purpose of metabolite analysis. As with the gaseous phase of breath 
the optimal methods for sample collection, processing and analysis are not known.  
1.6.2 Metabonomics of Breath Condensate –Mass Spectrometry 
With its greater sensitivity MS potentially has advantages over NMR spectroscopy for the analysis of 
EBC given the very low concentrations of metabolites within the fluid. Most work has focussed on 
specific markers or panels of markers with little work ustilising MS as a profiling tool (206, 207). 
Many specific substances within EBC have been explored including  glucose (208), urea (209, 210), 
volatile organic compounds (211, 212), aldehydes (213-216),  isoprostanes (195, 217-226), markers 
of oxidative stress (218), cystinyl leukotrienes (218, 227, 228), leukotrienes (189, 227, 229-233), 
eicosanoids (234-239), 12-HETE (240), lysophosphatidic acid (241), asymmetric dimethylarginine 
(ADMA) (242, 243), adenosine (209), phenylalanine (209), lysine (244), tyrosine (245), 
hydroxyproline (245), proline (245),  purines (246-249), metallic elements (250), 3-nitrotyrosine 
(245, 251-254), and proteins (255) using a number of MS methods including LC-MS (206-208, 218), 
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) (217, 241, 255), GC-MS (211) and 
Ultra Performance Liquid Chromatography Tandem Mass Spectrometry (UPLC-MS/MS) (227, 243). 
The majority of work using MS has, again, focussed on relatively stable diseases in community 
patients including healthy subjects (215, 238, 256), asthma (189, 206, 218, 227, 232, 234-236, 239, 
242, 248), COPD (216, 247, 250, 255), pulmonary fibrosis (223, 224, 241), cystic fibrosis (208, 209), 
pulmonary hypertension (211), brochopulmonary dysplasia (207), pneumoconiosis (229), silicosis 
(221), asbestosis (226), Churg Strauss (240) and seasonal rhinitis(233). ARDS (195) has been studied 
in critically unwell patients. Almost all studies have been performed in spontaneously ventilating 
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patients with only two in those requiring mechanical ventilation (195, 210) one of which (210) did 
not investigate particular disease state and only looked at urea measurement. No studies have been 
carried out profiling EBC in patients with pneumonia either with or without the need for mechanical 
ventilation.  EBC analysis is appealing for the diagnosis of pneumonia in ventilated patients as it is a 
non-invasive, easily obtained biofluid that directly samples from the site of pathology. 
1.7 Hypothesis and Aims 
1.7.1 Hypothesis 
The application of metabolic and inflammatory profiling to biofluids including serum, urine and 
breath condensate obtained from patients ventilated on the Intensive Care Unit will aid the 
diagnosis of pneumonia and ventilator associated pneumonia. 
1.7.2 Aims 
The following aims will be addressed: 
x Can metabolic profiles of serum and urine be used to aid diagnosis of patients with 
pneumonia and VAP? 
x To investigate the potential of using 1H-NMR and MS as methods for analysing EBC collected 
from ventilated patients. 
x Can metabolic profiling of EBC aid in the diagnosis of pneumonia and VAP? 
x Can comparing metabolic profiles of breath condensate, serum and urine give an insight into 
local and global metabolic changes? 
x Can a panel approach to the measurement of eicosanoids aid the diagnosis of both 
pneumonia and VAP?  
x Can a panel approach to the measurement of cytokines aid the diagnosis of both pneumonia 
and VAP?  
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x Can combining eicosanoid and cytokine profiles into an ‘inflammatory profile’ improve the 
diagnostic potential of this approach? 
x Can multivariate methods applied to routinely collected clinical data produce discriminant 
models to differentiate those with and without pneumonia? 
x Can combining clinical data with profiling data from biofluids improve diagnostic potential of 
these approaches? 
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Section II – Methodology 
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2. PROTOCOLS AND METHODS 
2.1 Patient Recruitment. 
All patients were recruited in line with the independent research ethics committee approval (REC 
10/H0709/77). Adult patients (age >16yrs) were screened at both Charing Cross and St Mary’s 
Hospitals, Imperial College Healthcare NHS Trust. Patients were eligible for recruitment if they 
fulfilled the following criteria: 
1. Patients requiring intubation and ventilation who were expected to be ventilated for >48 
hours 
2. Patients who could be recruited within 48 hours of intubation 
3. Patients fulfilling 2/4 of the criteria of the systemic inflammatory response syndrome (SIRS) 
as follows: 
(1) Fever (>380 C) or hypothermia (< 360 C),  
(2) Tachycardia (heart rate > 90 beats per minute), 
(3) Tachypnoea (respiratory rate > 20 breaths per minute or PaCO2 < 4.3 kPa) or need 
for mechanical ventilation, 
(4) Abnormal leukocyte count (> 12,000 cells/mm3, < 4000 cells/mm3, or > 10% 
immature [band] forms). 
Patients were excluded if the following criteria were met: 
1. Refusal of assent from the patients next of kin 
2. Pre-existent immunosuppression, either congenital or acquired 
3. Use of granulocyte colony stimulating factor 
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Three groups of patients were recruited. The predominant group was a cohort of patients with 
isolated neurological pathology or brain injury (BI), such conditions included subarachnoid 
haemorrhage (SAH), isolated head injury, cerebrovascular accidents (CVA), isolated brain tumours 
and status epilepticus. Patients with disseminated pathology that may have effect on their lungs 
such as polytrauma or disseminated malignancy with cerebral metastasis were not recruited into 
this group. A second group of patients admitted with a primary diagnosis of pneumonia were 
recruited to act as a positive control group. Finally a, small, third group of patients was enrolled with 
a range of conditions who’s samples could be used for method development. 
2.1.1 Consent 
As, by definition, patients recruited to the study were undergoing invasive ventilation it was not 
possible to obtain direct patient consent. Instead informed assent was obtained from the patient’s 
personal consultee or where no such person existed a professional consultee caring for the patient 
but not directly involved in the study. All patients were followed up once mechanical ventilation had 
ceased and where patients regained capacity retrospective consent was obtained for involvement in 
the study. 
2.1.2 Sample collection 
The first set of biofluid samples, exhaled breath condensate, serum and urine, were obtained from 
recruited patients as soon as possible after personal consultee assent had been obtained. 
Subsequent samples were collected on alternate days until either four sets of samples had been 
obtained over the course of the first week or the patient no longer required Intensive Care.  
 2.1.2.1 Serum 
All blood was drawn from indwelling vascular access. Where a patent arterial catheter was in place 
this source was used for sample collection, if no arterial access was available blood was drawn from 
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the central venous catheter. 5ml of blood was aspirated from the line to clear the saline flush prior 
to sample collection. Serum samples were collected into 10ml, red-topped Vacutainer® (New Jersey, 
USA) tubes containing a silicone clot activator. 10ml of blood were drawn into the tube from the 
indwelling catheter and placed directly on ice. Samples were left to clot for 30 minutes on ice in 
order to limit metabolic activity within the sample during clotting. Samples were then centrifuged at 
1600g at room temperature for 10 minutes prior to being divided into 100-500µl aliquots. Aliquots 
were then kept frozen at -80°C before analysis. A clotting time of 30minutes was used to balance the 
time needed to allow the samples to clot adequately whilst minimising the time between sample 
collection and aliquots being frozen (110, 257). 
After analysing the first samples it became apparent that in some aliquots clotting had continued 
during the freezing process leaving insufficient sample volume to run the required experiments. In 
order to improve the volume of serum obtained in samples collected latterly, a second red-topped 
Vacutainer was collected simultaneously. Whilst the first was processed as described above, the 
second was centrifuged for a further 5 minutes to improve clot and serum separation. This then 
provided two groups of paired samples, those centrifuged for 10 and those for 15 minutes. Where 
possible 10 minute samples were used for all analysis, however, where insufficient sample was 
obtained a 15 minute sample was substituted. Where possible a direct comparison of 10 to 15 
minute samples was made where paired samples existed. 
 2.1.2.2 Urine 
All urine samples were collected from indwelling urinary catheters. The catheter was clamped for 
20-30min prior to sample collection to ensure a fresh sample was obtained. 5ml of urine was then 
aspirated from the side port of the catheter before being placed into a 10ml red-topped Vacutainer® 
(New Jersey, USA) tube. Immediately after collection collected samples were centrifuged at 1900g, 
at room temperature for ten minutes before being divided into aliquots of 600-700µl. All aliquots 
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were immediately frozen at -80°C, the time between a samples collection and its placement in the 
freezer was kept to a minimum. 
 2.1.2.3 Exhaled Breath Condensate 
Exhaled breath condensate (EBC) was collected using the commercially available RTube™ 
(Respiratory Research, USA) device. This device consisted of a single use polypropylene tube with a 
one-way silicone rubber valve, figure 2.1. For sample collection the disposable tube was covered 
with a re-useable aluminium tube which is otherwise kept at -80oC this acted as a condenser. The 
time between removing the condenser from the freezer and connecting the collection equipment to 
the ventilator circuit was kept to a minimum. To allow the aluminium tube to be handled a 
polyester/cotton insulator was used. The device is predominantly intended for sample collection 
from spontaneously breathing subjects and comes fitted with a mouth piece and one way inspiratory 
valve combined as a plastic T-piece. In order to fit the device into the ventilator circuit the mouth 
piece was removed and the plastic T-piece inverted and placed on in the top of the RTube™, figure 
2.1. The rearranged equipment could then be placed into the expiratory limb of the ventilator 
circuit. In order to prevent excessive expiratory pressure a small v-shaped nick was made in the 
silicone valve using sterile scissors. The presence of the silicone valve ensured that only expiratory 
breath was being condensed.  
EBC samples were collected by placing the collection equipment in the expiratory limb of the 
ventilator circuit for 15 minutes. One to two minutes prior to collection the heat and moisture 
exchange (HME) filter was removed. This ensured sufficient moisture content of the exhaled breath 
passing through the RTube™ to allow an adequate amount of condensate to be collected. During 
EBC collection patients underwent full monitoring of saturations, respiratory rate, end-tidal CO2, 
heart rate and blood pressure as well as the respiratory parameters being delivered by the 
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ventilator. This ensured the safety of sample collection and allowed collection to be terminated in 
case of patient instability. Prior to sample collection the ventilator settings were set by the physician 
responsible for the patient’s care and these were unchanged during collection. A record was kept of 
all settings at the time of collection. 
After 15 minutes of collection time the EBC was divided into aliquots by pushing the silicone valve up 
to the top of the collection tube using a solid aluminium plunger. Samples were divided into aliquots 
of 500µl and frozen immediately at -80°C. 
 2.1.3 Clinical Data Collection 
A comprehensive set of clinical data was recorded for each day of a patients ICU stay. Data included 
all physiological variables, laboratory test results, radiology results, arterial blood gas results, 
microbiology results and administered drugs, fluid and feed, table 2.1. Data were collected at 
8:00am every morning and covered the preceding 24h period. For all variables the minimum and 
maximum values were recorded for the 24h period. 
2.1.4 Patient Follow Up 
Whilst on ICU patients were followed up daily and following step down to the ward patients were 
followed up until discharge or death with significant events during their stay recorded. 
2.2 Diagnosis of Pneumonia 
2.2.1 Brain Injury Patients Developing Ventilator Associated Pneumonia 
Patients from the brain injury group were followed up daily and a diagnosis of ventilator associated 
pneumonia was made based on Clinical Pulmonary Infection Scoring (CPIS) (83), table 2.2. In contrast   
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 Table 2.1 Clinical data collected for all enrolled patients 
Bedside Variables Laboratory Variables Drugs 
Ventilator Settings Laboratory Results  
Ventilator mode White Blood Cell Count (x10^9/L) All drugs administered over the 
preceding 24h with timings and doses 
Peak end expiratory pressure (PEEP) (cmH2O) Haemoglobin (g/dl)  
FiO2 Platelet Count (x10^9/L)  All fluids given over the preceding 24h 
with timings and volumes 
Respiratory rate set (breaths/min) Haematocrit (%)  
Respiratory rate measured (breaths/min) Prothrombin Time (s) Type and volume of feed administered 
with timing 
Set tidal volume (ml) Activated Partial Thromboplastin Time (s)  
Expiratory tidal volume (ml) Fibringogen (g/L) Blood products given with timing 
Pressure support (cmH2O) Sodium (mmol/L)   
Pressure control (cmH2O) Potassium (mmol/L)   
Expriatory minute volume (L) Creatinine (µmol/L)   
Peak airway pressure (cmH2O) Urea (mmol/L)   
Inspiratory:Expiratory ratio Chloride (mmol/L)  
 Magnesium (mmol/L)   
Physiological Parameters C-Reactive Protein (mg/l)   
Heart rate (beats/min) Alanine Transaminase (IU/L)  
Systolic blood pressure (mmHg) Alkaline Phosphatase (IU/L)  
Mean arterial pressure (mmHg) Bilirubin (µmol/L)   
Diastolic blood pressure (mmHg) Albumin (g/L)  
Oxygen saturations (%) with associated FiO2 Corrected Calcium (mmol/L)   
Glasgow Coma Scale Phosphate (mmol/L)  
Temperature (°C)   
Central Venous Pressure (CVP)(cmH2O) Microbiology Results  
Hourly urine output (ml/h) Culture results from tracheal aspirates  
Total urine output over 24 hours (ml) Culture results from blood cultures  
Total fluid input over 24 hours (ml) Other microbiology specimens sent  
Total oral input over 24 hours (ml)   
Amount of tracheal secretions over 24h Radiology Results  
Colour of tracheal secretions over 24h Chest radiograph reports  
 Computed Tomography (CT) reports  
Blood Gas Parameters   
PaO2:FiO2 ratio (kPa)   
PaCO2 (kPa)   
pH   
Bicarbonate (mmol/L)   
Base excess   
Lactate (mmol/L)   
Glucose (mmol/L)   
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to the original published score this study gave a score of 0 to a temperature of 36.0-38.4 compared 
to 36.5-38.4 as published. This change was made as it was unclear what score temperatures of 36-
36.5 should be given. 
Table 2.2. Clinical Pulmonary Infection Score (CPIS) modified from Pugin et al, 1991 (83) 
Clinical Feature Score 
Temperature (oC) 
36.0-38.4 
38.5-38.9 
≥39 ≤36 
 
0 
1 
2 
White Cell Count (mm-3) 
4,000-11,000 
>11,000,  <4,000 
Band forms >500 
 
0 
1 
+1 
Radiology 
No infiltrate 
Diffuse (Patchy) Infiltrate 
Localised Infiltrate 
 
0 
1 
2 
Oxygenation (mmHg) 
PaO2/FiO2 > 240 or ARDS 
PaO2/FiO2 ≤240 
 
0 
2 
Secretions 
<14 of total secretions in 24h 
≥14 of total secretions 
Plus purulent secretions 
 
0 
1 
+1 
Microbiology 
Pathogenic bacteria cultured ≤ 1+ or no growth 
Pathogenic bacteria cultured ≥ 1+ 
Gram stain ≥ +1 with same pathogenic organism 
 
0 
1 
+1 
 
Scores were calculated on a daily basis using clinical data from the preceding 24h. For variables that 
were not recorded on a daily basis such as radiology reports and microbiology data it was assumed 
that the last documented score remained true until there was documented change, for example new 
radiological findings or a newly positive or negative culture result. The CPIS gives a score ranging 
from 0-12 with a score ≥7 being taken to signify VAP. However, in our institution band form 
measurement and gram staining of tracheal secretions are not routinely performed limiting the 
score to 0-10, leaving patients with scores of five and six borderline for the diagnosis of VAP. To 
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account for this all scores ≥7 after 48h of ventilation were taken as confirmed diagnoses of VAP and 
those <5 as definite controls, figure 2.2. Borderline cases with scores of five or six were assessed by 
an independent clinician and classified as cases or controls. Patients with high scores within the first 
48h of ventilation, where there was also clinical suspicion were treated as cases of primary 
pneumonia and not VAP. Patients with a CPIS <5 at the time of the first sample collection were 
considered free of infection and used as the control group, figure 2.2. Where any conflict existed 
between the CPIS score and the clinical judgement the clinical records were reviewed and a decision 
made regarding clinical grouping. Where this did not clarify the situation cases were passed to an 
independent assessor.  
2.2.2 Pneumonia 
Patients admitted for ventilation with a primary diagnosis of pneumonia were initially identified 
based on the clinical judgement of the physician with responsibility for their care. This was based on 
features from the history, clinical examination findings, laboratory tests and radiological 
investigations.  However, as there is a recognised degree of intra-observer variability when making 
this diagnosis more objective criteria were required. The CPIS score was calculated for all patients 
felt to have pneumonia on admission to ICU and only those patients scoring ≥6 within 48h of the 
timing of the first sample of stay were taken as confirmed diagnoses. A lower CPIS target was 
accepted in this group due to difficulties obtaining certain clinical parameters, such as 
microbiological specimens when patients initially present to hospital compared to the ease of 
acquisition from an already intubated and ventilated patient. In order to be classified as a case of 
pneumonia there had to be both a clinical suspicion at the time of admission and a high enough 
CPIS, figure 2.3. Where any conflict existed between the CPIS score and the clinical judgement the 
clinical records were reviewed and a decision made regarding clinical grouping. Where this did not 
clarify the situation cases were passed to an independent assessor for classification. 
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2.3 Specific Processing 
Details of specific experimental assays used for each experiment are given in the relevant chapters. 
Nuclear Magnetic Resonance Spectroscopy for global metabolic profiling of serum and urine, 
chapter 3, targeted measurement of oxylipins using mass spectrometry and cytokine measurement 
using flow cytometry, chapter 4,  and global metabolic profiling of breath condensate using mass 
spectrometry, chapter 5. 
2.4 Statistical Analysis  
Statistical analysis was performed using a combination of multivariate and univariate techniques. 
Routine data handling was performed in Excel 2010 (Microsoft, USA). Univariate statistical analysis 
was used to compare individual analytes and characteristics of included patients using SPSS version 
22 (IBM, UK) and Excel 2010 (Microsoft, USA).  The Student’s t-test was used to compare continuous 
variables between groups of patients and Fisher’s exact test to compare categorical variables. 
Normality of metabolite distributions was determined using Kolmogorov-Smirnov and Shapiro-Wilk 
tests of normality. Non-normally distributed analytes were compared using the Mann-Whitney U 
test. To control for the false discovery rate and limit the number of type I errors the Benjamini-
Hochberg procedure was used when multiple univariate comparisons were made.  A p-value of 0.05 
or less was taken to represent statistical significance.  
For much of the data there were far more variables than there were observations, making 
multivariate analysis an ideal way to evaluate the data. All multivariate analysis was performed using 
the SIMCA statistical package (Umetrics, Sweden).  Initial exploration of data sets was performed 
with principal component analysis (PCA). PCA is an unsupervised method of multivariate analysis, 
meaning that during analysis the model has no prior knowledge of the observation classifications of 
interest and instead finds the largest directions of natural variation. It employs orthogonal 
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transformation of a data set of observations and correlated variables into a matrix of uncorrelated 
variables. The transformation is performed in such a way that the first set of variables, or 
component, demonstrates the largest variation from within the data and all subsequent  
components demonstrate the next greatest direction of variation in an orthogonal direction to the 
previous component. PCA was performed first on the data to look for natural separation of groups of 
observations that would either explain groups of clinical interest or detect clustering not overtly 
apparent in the data that may have affected further analysis. Data from PCA analysis were displayed 
on scores plots which plot two components of interest against each other. Data points on the scores 
plots were artificially coloured to represent groups of clinical interest, although these data were not 
used in construction of the models. PCA was also used to detect significant outliers. On the scores 
plots the Hotelling’s ellipse represents a 5% confidence interval, a multivariate equivalent of 
Student’s t-test, and observations lying outside of this were considered strong outliers which 
warranted further investigation to look for explanations for why an individual was an outlier. The 
amount of the total population variance explained by a PCA model is explained by the R2X value of 
the model, this is expressed as a decimal with a model with an R2X of 1.0 explaining all of the 
variance within a data set. The predictive value of the model is expressed as the Q2X, again 
expressed as a decimal with values approaching 1.0 demonstrating the best prediction. In the case of 
PCA, the Q2X value does not inform about class but only reflects the overall variance in the total 
dataset. 
Supervised multivariate analysis using orthogonal partial least squared discriminant analysis (OPLS-
DA) was used to generate models to optimally separate predefined groups. OPLS-DA is another form 
of multivariate analysis similar to PCA. However, in this analysis the model attempts to find variation 
in the original data set, X, that explains the clinical classifications represented in a second matrix, Y. 
OPLS-DA differs from partial least squared analysis discriminant analysis (PLS-DA) in that the data in 
the X-matrix is separated into that which predicts the Y data and that which is unpredictive or 
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orthogonal to it, improving visualization of metabolites associated with clinical parameters. OPLS-DA 
models were cross validated using seven fold cross-validation using a “leave-one-out” methodology. 
This method uses every 7th observation as a validation set that is predicted by the model, the 
predicted values can then be compared to the actual classes. This is repeated until every observation 
has been left out once and once only. The cross validation allowed a value, Q2Y, to be generated that 
estimated the predictive capacity of the model with a value of 1.0 representing a completely 
predictive model for sample class. The degree of variation in the original data set explained by the 
model is again given by R2X with a value of 1.0 implying that all the variation is explained, on the 
other hand the amount of variation between the groups being compared explained by the model is 
given by R2Y. To assess the reliability of the OPLS-DA models a cross-validated analysis of variance 
was used (CV-ANOVA) which analyses whether the model has significantly smaller cross validated 
predictive residuals than just the variation around the global average, as would be expected if the 
model was generate by chance. This test tests the hypothesis that the residuals of the model are 
those that would be obtained by chance, if no relationship existed, and acts as a test of significance 
of the Q2Y (112). 
The number of components in the OPLS-DA models were limited to being no more than half the 
number of samples in the smallest group used in the model and components were no longer added 
when they failed to improve the Q2Y by 0.05 or more. Data from the OPLS-DA models were again 
displayed on scores plots with the first component plotted against the orthogonal component, data 
were displayed before and after cross-validation.  
The ideal way to assess the predictive models is to challenge them with a new data set that has not 
been used to build the original model. Where there were sufficient samples from the patients 
categorised by the independent assessor these were used as a small test set, of around ten patients, 
to assess the predictive capacity of the models. When this was possible the unseen data were put 
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into the model and the classifications based on the model were compared with those from the 
assessor. Based on the number of agreements and disagreements the sensitivity, specificity, positive 
and negative predictive values of the models could be calculated. 
In order to test whether the models were performing better than chance. Permutation testing was 
performed on a similar PLS-DA model to the OPLS-DA model in question. The Y variables were then 
randomly generated 20 times, in order to scramble the true class information, and a new PLS-DA 
model constructed for each permutation. The Q2Y and R2X could then be compared with those 
generated from the random models.  
To identify analytes that were important in separating clinical groups a number of methods were 
employed.  Firstly, when the number of analytes were relatively small the loadings plots for the 
model could be examined directly. The loadings plot plots the weight for each variable against axes 
representing the components of the relevant model. As such it looks similar to the scores plot but 
instead of each data point representing an observation they represent the analytes. The scores plots 
and loadings plots could be directly compared and the analytes at the extremes of each axis could be 
seen to be causing most of the separation in the equivalent direction on the scores plot.  
Analytes were also assessed using the ‘s-plot’. The s-plot  is used to visualize both the covariance and 
the correlation between the variables and the predictive score. Thus the most discriminant analytes 
will be associated with both a high correlation and covariance and will be at the extremes of the ‘S’. 
Data that underwent univariate scaling did not produce the typical ‘S’ as the correlation and 
covariance showed a linear relationship. Similar to the s-plot, spectral data from NMR data were 
displayed on an s-line plot, or regression coefficient plot. Here the variables are plotted against the 
loading for that variable, giving the overall appearance of the original spectrum. However, instead of 
all of the spectral peaks pointing in the upward direction as seen in the original NMR data, the peaks 
are directed either upward or downward depending on the clinical group the metabolite 
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predominates in. The strength of the metabolite’s importance in separating the two groups is given 
by colouring each peak based on the absolute correlation variable for that variable based on the 
clinical classification. 
Where several analytes appeared to cause separation of a model the Variable Importance for the 
Projection (VIP) was used to help define those variable most important in the model. VIP is a 
parameter which summarizes the importance of the variables, it is a weighted sum of squares of the 
OPLS-DA weights, taking into account the amount of explained Y-variance in each dimension. 
Variables with large VIP, larger than 1, were considered the most important for explaining the 
classification (112). 
To aid the identification of metabolites in NMR data Statistical Total Correlation Spectroscpy 
(STOCSY) was used to correlate peaks of interest with other peaks in the spectrum using an in-house 
MatLab 2013 (MathWorks, Massachusetts, USA) script. This process correlates a selected peak with 
all other peaks in the spectrum. Peaks with the highest correlation are likely to be part of the same 
metabolite where as those with an intermediate correlation co-efficient are likely to be associated 
with the index peak but not within the same metabolite, for example as part of the same metabolic 
pathway. 
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2.5 Patient Details. 
Sixty-three patients were recruited in total, figure 2.4. Of these one had to be excluded as the 
patient withheld retrospective consent. Of the remaining 62 patients nine had diagnoses other than 
brain injuries or pneumonia leaving a potential 36 brain injured and 17 pneumonia patients. 
Following the classifications described earlier four of the brain injured patients had pneumonia at 
the time the first sample was collected as did eleven of the pneumonia group, leaving 15 patients 
classified as having pneumonia at the time the first samples were collected. Classification of the 
brain injured patients found 21 had no suggestion of pneumonia when the first sample was taken, of 
which ten never developed signs of pneumonia. From this group of 21 patients the control group 
was drawn. Six of the brain injured patients developed pneumonia based on CPIS during their stay, 
five of these developed pneumonia after 48h of ventilation so were defined as VAP. One of the brain 
injured patients did not have samples taken at the first time point and was excluded from further 
analysis.  
Seventeen brain injured patients were borderline for either a diagnosis on pneumonia at admission 
or for the development of VAP. Similarly six of the potential cases of pneumonia failed to be 
classified using the defined algorithm. These 22 patients were submitted to an independent assessor 
for further classification. When this was completed, seven patients were classified as having 
pneumonia at admission, two of whom had associated brain injuries, six of the brain injured patients 
were classified as not having pneumonia when the first sample was taken and 3 were felt to develop 
VAP. One patient was excluded from further analysis as they had initially been classified as not 
having pneumonia at admission but were submitted as a potential VAP but were felt to have had 
pneumonia at recruitment by the independent assessor. Due to this conflict they were excluded 
from further analysis.  
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Four of the recruited patients only had breath condensate collected as they had been co-enrolled 
into an interventional trial that precluded further urine or serum sample collection. 
Initial statistical models were made based on the classifications based on the described algorithms. 
The patients independently classified were used to further explore the data and test the ability of 
the models to categorize patients. 
The majority of the brain injured patients had suffered either a subarachnoid haemorrhage, or a 
haemorrhagic cerebrovascular accident, table 2.3. Of those patients initially classified as having 
pneumonia at enrolment, the majority were felt to have been at risk of aspiration, five had 
associated brain injuries and one had a pneumonia in the context of endocarditis, table 2.4. 
Table 2.3 Causes of brain injury in the recruited patients. 
Cause of Brain Injury n 
Status Epilepticus 4 
Thrombotic CVA 6 
Haemorrhagic CVA 10 
Subarachnoid  haemorrhage 12 
Loss of consciousness  1 
Subdural Haematoma 2 
Motor Neurone Disease 1 
 
Table 2.4 Causes of pneumonia in those with pneumonia at enrolment 
Cause of Pneumonia n 
Community  Acquired 2 
Aspiration 8 
Endocarditis 1 
Empyema 2 
Hospital Acquired 2 
  
Associated with brain injury 5 
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The demographic details of the patients between the two groups based on the initial classification, 
table 2.5, were similar. The features that differentiated the groups were those that implied 
pulmonary infection. These included CPIS, C-reactive protein, FiO2:PaO2 ratio and the use of 
antibiotics. The organisms causing pneumonia in those admitted with pneumonia and those 
developing VAP can be seen in table 2.6. 
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Table 2.5. Clinical features of included patients based on initial classification. Continuous variables 
are given as mean and standard deviation and categorical variables as number and percentage. p-
values presented in bold text relate to parameters that were significant at the p<0.05 level. P-values 
given in demographic tables are not corrected for multiple comparisons. 
 Pneumonia (P) Brain Injury (BI) p-value 
(BI vs P) 
VAP p-value 
(BI vs VAP) 
n 15 21 - 5 - 
Age (Mean +/- SD) 54.7±16.8 52.3±14.9 0.65 50.8±17.2 0.87 
Sex, Number of males (%)  10 (67) 12 (57) 0.73 3 (60) 1.00 
Ethnicity, number  White 
European (%) 
11 (73) 15 (71) 1.00 4 (80) 1.00 
Outcome, Number alive (%) 10 (67) 16 (76) 0.71 3 (60) 0.59 
APACHE II Score (Mean +/- 
SD) 
19.7±5.8 17.0±6.0 0.18 17.8±9.4 0.86 
SOFA Score (Mean +/- SD) 10.5±3.1 8.9±2.6 0.12 8.6±3.1 0.87 
CPIS (Mean +/- SD) 5.9±1.1 2.1±1.4 <0.001 7.0±1.6 <0.01 
Lowest WCC (109/L) (Mean 
+/- SD) 
15.6±7.2 10.0±3.8 0.01 10.5±3.2 0.76 
Highest WCC (109/L) (Mean 
+/- SD) 
16.1±7.0 11.2±3.9 0.03 10.5±3.2 0.70 
Lowest CRP (mg/L) (Mean 
+/- SD) 
180.4±104.1 49.4±54.2 <0.001 116.7±28.2 <0.01 
Highest CRP (mg/L)(Mean +/- 
SD) 
196.3±95.8 62.0±52.5 <0.001 116.7±28.2 <0.01 
Lowest Temperature (°C) 
(Mean +/- SD) 
35.9±0.8 36.0±0.7 0.58 36.0±1.6 0.95 
High Temperature (°C) 
(Mean +/- SD) 
37.6±0.9 37.6±0.7 0.77 38.0±1.3 0.45 
Lowest FiO2 (Mean +/- SD) 0.43±0.14 0.40±0.22 0.54 0.36±0.07 0.51 
Lowest PaO2:FiO2 (Mean +/- 
SD) 
24.4±9.2 41.8±15.5 <0.001 18.6±8.5 <0.001 
Lowest MAP (mmHg) (Mean 
+/- SD) 
70.7±10.2 74.0±11.3 0.36 71.0±12.4 0.64 
Use of noradrenaline, N (%) 11 (73) 13 (62) 0.72 1 (20) 0.15 
Use of antibiotics N (%) 15 (100) 10 (48) <0.001 5 (100) 0.05 
Enteral nutrition, N (%) 13 (87) 15 (71) 0.42 5 (100) 0.30 
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Table 2.6. Organisms causing pneumonia in those admitted with pneumonia and those developing 
VAP from the group of patients based on original classification. Organisms grown from sputum 
sampling. (*based on urine antigen testing.) 
Admission 
Pneumonia 
VAP 
Organism n Organism n 
Morexella 1 S Aureus 3 
Enterobacter 1 Klebsiella 1 
Pseudomonas 2 Serratia 1 
E. Coli 1   
Pneumococcus 2   
  Morganella 1   
Legionella* 1   
Haemophlus 1   
Mixed growth 1   
Nil 5   
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Section III – Clinical Studies 
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3. 1H-NMR ANALYSIS OF SERUM AND URINE 
 
3.1 Summary 
1H-NMR spectroscopy has been used to analyse biofluids from patients with a range of conditions in 
order to employ a metabonomic approach to further understand the underlying pathology. Limited 
work has been done using this technique in either samples obtained from critically unwell patients 
or those with pneumonia. In this chapter 1H-NMR spectroscopy was employed to analyse both 
serum and urine samples collected from patients admitted to intensive care with and without 
pneumonia. Analysis of serum samples demonstrated potential to differentiate these groups with 
performance being better for patients admitted with pneumonia than for those who developed VAP. 
Interesting metabolic differences were observed between the groups with lipids, amino acids and 
glycoproteins appearing to be important in separating the groups perhaps representing changes in 
energy metabolism. Analysis of urine was more challenging with metabolites being much more 
difficult to identify perhaps relating to the fact that intensive care patients receive a large number of 
drugs many of which are excreted intact or in part in the urine. Many of the peaks seen in the urine 
samples probably represented drugs and their metabolites limiting the ability to pursue the aim of 
this study which was to identify changes in innate metabolism. Overall serum seemed a much more 
robust biofluid to analyse when applying metabonomic methods to critical care patients and more 
specifically was a better method by which to identify those patients with pneumonia. 
3.2 Background 
Little work has been done characterising pneumonia using metabonomic techniques. Elevated levels 
of lipoproteins, triglycerides, unsaturated and polyunsaturated fatty acids, ω-3 fatty acids, lactate 
and 3-D-hydroxybutyrate and reduced glucose levels have been found in the plasma of rats infected 
with Klebsiella Pneumoniae compared to controls (149) and differentiation of mice with pneumonia 
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caused by Staphlococcus Aureus or Streptococcus Pneumonia from control animals has been 
observed via urine metabolic profiling  (150). Similarly work using Chlamydia Pneumoniae  infected 
cell lines (113) identified a number of metabolic pathways that were altered by including those 
involved in carbohydrate and lipid metabolism along with altered concentration of several amino 
acids. 
Work in human subjects has predominantly focused on community acquired pneumonia. A small 
study using MS analysis of plasma and urine from Gambian children, using eleven cases of 
pneumonia and eleven controls, found elevated uric acid, hypoxanthine, glutamic acid and L-
tryptophan but reduced adenosine diphosphate levels within plasma samples. In this study 
clustering based on sex was noted in the pneumonia group that was not seen in the controls 
suggesting differences in inflammatory responses between boys and girls (153). Another study 
looking at metabolic profiling of urine compared 47 patients with Streptococcus Pneumoniae 
pneumonia to 47 matched controls and found numerous urinary metabolites to separate the groups 
including citrate, succinate, 1-methylnicotinamide, several amino acids, glucose, lactate, acetone, 
carnitine, acetylcarnitine, hypoxanthine and acetate (154). This study attempted to address several 
potential confounding factors associated with this type of investigation by comparing cases to 
several control groups such as those with other types of lung disease, those with other types of 
pneumonia and those with other acute illnesses. In most cases multivariate statistical models 
provided reasonable prediction accuracy. This study also attempted to look at the metabolic 
trajectory of patients with pneumonia by taking serial urine samples and looking at the change in 
metabolic profiles over time. Work has not been restricted to bacterial infection, a study using UPLC-
MS analysis of serum (258) compared samples taken during acute infection with Influenza A with 
those taken after recovery and found a number of biomarkers associated with viral infection many 
of which were inflammatory molecules such as prostaglandins and leukotrienes as well as a number 
of amino acids. 
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Within critical care work has focussed on outcomes of patients with community acquired pneumonia 
(CAP) and sepsis (155). MS analysis of plasma, from 15 patients who died matched to the same 
number of survivors, found higher levels of bile acids, steroid hormone metabolites, markers of 
oxidative stress and nucleic acid metabolites in non-survivors, however, the statistical models based 
on these differences had only modest sensitivity with an area under the receiver operating curve 
(AUROC) of 0.67 which is less than that expected from the APACHE II scoring. From these studies 
only one (154) has attempted to look at the changes in metabolic trajectories over time. 
It is often difficult to distinguish VAP from acute lung injury (ALI) or acute respiratory distress 
syndrome (ARDS). A metabonomic study of sepsis induced ALI and ARDS (106) found differences in 
plasma levels of glutathione, adenosine, phosphatidylserine and sphingomyelin compared to healthy 
controls. 
To date no work has been done using metabonomic methods specifically focusing on VAP or looking 
at methods for differentiating patients with pneumonia from similar critically unwell patients 
without pneumonia. Healthy volunteers have often been used as controls for pneumonia cases in 
the literature. This approach has several disadvantages as healthy controls may be expected to be 
metabolically much further away from pneumonia patients than similar severely ill patients. In this 
study an attempt was made to overcome this problem by using a control group consisting of patients 
similarly ventilated on ICU without pneumonia or infection. 
3.3 Aims 
The overall aim of this study was to use metabonomic techniques to attempt to improve the 
diagnosis of pneumonia in patients requiring ventilation, specifically those going on to develop VAP.  
The following questions were addressed: 
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1. Can metabolic profiles of serum and urine be used to aid diagnosis in patients 
with pneumonia and VAP? 
2. Can comparing metabolic profiles of serum and urine give an insight into local and 
global metabolic changes? 
3.4 Protocols 
3.4.1 Patient Recruitment and Sample Collection 
Patients were recruited and serum samples taken as described in chapter 2. Patients were defined as 
either having pneumonia or a brain injury as described earlier. All patients were followed up over 
time and those brain injured patients developing VAP were defined based on CPIS scoring, for a 
breakdown of the CPIS score used see chapter 2. Patients with borderline scores were assessed and 
classified as VAP or no VAP by an independent assessor. 
3.4.2 Sample Processing 
All samples were transported between sites on ice if preparation was to be done immediately or on 
dry ice and placed directly into a -80°C freezer if preparation was to be carried out at a later date. 
Samples were allowed to thaw at room temperature before further preparation. 
 3.4.2.1 Serum 
A volume of 300 PL of serum was mixed with 300 PL of H2O:D2O buffer containing 1.5 M of KH2PO4, 
TSP and NaN3 at pH 7.4. Samples were vortexed and centrifuged at 12000 g for five minutes to 
remove solid material. 550 PL of the supernatant was placed into 5 mm NMR tubes and immediately 
loaded onto a refrigerated SampleJet robot (Bruker Corporation, Germany) and kept at 5°C until 
measurement. All measurements were carried out within 24h of sample preparation. 
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 3.4.2.2 Urine 
A volume of 540 PL of urine where mixed with 60 PL of D2O buffer containing 1.5 M of KH2PO4, TSP 
and NaN3 at pH 7.4. Samples were vortexed and centrifuged at 12000g for five minutes to remove 
solid material. 550 PL of the supernatant was placed into 5 mm NMR tubes and immediately loaded 
onto a refrigerated SampleJet robot (Bruker Corporation, Germany) and kept at 5°C until 
measurement. All measurements were carried out within 24h of sample preparation. 
3.4.3 1H-NMR 1D Experimental Data Acquisition 
All 1H-NMR experiments were performed using a Bruker Avance III 600 spectrometer working at 14.1 
T equipped with a BBO probe.  
3.4.3.1 Serum 
1H-NMR spectra of serum samples were collected at a constant temperature of 310K using the 
relaxation edited Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence. This allows low molecular 
weight species to be detected by eliminating signals from proteins. A total of 32 free induction 
decays (FID) were acquired for each experiment in 96 K data points using a 20 ppm spectral width 
centred at 4.75 ppm. The relaxation delay was set at 4 s and a water pre-saturation pulse was 
applied during this period to cancel the water signal. The receiver gain was kept constant at a value 
of 90.5. All experimental acquisition was automated and samples were held in the spectrometer for   
five minutes before data acquisition to allow temperature equilibration. For each sample a standard 
1D pulse sequence using the first part of a Nuclear Overhauser Effect pulse sequence to achieve 
presaturation of the water peak (110), and J-resolved 2D experiments were also performed using the 
same parameters as above.  
To aid metabolite identification further 2D experiments were carried out on selected samples. 
Correlation Spectroscopy (COSY), to demonstrate proton spins that are directly coupled to 
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each other, and Total Correlation Spectroscopy (TOCSY), to demonstrate coupled protons within 
6 bonds in a molecule, experiments were performed. For COSY experiments a 12 ppm spectral 
width was used with a relaxation delay set at 1.2s during which a water pre-saturation pulse was 
applied to cancel the water signal. For TOCSY experiments a 12 ppm spectral width was used with a 
relaxation delay set at 2.0s during which a water pre-saturation pulse was applied to cancel the 
water signal. 
 3.4.3.2 Urine 
A standard one-dimensional experiment using the first increment of the NOESY pulse sequence to 
achieve pre-saturation of the water resonance (110) and a 2D J-resolved  experiment were run for all 
samples in automation at a constant temperature of 300 K. 32 FIDs were accumulated for each 
experiment in 64 K data points using a 20 ppm spectral width centred at 4.75ppm. The relaxation 
delay was set at 4s and a water pre-saturation pulse was applied during this period to cancel the 
water signal. The receiver gain was kept constant at a value of 90.5. All experimental acquisition was 
automated and samples were held in the spectrometer for five minutes before data acquisition to 
allow temperature equilibration. 
3.4.4 Pre-Processing 
The FID values were multiplied by an exponential function equivalent to a 0.3Hz line broadening 
factor before Fourier transformation. The resulting spectra were subject to automated phasing, to 
ensure all spectral peaks were directed upwards, and baseline correction, to ensure the baseline of 
all spectra was set to 0, using TopSpin 3.2 (Bruker Corporation, Germany). Where necessary manual 
correction to the pre-processing was performed using TopSpin 3.2 (Bruker Corporation, Germany).  
Spectra were imported into MatLab 2013 (MathWorks, Massachusetts, USA) using in-house scripts 
for all pre-processing steps. Spectra from serum samples were calibrated to the α-glucose signal at 
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5.23ppm and the spectra from urine samples to TSP at 0ppm. For all spectra the region from 0.1-
10ppm, to exclude the peak due to TSP, was divided into approximately 40,000, serum, or 34,000, 
urine, data points. The water signal region (4.5-4.85ppm, serum and 4.72-4.84ppm, urine) for all 
spectra and the signals due to urea in urine spectra (5.65-6.0ppm) were removed prior to further 
processing. All samples underwent probabilistic quotient (median fold) normalisation (259), which is 
typically used for pre-processing of human urine samples. Urine spectra also underwent a further 
step of automated peak alignment using an in-house statistical algorithm to improve alignment of 
peaks from one spectrum to another.   
3.4.5 Statistical Analysis 
Prior to multivariate analysis all spectral data were scaled to unit variance. By standardising the 
variance of variables this attempts to take into account the potential influence on multivariate 
models of analytes with naturally higher concentrations that tend to be associated with higher 
variance and allows variables with generally lower values to be given similar weight within the 
model. Multivariate statistics were used to analyse the data. Initial exploration with principal 
component analysis (PCA) was performed to look for natural clustering and to detect outliers before 
supervised multivariate analysis using orthogonal partial least squared discriminant analysis (OPLS-
DA) was used to generate models to optimally separate predefined groups. OPLS-DA models were 
cross validated using seven fold cross-validation using a “leave-one-out” methodology. Important 
metabolites in each model were identified by examining the loadings associated with each model 
and the most important metabolites were selected by picking those associated with the highest 
correlation coefficients for each model. All multivariate analysis was performed using the SIMCA 
13.0 statistical package (Umetrics, Sweden). Further discussion of multivariate techniques can be 
found in chapter 2. 
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3.4.5 Metabolite Identification 
Metabolites recognised as being important in the multivariate models were identified using a 
combination of techniques. Initially Statistical Total Correlation Spectroscopy (STOCSY) using an in-
house script MatLab 2013 (MathWorks, Massachusetts, USA) was used to look for peak correlation 
within the acquired spectra. Further metabolite structure could be confirmed using a combination of 
2D experiments, J-Res, COSY and TOCSY, performed on selected samples. Metabolites were then 
found in the SBASE data base using AMIX 3.9.11 software (Bruker BioSpin) or in published literature.  
3.5 Results 
3.5.1 Patients 
Thirty three patients, that fulfilled the criteria defined in chapter 2, had either adequate serum or 
urine samples or both for 1H-NMR analysis. Of those with serum samples, 12 had pneumonia on 
admission and 21 had brain injuries with no suggestion of pneumonia when the first serum sample 
was taken. Of those with urine samples 13 had pneumonia and 20 brain injuries when the first 
samples were taken. The discrepancy in the number of cases and controls between the serum and 
urine reflects differences in the samples available from the patients recruited. Five brain injured 
patients went on to develop VAP based on CPIS scoring. As previously described in chapter 2, 
patients with borderline CPIS scores were reviewed by an independent clinical assessor and 
classified as non-infected, pneumonia or VAP based on clinical course. Based on this assessment a 
further five brain injured patients were classified as not having pneumonia on admission, four 
patients were defined as pneumonia and two as VAP. All initial comparisons were made with the 
original grouping of patients based on CPIS. Clinical features of these patients can be seen in table 
3.1.  
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Table 3.1. Clinical features of included patients with a) serum and b) urine for NMR analysis. 
Continuous variables are given as mean and standard deviation and categorical variables as number 
and percentage. P-values presented in bold text relate to parameters that were significant at the 
p<0.05 level. The clinical parameters compared were taken from the 24h prior to 8:00 am on the day 
of sampling, for the pneumonia and brain injured patients this was time point 0 and for cases of VAP 
this was the 24h prior to the sample taken soonest after the onset of VAP. 
a. 
 Pneumonia (P) Brain Injury (BI) p-value 
(BI vs P) 
VAP p-value 
(BI vs VAP) 
N 12 21 - 5 - 
Age (Mean +/- SD) 53.5±17.2 52.3±14.9 0.84 50.8±17.2 0.87 
Sex, Number of males (%)  9 (75) 12 (57.1) 0.46 3 (60.0) 1.00 
Ethnicity, number  White 
European (%) 
8 (66.7) 15 (71.4) 1.00 4 (80.0) 1.00 
Outcome, Number alive (%) 7 (58.3) 16 (76.2) 0.43 3 (60.0) 0.59 
APACHIE II Score (Mean +/- SD) 19.8±6.5 17.0±6.0 0.22 17.8±9.4 0.86 
SOFA Score (Mean +/- SD) 10.1±3.3 8.9±2.6 0.29 8.6±3.1 0.87 
CPIS (Mean +/- SD) 5.8±1.1 2.14±1.4 <0.001 7±1.6 <0.01 
Lowest WCC (109/L) (Mean +/- 
SD) 
15.8±7.9 10.0±3.8 0.03 10.5±3.2 0.76 
Highest WCC (109/L) (Mean +/- 
SD) 
16.4±7.6 11.2±3.9 0.04 10.5±3.2 0.70 
Lowest CRP (mg/L) (Mean +/- SD) 154.5±94.0 49.4±54.2 <0.01 116.7±28.2 <0.01 
Highest CRP (mg/L)(Mean +/- SD) 174.4±87.9 62.0±52.5 <0.01 116.7±28.2 <0.01 
Lowest Temperature (°C) (Mean 
+/- SD) 
35.7±0.8 36.0±0.7 0.30 36.0±1.6 0.95 
High Temperature (°C) (Mean +/- 
SD) 
37.7±1.0 37.6±0.7 0.67 38.0±1.3 0.45 
Lowest FiO2 (Mean +/- SD) 0.45±0.2 0.39±0.2 0.42 0.36±0.1 0.51 
Lowest PaO2:FiO2 (Mean +/- SD) 24.9±9.5 41.8±15.5 <0.001 18.6±8.5 <0.001 
Lowest MAP (mmHg) (Mean +/- 
SD) 
72.7±10.2 74.0±11.3 0.72 71.0±12.4 0.64 
Use of noradrenaline, N (%) 8 (66.7) 13 (61.9) 1.00 1(20.0) 0.15 
Use of antibiotics N (%) 12 (100) 10 (47.6) <0.01 5 (100) 0.05 
Enteral nutrition, N (%) 11 (91.7) 15 (71.4) 0.22 5 (100) 0.298 
Time to sampling from start of 
ventilation (h) (Mean +/- SD) 
44.3±10.1 40.1±16.9 0.37 143.4±44.9 <0.01 
Time of day of sample, Number 
taken in the morning (%) 
8( 66.7) 13 (61.9) 1.00 5 (100) 0.28 
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b. 
 Pneumonia (P) Brain Injury (BI) p-value 
(BI vs P) 
VAP p-value 
(BI vs VAP) 
N 13 20 - 5 - 
Age (Mean +/- SD) 53.5±16.5 53.6±13.9 0.98 50.8±17.2 0.75 
Sex, Number of males (%)  9 (69.2) 11 (55) 0.49 3 (60.0) 1.00 
Ethnicity, number White 
European (%) 
9 (69.2) 15 (75) 1.0 4 (80.0) 1.00 
Outcome, Number alive (%) 8 (61.5) 15 (75) 0.46 3 (60.0) 0.60 
APACHIE II Score (Mean +/- SD) 19.6±6.3 16.9±6.1 0.22 17.8±9.4 0.84 
SOFA Score (Mean +/- SD) 10.2±3.2 8.8±2.7 0.20 8.6±3.1 0.92 
CPIS (Mean +/- SD) 5.8±1.0 2.2±1.4 <0.001 7.0±1.6 <0.01 
Lowest WCC (109/L) (Mean +/- 
SD) 
15.8±7.5 9.8±3.8 0.02 10.5±3.2 0.65 
Highest WCC (109/L) (Mean +/- 
SD) 
16.4±7.3 11.0±3.9 0.03 10.5±3.2 0.78 
Lowest CRP (mg/L) (Mean +/- SD) 165.7±98.7 48.6±55.5 <0.01 116.7±28.2 <0.01 
Highest CRP (mg/L)(Mean +/- SD) 184.1±91.3 61.8±53.8 <0.001 116.7±28.2 <0.01 
Lowest Temperature (°C) (Mean 
+/- SD) 
35.8±0.8 36.0±0.7 0.46 36.0±1.6 0.95 
High Temperature (°C) (Mean +/- 
SD) 
37.7±1.0 37.6±0.7 0.70 38.0±1.3 0.47 
Lowest FiO2 (Mean +/- SD) 0.44±0.1 0.40±0.2 0.57 0.36±0.1 0.42 
Lowest PaO2:FiO2 (Mean +/- SD) 24.0±9.7 41.4±15.7 <0.001 18.6±8.5 <0.001 
Lowest MAP (mmHg) (Mean +/- 
SD) 
71.7±10.4 74.0±11.6 0.56 71±12.4 0.64 
Use of noradrenaline, N (%) 9 (69.2) 12 (60) 0.72 1 (20.0) 0.16 
Use of antibiotics N (%) 13 (100) 9 (45) <0.01 5 (100) 0.05 
Enteral nutrition, N (%) 12 (92.3) 14 (70) 0.2 5 (100) 0.29 
Time to sampling from start of 
ventilation (h) (Mean +/- SD) 
43.5±11.4 40.8±17.3 0.59 144.6±45.4 <0.001 
Time of day of sample, Number 
taken in the morning (%) 
5 (39) 9 (45) 1.00 5 (100) 0.046 
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Patients were similar across the groups with respect to their demographic details. Features that 
identified the pneumonia and VAP groups from those with brain injuries included markers of 
infection such as CRP, white cell count, use of antibiotics and the higher oxygen requirement as 
would be expected in patients with pulmonary infection. 
3.5.2 Serum 
3.5.2.1 10 Minutes vs 15 Minutes of Centrifugation 
Whilst processing the first batch of serum samples collected from this critically ill population it 
became apparent that some of the stored aliquots contained substantial amounts of clot when 
thawed providing insufficient serum for NMR analysis.  In order to prevent further loss of data from 
the 30th patient recruited serum samples were collected in duplicate, one centrifuged for the 
standard 10 minutes and a second sample collected simultaneously that was centrifuged for an extra 
5 minutes to try to provide a greater volume of supernatant that could be used if the 10 minute 
sample proved inadequate. 
In order to ensure that there were no systematic differences between those samples that were 
centrifuged for 15 minutes compared to those that had the original 10 minutes a PCA was 
constructed for all patients who had paired samples spun for both lengths of time, figure 3.1. This 
demonstrated that there was no natural clustering of samples from the two groups with samples 
from the same patient and time point generally lying close together. It was not possible to construct 
an OPLS-DA model to differentiate the two groups as the Q2Y remained negative (R2Y 0.62 Q2Y -0.77). 
The results of this analysis suggested that the use of aliquots centrifuged for 15 minutes alongside 
those that were centrifuged for 10 minutes would be possible when a 10 minute duration provided 
insufficient serum for analysis for a given patient. 
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Figure 3.1 PCA scores plot comparing serum samples centrifuges for 10mnutes vs 15 minutes prior to 
freezing, paired samples only  (R2X 0.48, Q2X  0.32). Green circles – 10 minutes in the centrifuge, blue 
squares – 15 minutes in the centrifuge, red rings indicate examples of paired samples. It is not 
possible to form an OPLS-DA model to separate the two groups (R2Y 0.62, Q2Y -0.77).      
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3.5.2.2 Brain Injury vs Pneumonia 
The 21 patients who had no evidence of pneumonia based on CPIS when the first serum sample was 
taken were compared to the 12 patients who had pneumonia at the time of sampling. Initial PCA 
showed that there were two patients from the brain injured group who were outliers as defined as 
lying outside of the Hotelling’s ellipse (multivariate approximation to the 95% confidence interval 
derived for the Students’ t test), figure 3.2. Of these two patients one was a more extreme outlier 
than the other which sat near the ellipse. When the raw spectra of these two samples were 
examined there were no technical differences that could be seen leading to them being outliers. The 
predominant differences between these samples and the others were that the furthest outlier, at 
the extreme left of the plot, demonstrated high levels of the ketone bodies, 3-hydroxybutyric acid 
and acetoacetic acid, that were not seen in the other patients, figure 3.3. These findings fit clinically 
with the presentation of this patient who had been drinking heavily before attending hospital after a 
fall and head injury and in whom it took some time to establish feeding. When all of the samples 
from this patient were examined over time the levels of ketone bodies could be seen to fall as 
feeding was established. The second outlying spectrum was associated with some broad signals in 
the 5.75-5.38 ppm region that are yet to be identified as well as pronounced glucose and mannitol 
peaks. This patient was given mannitol prior to enrolment for control of intracranial pressure. As 
there were no gross technical reasons for these samples to be outliers they have been kept in all 
further analysis.     
If the third and fourth components of this model were examined some separation between the two 
groups (pneumonia vs brain injury) could be seen along the third component although there 
remained a large degree of overlap, as is expected with human populations subject to a high degree 
of genetic and environmental diversity. 
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Figure 3.2 PCA scores plot comparing samples taken from patients with brain injuries, blue circles, and patients with pneumonia, red squares, at the start of 
ventilation (R2X 0.31 Q2X 0.05). The ellipse represents Hotelling’s T2 at p=0.05 a) first and second components showing no natural separation between the 
two groups in either component, two of the brain injured patients are outliers as demonstrated by lying outside the Hotelling’s ellipse, numbered, b) some 
separation can be seen between the groups when the second and third components are examined, the majority of the separation is along component 3, y-
axis.  
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Figure 3.4. OPLS-DA model with one orthogonal component comparing patients admitted with brain injuries, blue circles, to those with pneumonia, red 
squares, at the start of ventilation (R2Y 0.95 Q2Y 0.37 p= 0.01) a) before and b) after cross validation. Before cross validation the groups can be seen to be 
separated with pneumonia samples separated in the positive direction along the first component. After cross validation this separation is less with several 
samples crossing between groups.   
 
  a. b. 
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Supervised models with OPLS-DA (R2Y 0.95 Q2Y 0.37 p= 0.01), figure 3.4, and a PLS-DA (R2Y 1.0 Q2Y 
0.78) could be built to separate the two groups of patients. However, the PLS-DA model required 
four components in order to achieve this level of predictive capacity, reflecting the extreme variation 
in this dataset. After cross validation of the OPLS-DA model several patients could be seen to move 
between the groups. One pneumonia patient was misclassified as a brain injury after cross 
validation. Interestingly although this patient had features of pneumonia on admission with chest x-
ray changes, a high white cell count, pneumococcus isolated from the sputum and an initially high 
oxygen requirements they showed a rapid clinical improvement and were extubated rapidly. Four of 
the 21 brain injured patients were misclassified as pneumonia. Of these one went on to develop VAP 
as defined by CPIS, one did not develop a CPIS high enough to define VAP but was classified as such 
by an independent assessor and two never showed evidence of VAP, although one of them had an 
acinetobacter species isolated from their sputum. 
When the model was validated with the nine patients that had samples taken at the first time point 
who initially had borderline CPIS and were classified by an independent assessor the model had a 
sensitivity of 0.5, specificity of 1.0, positive predictive value of 1.0 and a negative predictive value of 
0.71. The metabolites identified as being important in causing the separation in this model can be 
seen in figure 3.5 and 3.6.  Many of the metabolites that seem to be important in this comparison 
appear to be lipid species along with contribution from the amino acids phenylalanine and alanine 
and also formate. 
  If only those brain injured patients who did not go on to develop VAP were considered as a 
comparison group to those with pneumonia at the time of sampling the OPLS-DA model did not 
improve (R2Y 0.96 Q2Y 0.32 p= 0.11) and if validated with the independently assessed patients there 
were no improvements in the model summary statistics, sensitivity 0.75, specificity 0.6, positive 
predictive value 0.6 and negative predictive value 0.75. Within this model the same metabolites   
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Figure 3.5. OPLS-DA regression coefficient plot coloured according to the correlation between the metabolic NMR data and the class information relating to 
supervised multivariate statistical analyses from figure 3.4. Metabolites dominating in the pneumonia group deflect upwards and in brain injuries 
downwards. The strength of the correlation of metabolites to this model is given by the intensity of the colour of the peak with red representing the 
strongest correlation and dark blue no correlation. Figure 3.6 zooms in on important areas of the spectrum with important metabolites labelled.    
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caused most of the separation as with the previous model taking all brain injured patients with lipid 
species, alanine and formate seeming to be of greatest importance. 
3.5.2.3 Brain Injury vs VAP 
When a three component PCA (R2X 0.34 Q2X 0.04) was constructed to explore the comparison of the 
21 patients with brain injury but no evidence of pneumonia to the samples taken from the five 
patients who developed VAP at the time that the infection developed no clear separation could be 
seen along any components. The same patients whose samples were outliers in the previous PCA 
models remained similarly placed. An OPLS-DA model with one orthogonal component (R2Y 0.94, 
Q2Y 0.07, p=0.8), figure 3.7, had only a very limited ability to separate those with VAP from brain 
injuries at the time point of admission. After cross validation several brain injured patients were 
miss-classified as VAP including the same brain injured patients that were miss-classified as 
Pneumonia in the earlier model comparing brain injuries to pneumonia. The VAP patient that most 
closely approached the brain injury group was the earliest to be diagnosed with VAP out of the five 
patients. The sample used for this patient was taken as the CPIS was rising as the peak CPIS occurred 
on a time point in an interval between the 48hly samples, perhaps missing the peak of the metabolic 
changes associated with VAP. When this model was used to classify the next sample taken from this 
patient it falls well within the VAP group suggesting metabolic changes are developing in the initial 
sample. 
When only brain injured patients who did not go on to develop infection were taken as the control 
group the predictive capacity from cross validation improved to a Q2Y of 0.16 (R2Y 0.98, Q2Y 0.16, 
p=0.70). Similarly, when a larger group of patients was taken that combined the original patients 
classified via CPIS with those classified by an independent clinical assessor the model also marginally 
improved (R2Y 0.94, Q2Y 0.27, p=0.055) when all brain injured patients were taken and to a greater 
degree when only those without infection at the first time point were taken (R2Y 1.0, Q2Y 0.53,  
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Figure 3.7 OPLS-DA model with one orthogonal components comparing serum from patients admitted with brain injuries at the start of ventilation, blue 
circles, to serum from those who developed VAP at the time infection developed, green triangles, (R2Y 0.94, Q2Y 0.07, p= 0.8) a) before and b) after cross 
validation. Before cross validation the groups can be seen to be separated with VAP samples distributed in the positive direction along the first component. 
After cross validation this separation is less with several samples crossing between groups.   
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p=0.37).  However, the metabolites causing separation between brain injured patients with VAP and 
those at admission were similar between all of the above comparisons, figure 3.8, with lipids, 
glycoproteins and some amino acids such as phenylalanine leading to the separation between 
groups. 
3.5.2.4 Time Course 
As any metabolic changes seen when samples taken from patients with brain injuries at the start of 
ventilation were compared to those when VAP developed could have been related to the length of 
stay on intensive care as opposed to the development of infection further analysis was performed 
on sequential time points from the brain injured patients who did not go on to develop VAP.  When 
OPLS-DA was used to compare the first time point to the fourth time point some, although limited, 
separation was seen when both the original groups based on CPIS (R2Y 0.98, Q2Y 0.11, p=0.82) and 
combined groups including the independently classified patients (R2Y 0.99, Q2Y 0.09, p=0.96) were 
used, although in neither case did the models reach statistical significance, possibly due to the small 
group sizes in these comparisons. Although few of the metabolites had a particularly strong 
correlation in these models, figure 3.9, there was a trend for phenylalanine and acetyl groups from 
glycoproteins to increase over time and glucose, citrate, and glutamine to decrease. When the first 
time point was compared to either time point two or three, the metabolic changes were less marked 
suggesting that the changes seen between time point one and four were gradual over the course of 
the ICU stay and did not happen rapidly, for example after treatment was commenced.   
When the patients admitted with pneumonia were examined over the course of their stay an OPLS-
DA model with only one component (R2Y 0.70, Q2Y 0.10, p=0.44) comparing the first time point to 
the last time point demonstrated that there were strongly correlated changes in lipid signals over 
time with all lipid regions tending to increase with glucose, again, showing a tendency to fall, figure  
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3.10. However, when only paired samples, those patients who had samples from both time point 
one and four, were used the strength of the correlation of the lipid signals diminished although the 
trends remained. Although the correlation was not as strong in this cohort of patients, phenylalanine 
appeared to reduce over time in contrast to the trend seen in the brain injured patients. If the fourth 
time point samples from brain injured patients were compared to the same time points from 
patients with pneumonia an OPLS-DA model (R2Y 0.99, Q2Y 0.20, p=0.81) demonstrated that at this 
time during ICU stay lipids tended to be higher within the pneumonia patients compared to those 
with brain injuries. 
When the fourth time point from brain injured patients who did not develop VAP was compared to 
the time point where VAP developed in the infected patients it was not possible to construct an 
OPLS-DA model that would separate the groups (R2Y 0.93, Q2Y -0.38). However, if the combined 
group of patients, including those classified by an independent assessor, was used a positive Q2 was 
obtained (R2Y 1.0, Q2Y 0.28, p=0.73). In this model, figure 3.11, few metabolites had a co-efficient of 
correlation much above 0.5. Those metabolites that were most strongly correlated with one or other 
disease class were phenylalanine which remained higher in the VAP group and glucose and alanine 
which were higher in those that did not go on to develop VAP. 
Using the original group based on CPIS or the combined group using the independently classified 
patients it was not possible to build an OPLS-DA model that would distinguish the time that VAP 
developed from the first sample taken when these patients were admitted to intensive care with the 
Q2 never being positive (R2Y 0.92, Q2Y -0.10). 
 
????
?
?
?
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ??????????????????
???? ???? ?????? ???????????? ????????? ??? ???????????????????????? ???????????? ????????? ?????????? ????????? ?????????????? ?????? ????????????? ???? ???? ??? ??? ???
??????????????????????? ???????? ?????????????? ????????????????????????????????????????????????????????????????????????????????????? ?????????????????
?????????????????????????????????? ????????????????????????????????????????????????????????? ??????????????????? ?????????????????????????????????????????????
???????????? ?????????????????????????????????????????????????????????????????????????????
113 
 
 
 
Figure 3.12 One component PCA analysis comparing urine samples taken from patients with brain injuries, blue circles, and patients with pneumonia, red 
squares, at the start of ventilation (R2X 0.19 Q2X 0.06). The first component is given on the y-axis against the sample number, x-axis. Three outliers can be 
identified, two from the brain injury group and one from the pneumonia group as can be seen with the three points lying below the 2 SD line. No clear class-
related separation can be seen along the first component of the remainder of the samples.  
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3.5.3 Urine 
3.5.3.1 Brain Injury vs Pneumonia 
Initial comparison, with PCA, of the 20 brain injured patients with the 13 pneumonia patients who 
had urine samples taken at the first time point following the onset of ventilation demonstrated three 
outliers, figure 3.12. When these outliers were examined, figure 3.13, no clear technical differences 
could be seen leading to these samples being outliers. Instead there seemed to be differences in 
both the presence of some metabolites and the quantities of others.  As there were no technical 
reasons to omit these patients they were included in further analysis. 
When an OPLS-DA model was made of this data, figure 3.14, (R2Y 0.83, Q2Y 0.37, p=0.009) it had a 
sensitivity of 0.75, specificity of 0.8,  positive predictive value of 0.75 and negative predictive value 
of 0.8 after validation with the independently classified patients,  four with pneumonia and five with 
brain injuries. If only those patients who did not go on to develop VAP were used the model had a 
similar performance (R2Y 0.92, Q2Y 0.45, p=0.08) at cross-validation. In case the outliers identified in 
the PCA were exerting a disproportional effect on the model it was repeated excluding these three 
patients. With this model the general pattern remained the same with similar model statistics (R2Y 
0.97 Q2Y, 0.33, p=0.13).  
The metabolites that caused the majority of the separation, figure 3.15, were more difficult to 
characterise than in the serum models due to marked heterogeneity of the urine samples. Of those 
metabolites identified creatinine excretion appeared higher in the brain injury group. When the 
clinical data was examined, although there was no significant difference between the two groups, 
there is a trend to the serum creatinine to be higher in the pneumonia patients (91.9±71.5 vs 
74.3±22.6 µmol/l, p=0.33) with similar average hourly urine output within the 24h prior to sampling 
(113.3±59.0 vs 130.4±99.9 ml/h, p=0.55). This data may represent a lower creatinine clearance  
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Figure 3.14 OPLS-DA model with one orthogonal components comparing urine from patients admitted with brain injuries at the start of ventilation, blue 
circles, to urine from those with pneumonia, red squares, (R2Y 0.83 Q2Y 0.37 p= 0.009) a. before and b. after cross validation. Before cross validation the 
groups can be seen to be separated with pneumonia samples distributed in the positive direction along the first component, even before cross validation one 
of the brain injury patients can be seen to fall within the pneumonia group. One of the pneumonia samples can be seen to be on outlier along the orthogonal 
component, y-axis. After cross validation this separation is less with several samples crossing between groups, especially with brain injured patients being 
miss-classified as pneumonia. 
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associated with pneumonia and infection. Also when serum levels of lactate close to the time of 
sampling were compared there was no significant difference between the groups (1.43±0.91 vs 
1.26±0.50 mmol/l, p=0.54). 
3.5.3.2 Brain Injury vs VAP 
PCA of the urine samples taken from the brain injured patients at the point of admission to ICU and 
those taken at the time that VAP developed  (R2X 0.311, Q2X 0.02) demonstrated the same outliers 
as when the brain injured patients were compared to those with pneumonia but with no clear 
separation of the samples into groups. OPLS-DA was also unable to separate the two groups (R2Y 
0.61, Q2Y -0.08) even if a combined patient group was used (R2Y 0.51, Q2Y -0.09). However, if only 
those patients who did not get VAP were used as controls the Q2 of the model improved (R2Y 0.90, 
Q2Y 0.33, p=0.31). When the metabolites causing separation in this model were examined very few 
had strong correlations with either group and those that did appeared to be present in only one or 
two of the samples analysed. This indicated the impact on the model that a few metabolites may 
have if present in large quantities in a few samples. The fact that these metabolites were not 
universally present raised the possibility that they may arise from an exogenous source such as drugs 
that were not universally administered to all patients or that were metabolised differently in 
different patients producing differing metabolic profiles. 
3.5.3.3 Time Course 
When the urine samples collected at the first time point, n=11 from those patients with brain 
injuries who did not develop VAP were compared to those from the fourth time point, n=5, using 
OPLS-DA (R2Y 0.91, Q2Y 0.31, p=0.36), figure 3.16, the metabolites that could be identified that 
seemed to separate the two groups were often related to medication metabolites such as 
paracetamol-glucuronide and mannitol. The metabolic changes observed seemed to be gradual as it  
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was not possible to build predictive models to separate time point one from either time point two or 
three. When the same comparison, of time point one and four, was made for the patients who were 
admitted with pneumonia (R2Y 0.47, Q2Y 0.02, p=0.82) the model had only a minimal predictive 
capacity. However, the metabolites associated with this model had much stronger correlations with 
the groups, figure 3.17. Several metabolites were strongly associated with time point one, however, 
of those that were identifiable several appeared to be drugs or their metabolites. The fact that many 
of the peaks were not clearly identifiable when compared to metabolites contained within the 
database may imply that they were also related to drug metabolism and not naturally occurring 
metabolites. 
When the urine samples taken when brain injured patients developed VAP were compared to 
samples taken at a similar time from those who did not go on to develop infection an OPLS-DA could 
be constructed (R2Y 0.74, Q2Y 0.29, p=0.30), figure 3.18, with a number of strongly associated 
metabolites. If the combined group of patients was used to construct the model the Q2Y rapidly 
diminished (R2Y 0.61, Q2Y 0.04, p=0.78) although the pattern of metabolite changes appeared similar 
warranting further investigation of the potential of these metabolite as classifiers. However, as with 
the previous models the metabolites in question were difficult to identify and some of them 
appeared to be related to drug metabolites. 
Looking only at the brain injured patients who developed VAP during their stay, an OPLS-DA model 
based on the original group was unable to differentiate the time that VAP developed from the initial 
time point after admission (R2Y 0.87, Q2Y -0.12). If, however, the combined group was used the Q2Y 
improved (R2Y 0.55, Q2Y 0.10, p=0.49) although the spectral region most strongly associated with 
this model was that associated with mannitol suggesting that we were not seeing genuine 
differences due to disease but associated treatments. 
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3.5.3.4 Treatment Effect 
As illustrated in the last examples, the fact that many drugs are excreted via the urine risked these 
models showing effects based, not on differences due to pathology, but due to the effects of 
treatments that may be more common in one or more of the groups. 
In an attempt to address this problem a correlation matrix was constructed to correlate the samples 
taken whilst patients were on each documented drug with the urine 1H NMR spectra. This allowed 
peaks that seemed important in discriminant models to be correlated with drug data to try to 
establish if they were potentially related to treatment as opposed to disease.  
Also the rates of drug use in each group were compared. OPLS-DA models were constructed 
comparing samples taken whilst patients were on a given drug with those taken in the absence of 
the drug for drugs where there was a difference of more than 20% in the use of a drug between 
groups of clinical interest. Where discriminant models could be built loadings from these models 
were inspected in an attempt to identify metabolites that were associated with a given drug, figure 
3.19. Since the number of drugs collectively given to these patients exceeded 220 then detailed 
assignment of all drugs and their urinary metabolites was not practical.  
Spectral features that appeared to be commonly connected to particular drugs or that were found 
by database searching, such as mannitol, that appeared important in comparisons that had 
previously been made could then be digitally removed from the spectra and the models 
reconstructed.  
If the OLS-DA model comparing patients with brain injuries and pneumonia was reconstructed with 
the peaks from mannitol and those that were associated with both Tazocin and Meropenem use 
removed the overall Q2Y remained similar (R2Y 0.87, Q2Y 0.33,  p=0.02) to the model produced  
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Figure 3.19. OPLS-DA, with one component, (R2Y 0.63, Q2Y 0.50, p<0.001) comparing metabolic NMR data from urine samples from patients receiving the 
antibiotic tazocin, red bars, with those not on antibiotics, yellow bars. a. Scores plot for the comparison with b. the regression coefficient plot for the OPLS-
DA model with those peaks deflected downwards representing those more abundant in patients receiving tazocin, the colour of the peaks representing the 
strength of the association. c. STOCSY regression co-efficient plot showing the statistical correlation of the peak at 7.48ppm with all other peaks in the 
spectra, across all urine samples. The strength of correlation is given by the colour of the peaks. The most strongly correlated peaks coincide with those 
discriminating patients receiving tazocin in figure 3.19b. 
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earlier. Examining the loading of this model suggested that creatinine excretion remained higher in 
the brain injured group whilst lactate excretion was higher in the pneumonia group.  
3.6 Discussion 
The data in this chapter examine the ability of 1H NMR spectroscopy of serum and urine from 
patients on intensive care to differentiate patients with and without pneumonia.   Previously there 
has been limited work focussing on 1H NMR spectroscopy of biofluids from critically unwell patients. 
Specifically a limited number of studies have explored metabolic profiles of urine (260, 261) with a 
slightly greater number of studies examining blood, either serum or plasma, (100, 101, 145, 148, 
157, 262-264) with one focussing on a paediatric population (148).  
Models based on serum data have a moderate ability to differentiate pneumonia from brain injury at 
the first time point after enrolment. Several of the metabolites seen to be causing separation 
between patients with and without pneumonia appear to be lipid species. This is in keeping with 
animal work done looking at Klebsiella pneumoniae infection (149) where lipids were found to be 
elevated in infected animals’ plasma. Similarly in an animal model of Chlamydia Pneumonia (265) 
alterations in lipid profiles were found to be induced after inoculation of mice with the infecting 
organism, specifically acute and transient reduction in cholesterol levels. More generally lipids play 
an important role in sepsis with fatty acids being elevated in non-survivors (266). Other forms of 
inflammation are also associated with alteration in lipid profiles, experimental administration of 
endotoxin to human subjects has been seen to induce secretory phospholipase A2 and alter high 
density lipoprotein (HDL) composition (267). Within critical care populations alterations in circulating 
lipids have been seen to differentiate chronic from acute liver failure (262) and higher cholesterol 
levels have been associated with survival in heart failure (263). An animal model of ventilator 
associated lung injury found that using MS analysis of serum lipids distinct lipid profiles could be 
found for animals with and without lung injury (268). In a Swiss observational study patients with 
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bacterial CAP had lower total, HDL and low density lipoprotein (LDL) cholesterol and higher 
triglyceride concentrations than those without bacterial CAP (269) and similar changes in cholesterol 
were found in a Turkish study that compared patients with CAP to controls (270) with negative 
correlation being seen between cholesterol levels and the extent of radiographic pneumonia. Within 
this study a similar trend was seen with HDL levels being lower in those with pneumonia than in 
those with brain injuries. Total and HDL cholesterol and apolipoproteins A1 and B were reduced in 
the acute infective process in another observational study (271) with triglyceride levels increasing in 
those with atypical bacterial pneumonia. In children with complicated pneumonia apoliporotein A 
levels have also been seen to fall in acute infection (272). In chronic Chlamydia Pneumonia infection 
(273) triglyceride levels have been seen to rise and HDL cholesterol levels fall in comparison to 
uninfected individuals.  
Of course changes in the lipid profiles may not entirely be related to one of the groups having the 
presence of infection, it may be that alterations to serum lipids may tell us something about those 
patients who have sustained brain injuries. In one small study apopliporotein A4, amongst several 
proteins, was found to be reduced in those patients with subarachnoid haemorrhage who went on 
to develop vasospasm (274) and in another it has been suggested that first degree relatives of 
patients with aneurysmal subarachnoid haemorrhage who have elevated lipoprotein A need further 
follow up due to the increased risk of aneurism formation (275). Across a group of patients with 
cerebrovascular disease of differing aetiologies total and LDL cholesterol were higher than in the 
serum of controls where as HDL cholesterol decreased (276) but in a large observational study 
neither levels of cholesterol nor triglycerides were associated with the risk of aneurysmal 
subarachnoid haemorrhage (277) and in a Japanese case control study both HDL cholesterol and 
triglycerides were found to be lower in patients with subarachnoid haemorrhage (278). No 
significant risk was associated with HDL cholesterol, triglycerides, lipoprotein or apoprotein A1  
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when relatives of patients with subarachnoid haemorrhage were screened for the presence of 
aneurysms (279). 
Lipids may be elevated in the critically ill for a number of reasons. Not only do they provide a readily 
available source of energy but they may also have a role in regulating the immune response, for 
example they may have a protective effect by binding endotoxin (149, 280).  
 I also found that formate appeared elevated in those patients with pneumonia. Although formate 
has not previously been noted as a metabolite associated with pneumonia work it has been seen to 
be reduced in experimental models of sepsis (128, 129). At present it is unclear why there may be 
differences in the levels of formate in our pneumonia patients and in sepsis models, however, it may 
reflect differences in its oxidisation to carbon dioxide in the two groups. Differences may exist 
between animal models and the way in which formate is metabolised in critically unwell human 
subjects. It may also be the case that these animal models of septic shock are not comparable with 
the pneumonia population, many of which had infection and sepsis but not severe sepsis or septic 
shock. 
The other metabolites that discriminated patients with pneumonia from those with brain injuries 
were amino acids, especially phenylalanine, alanine and glutamine with the latter two being reduced 
in the pneumonia population and phenylalanine being increased. Phenylalanine has also been seen 
to be elevated in critically ill patients with acute compared to chronic liver failure (262) and both 
adults (145, 281) and children (148) with sepsis. Phenylalanine may be elevated in inflammatory 
conditions for a number of reasons. There may be a reduction in the conversion of phenylalanine to 
tyrosine, for example because of an increase in oxidative stress (282) or as a direct result of immune 
activation (283, 284). Alterations in the catabolism of skeletal muscle and the subsequent release of 
amino acids into the serum may also be responsible for differences in phenylalanine concentration 
in different conditions (284). 
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Although alanine has been seen to be increased in an animal model of sepsis (128) levels in adults 
with sepsis have been seen to be reduced as with the pneumonia patients in this study (145, 281) as 
they have in older children with SIRS (148). Similarly glutamine levels have been found to similarly 
reduce in both children (148) and adults (281) with sepsis in a similar fashion to these pneumonia 
patients. These changes may reflect alterations in nutritional status in these conditions or the 
alteration in the release of amino acids from muscle proteins.   
Comparison of this data to the limited amount of work that has been carried out using profiling of 
serum in pneumonia finds a number of differences. Work in Influenza A (258) found mainly 
inflammatory molecules such as prostaglandins and leukotrienes as well as a number of amino acids 
in samples taken prior to recovery. Similarly MS analysis of plasma from children with pneumonia in 
Africa (153) found elevated uric acid, hypoxanthine and glutamic acid levels with decreases in ADP 
and L-tryptophan. Finally data from a group of patients on ICU (155) with sepsis associated with 
community acquired pneumonia showed higher levels of bile acids, metabolites of steroid 
metabolism and those related to oxidative stress in non-survivors. The differences in these studies 
compared to the current data may be for a number of reasons. Some differences may arise from 
alterations in the metabolic response to viral infection compared to bacterial pneumonia, the 
differences between studies looking at single causative agents compared to multiple agents as in this 
work or general differences in study populations such as the differences between comparing 
survivors to non-survivors compared to comparisons of infected with non-infected Individuals. All of 
the above studies used MS based platforms where as we used NMR. Not all metabolites are 
detected by NMR so a future step in the metabonomic assessment of patients in critical care with 
pneumonia would be to apply an MS based profiling methodology to extend the number of 
metabolites detected. 
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Although the models attempting to differentiate patients who developed VAP from those with brain 
injuries were not able to discriminate infected from non-infected patients as well as the models 
exploring patients admitted with pneumonia some of the metabolic changes were similar. 
Phenylalanine and phospholipids were again discriminators in the infected group and some lipid 
species were more dominant in the non-infected group. Within this comparison other metabolites 
that have a closer association with energy metabolism such as lactate and succinate seemed to be 
important.  The differences in metabolic response to pneumonia at admission and to VAP can be 
explained in a number of ways. Firstly patients admitted with pneumonia may have been unwell in 
the community for a variable amount of time prior to admission to the intensive care unit potentially 
resulting in significant differences in their underlying nutritional state when compared to the brain 
injury patients. However, the patients with VAP were all derived from a group of brain injured 
patients who had been on the intensive care unit for roughly similar periods of time prior to 
infection during which time feeding regimens were established. Similarly it is possible that the 
metabolic ‘snapshots’ of the two types of infection occur at different times during the pathological 
process. Those admitted with pneumonia may have been at a later stage in their disease when the 
first sample was taken due to delays caused by recruitment and obtaining consent. These delays 
were not present for the samples taken from patients developing VAP as they had all been recruited 
as brain injured patients prior to the development of infection. Finally it is well known that 
organisms causing VAP are different from those causing pneumonia in the community and it is 
entirely possible that the differences in micro-organisms lead to differences in metabolic response. 
Some interesting differences were seen when the first time point from patients with brain injuries 
was compared to the fourth in those who did not go on to develop VAP. Over time glucose, 
mannitol, creatinine and 3-hydroxybutyrtae levels fell. These changes may represent treatment 
effect such as glycaemic control using intravenous insulin, the use of mannitol to treat raised 
intracranial pressure or its presence within several other drugs such as intravenous paracetamol, the 
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reduction of ketosis by the introduction of feed and the normalisation of renal function with 
adequate hydration. Several amino acids were seen to increase over time including phenylalanine, 
glutamine, lysine, leucine, valine and isoleucine. Such effects may be related to release from skeletal 
muscle or from the constituents of feed. Importantly other than the increase in phenylalanine over 
time the other metabolic changes seen with time were different to those seen in the patients who 
develop VAP suggesting that these changes may be disease related and not a feature of prolonged 
ICU stay. 
Interestingly the metabolic changes seen over time for patients admitted with pneumonia were 
quite different to those seen in brain injured patients. Although there was a similar reduction in 
glucose and mannitol over time there was an increase in several lipid species not seen in the brain 
injured group. This could be explained by the fact that the patients with pneumonia were more likely 
to have undergone a period of reduced oral intake prior to admission and with the establishment of 
feed, lipid levels could be replenished. Another explanation may be differences in the trajectory of 
inflammatory mediators between the two groups. 
Although models could be built using data from urine samples to differentiate pneumonia from brain 
injured patients metabolite identification within urine samples was much more difficult than for 
serum samples which may be reflected in the limited number of studies published using this biofluid 
in similar populations. Spectra obtained from urine were much more heterogeneous than those 
recorded in serum with several metabolites only appearing in a few urine samples where as in serum 
almost all metabolites were consistently present, although in differing concentrations. There are a 
number of possible explanations for the variability of metabolic spectra from urine. Firstly patients 
requiring critical care have a heavy burden of therapeutic drug use that quite easily exceeds 
medication use in other patient populations and animal models of disease studied previously. Within 
our population over 200 types of drug, fluid, blood product and feed were used with patients 
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receiving between five and 34 of these at any time point. Clearly, although some of these drugs will 
have a tendency to be co-administered, the potential number of combinations of drugs is enormous. 
Many of these drugs are either excreted unchanged in the urine or have urinary metabolites. The 
metabolism of these drugs may also be altered by a patient’s clinical condition such as the presence 
of organ dysfunction, especially renal and liver failure, or the presence of other co-administered 
drugs that either interact directly or cause alterations in metabolism, for example by up or down 
regulating hepatic enzymes. As such it is easy to imagine that many of the peaks seen within urine 
spectra actually represent drugs and their metabolites and these may differ from patient to patient 
for any given drug depending on their clinical situation. One of the studies investigating metabolic 
profiles of urine samples obtained from critically unwell patients has also remarked on the presence 
of drug signals in their samples (260). Urine concentration also varies widely between patients, 
especially when there may be a degree of renal impairment. An attempt to address this problem was 
made by normalising the spectra, however, without a substance of known fixed concentration the 
ability to completely account for variation in concentration is impossible. Misrepresentation of the 
concentration of individual metabolites with respect to overall urine concentration may have a 
significant impact on the ability of an individual metabolite to act as a differentiating substance. 
Because of the greater variability of urine samples, for example because of the greater variation in 
urinary pH, natural peak alignment from spectra to spectra was not as good as for serum. This made 
it necessary to implement a further peak alignment step using a mathematical algorithm. However, 
although this step improved overall peak alignment it had the potential to miss-align peaks that 
were in fact from different substances that happened to occur in similar spectral regions reducing 
the ability of these peaks to act as discriminating metabolites. 
For these reasons it was difficult to assess the multivariate models generated from urine data and 
the large number of unidentified metabolites raises the strong possibility that the ability of models 
133 
 
 
 
to discriminate groups was driven, not by genuine disease related metabolic changes, but by 
treatment effects and drug metabolites.  
Much of the previous work exploring the metabonomics of pneumonia has been done using urine 
specimens. However, in this study population none of the same discriminant metabolites were 
found but this may reflect the very different populations under investigation. Metabolic analysis of 
urine in critical care patients poses many challenges that are potentially not a problem in patients in 
the community, for example differences in drug use and presence of organ dysfunction. 
The current work was limited as there are only a small number of patients in each group, especially 
when time courses and VAP were being considered. This may explain why for several of the models 
the p-values are non-significant despite good Q2Y metrics. However, despite the small number of 
subjects the two groups were well matched for most baseline characteristics. These similarities 
limited the influence of confounding features on these models. The only significantly different 
features were those that are considered when making a diagnosis of pneumonia such as 
oxygenation, CRP and CPIS. Interestingly haemodynamic parameters, temperature and white cell 
count were also similar between groups.  
The diagnostic method for pneumonia in this sample was based on the treating consultant’s opinion 
of the underlying disease process refined by the CPIS score. However, in the absence of a gold 
standard by which to make the diagnosis this technique provided a refined group where borderline 
cases should have been excluded perhaps leading to some genuine cases being excluded. 
With the NMR methodology used it is difficult to identify specific lipids and establish which lipid 
species were responsible for group separation making more specific conclusions regarding the role 
of lipids difficult. This could be pursued further with the application of Liquid Chromatography – 
Mass Spectrometry lipidomic analysis. The present data is promising in demonstrating that 
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metabonomic analysis of serum of critically ill patients has the ability to differentiate two clinical 
groups, with and without pneumonia.  
3.7 Conclusion 
1H NMR analysis of serum from critically unwell patients showed an ability to differentiate those 
with pneumonia at admission from those without with a good degree of specificity. These 
techniques may also be beneficial in determining those patients who go on to develop VAP from a 
cohort of patients with brain injuries. The metabolites that differentiated the groups were 
predominantly lipids and amino acids with subtle differences in the metabolic profiles between 
those admitted with pneumonia and those who developed VAP.  
Conclusions that could be drawn from the analysis of urine samples from patients on intensive care 
were much more limited. Although models often appeared to have good predictive capacity the 
heterogeneity of these samples made metabolite identification difficult and raised the concern that 
much of what was seen related to metabolites of the large number of drugs used in critical care and 
not to genuine disease differences. 
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4. SERUM INFLAMMASOME PROFILING 
4.1 Summary 
Both eicosanoids and cytokines have been explored in some detail with regard to their involvement 
in the pathogenesis of a range of inflammatory conditions and sepsis. Limited work has been carried 
out using profiling techniques of either set of mediators alone or in combination to assist in 
diagnosis. This chapter explores profiling ‘the inflammasome’, a panel of eicosanoids measured with 
mass spectrometry and cytokines measured with flow cytometry to distinguish patients admitted for 
ventilation with pneumonia from those with brain injuries and also those patients developing 
ventilator associated pneumonia (VAP) from within those with brain injuries. Both eicosanoid and 
cytokine profiles independently showed some ability to separate pneumonia from brain injury, 
however, this ability was much less when VAP was considered. By combining both cytokine and 
eicosanoid profiles the ability to separate patients with VAP from patients with brain injury could be 
improved indicating the merit of combining metrics from different biological classes. Differentiation 
of VAP was best when equivalent time points post onset of ventilation from patients without VAP 
were considered. Inflammatory mediators identified as causing separation between the groups 
demonstrated biological plausibility based on previous published work. 
4.2 Background 
Eicosanoids, signalling molecules formed from the oxidation of 20-carbon fatty acids, and cytokines, 
a broad range of small signalling proteins produced in a variety of cell types, have both been 
implicated in the pathology of many important diseases ranging from autoimmune conditions such 
as asthma and rheumatoid arthritis to malignancy and sepsis. 
A range of animal studies and clinical observational studies have been performed to investigate the 
role of cytokines in pneumonia. Circulating levels of pro-inflammatory cytokines, such as tumour 
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necrosis factor alpha (TNFα), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-
12 (IL-12), and interferon gamma (IFNγ) have often been found to be elevated in patients with 
community acquired pneumonia (CAP).  For example, a study looking at nearly 2000 patients with 
pneumonia (163) found higher levels of IL-6, IL-10 and TNFα in those CAP patients with severe sepsis 
compared to those without, and higher IL-6 and IL-10 levels in non-survivors compared to survivors. 
In a paediatric population IL-6, IL-8 and IL-10 levels were found to be higher, not only in septic 
patients compared to controls, but also in those septic patients who went on to develop nosocomial 
infections than those who did not (165). Specific micro-organisms, such as mycoplasma, have also 
shown similar patterns of cytokine response (166) with IL-4, IL-6 and IL-10 being higher in 
mycoplasma pneumonia than in controls with levels improving over time. The inflammatory 
response to CAP may not be the same throughout life and may alter with age, for example, IL-8 has 
shown a trend to be elevated at admission in older patients with CAP compared to those younger 
than 50yrs (164).  
A smaller body of work exists looking at the role that fatty acids and their metabolites, eicosanoids, 
have in the pathophysiology of pneumonia. Streptococcus Pneumoniae, a common cause of 
pneumonia, has been shown in models of lung infection to be capable of inducing COX-2 expression 
within lung tissue (161). Specific molecules such as the leukotrienes, especially leukotriene B4 
(LTB4), are thought to be important in protecting the lungs from infection. LTB4 is important in 
chemoattraction and leukocyte activation and may act to increase IL-6 levels (159). Specifically LTB4 
has been associated with pulmonary complications following trauma (160). Other fatty acid 
metabolites, such as the lipoxins, have been implicated in the resolution of pulmonary inflammation. 
Lipoxin A4 can be generated in response to lung injury and has been found in the broncheoalveolar 
lavage (BAL) fluid of patients with several pulmonary diseases including pneumonia (162). One 
proposed mechanism of action of Lipoxin A4 is to inhibit LTB4 mediated chemoattraction. 
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Much of the work looking at these inflammatory molecules has focused on local production within 
the alveoli and lung tissue by looking at BAL fluid and exhaled breath condensate (EBC) levels. For 
example IL-8, LTB4, C4, D4, and E4 have been seen to be at higher concentrations in the BAL fluid of 
pneumonia patients in whom organisms could be detected compared to controls (167). When work 
has been carried out looking at systemic levels of these mediators often only a few mediators are 
measured at a time and usually with a view to looking at mechanistic elements.  
A limited amount of work has been carried out looking at the diagnostic potential of cytokines or 
eicosanoids in pneumonia and a smaller amount of work exists trying to apply a panel approach to 
measuring an array of these inflammatory mediators. One study used a multiplex cytokine assay to 
attempt to diagnose tuberculosis by measuring cytokines produced from stimulated peripheral 
blood mononuclear cells and found IFNγ, interferon gamma inducible protein-10 (IP-10), monokine 
induced by interferon gamma (MIG), TNFα and IL-2 showed the most significant differences between 
active pulmonary tuberculosis patients and healthy controls (168). In another study measurement of 
IL-6 and IL-8 were used in conjunction with other biological and clinical data to attempt to classify  
ARDS cases into groups based on different phenotypes (169).  
In this chapter I outline a strategy for using a panel approach to measuring both metabolites of fatty 
acid metabolism, eicosanoids, cytokines and adhesion molecules to aid the diagnosis of both 
pneumonia and VAP. 
4.3 Aims 
The overall aim of this study was to use profiling techniques on a combination of inflammatory 
mediators including eicosanoids, cytokine and soluble adhesion molecules, here called the 
‘inflammasome’,  to attempt to improve the diagnosis of pneumonia in patients requiring 
ventilation, specifically those going on to develop VAP.  The following questions were addressed: 
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1. Can measuring a panel of eicosanoids improve the diagnosis for both pneumonia and 
VAP in ventilated patients on the Intensive Care Unit? 
2. Can measuring a panel of cytokines improve the diagnosis for both pneumonia and VAP 
in ventilated patients on the Intensive Care Unit? 
3. Can combining these methods improve the diagnostic potential of this approach? 
4.4 Protocols 
4.4.1 Patient Recruitment and Sample Collection 
Patients were recruited and serum samples taken as described in chapter 2. Patients were defined as 
either having pneumonia or a brain injury as described earlier. All patients were followed up over 
time and those brain injured patients developing VAP were identified based on CPIS scoring. For a 
breakdown of the CPIS see chapter 2. Patients with borderline scores were assessed and classified by 
an independent assessor. 
4.4.2 Eicosanoid Measurement 
Serum eicosanoid levels were measured using liquid chromatography coupled to tandem mass 
spectrometric detection (LC-MS/MS) using a targeted method developed internally for the Division 
of Computational and Systems Medicine of Imperial College London in collaboration with Arnaud 
Wolfer. It was designed to quantify 48 eicosanoids by using solid phase extraction of the analytes 
from complex biological matrices such as serum or plasma. The analytes were subsequently eluted in 
a small amount of organic solvent, followed by a chromatographic run optimized to separate all 
metabolites. Following negative electrospray ionization the analytes were selected by m/z, 
underwent collision and the most selective and quantitative product ions were again selected to be 
scanned by the detector.  
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4.4.2.1 Isotopically Labelled Internal Standards (IS) 
Multiple extraction steps introduce variability in analyte recovery post sample preparation, 
with losses of 50% or more depending on metabolite and sample-specific matrix content. In 
order to compensate for variation resulting from the sample preparation steps, seven 
deuterated internal standards (IS), covering each chemical family, were spiked in the serum 
samples prior to extraction. 
Seven deuterated internal standard solutions were combined into a single glass vial to give final 
concentrations of 2ng/µL of each. This stock solution was then further diluted into a working 
solution at a concentration of 300pg/µL with the addition of methanol and water reaching a final 
solvent ratio of 1:1. All standards were stored at -80°C prior to use. 
4.4.2.1 Standard Mixtures 
48 commercial solutions were used to generate standard solutions. 20µL of each eicosanoid was 
added to a single vial and the total volume adjusted to a final volume of 1ml with the addition of 
methanol to give a final concentration of 2ng/µL for each.  
Serial dilutions of this standard mixture were then prepared using a 1:1 water to methanol ratio  to 
give a thirteen point standard curve ranging from 1-10000pg/µL for free fatty acids and 0.1-
1000pg/µL for eicosanoids. A zero sample was also prepared containing only internal standards. 
100µL of each concentration on the calibration curve was added to a separate well on a new 
collection plate and 20µL of labelled internal standard was added to each. Blank samples were also 
prepared comprised of 120µL water/methanol with no internal standards. Once prepared the plate 
containing the calibration curve was stored at 4°C in the Sample Manager of the mass spectrometer. 
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4.4.2.3 Sample Preparation 
Serum specimens were transported on ice prior to analysis and allowed to thaw at room 
temperature. Prior to preparation samples were randomised and prepared in this new order and 
blinded to any clinical information.  
Samples were prepared in a 350µL 96-well collection plate (Waters, Manchester, UK), the 
preparation plate. 100µL of sample was placed in the relevant well and 20µL of IS at 300pg/µL were 
added to each well. The total volume in each well was made up to 150µL with the addition of 30µL 
of 2% formic acid solution in water to break small molecule-protein binding by acidification of the 
sample. The plate was then capped and gently mixed. 
4.4.2.4 Solid Phase Extraction 
Solid phase extraction was carried out using an Oasis Max Solid Phase Extraction (SPE) µElution plate 
(Waters, Manchester, UK). The plate was conditioned by addition of 200µL Methanol to each well. 
The wells were then dried with the use of a vacuum at 3”Hg until dryness was achieved. Liquid was 
collected into a 3ml 96-well ‘waste plate’ (Waters, Manchester, UK). 200µL of high purity, mass 
spectrometry grade, water was then added to equilibrate the sorbent and the wells were again dried 
by application of a vacuum at 5”Hg. 
The samples were then loaded into the SPE plate, limiting the time between sorbent equilibration 
and sample loading to preserve the sorbent quality. 50µL of 1:1 water to methanol solution were 
added to each well of the preparation plate which was capped and mixed before being transferred 
into the SPE plate. The vacuum was applied to the SPE plate at 3”Hg being increased to 5”Hg as 
needed until the wells of the SPE plate were empty, ensuring sufficient time for contact between the 
sample and the sorbent allowing retention of the analytes. 
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The plate was washed with 200µL of 2% ammonium hydroxide to break the hydrogen bonds 
between the eicosanoids and proteins. 5”Hg vacuum was then applied until the wells were dry. 
A further wash with 200µL 1:1 water to acetonitrile solution was applied to each well, to break 
hydrophobic bonding between proteins and the sorbent, and the plate was dried by applying a 
vacuum of 5”Hg. 
The ‘waste plate’ was then removed from the SPE device and replaced with a 350µL 96-well 
collection plate (Waters, Manchester, UK). The analytes were eluted by the addition of 25µL of 
methanol and 2% formic acid. The vacuum was applied at 3”Hg followed by 10-15”Hg for one 
minute. This step was repeated a further three times leaving approximately 100µL in the collection 
plate. 
The collection plate was removed from the SPE device and capped. The elution fraction was allowed 
to evaporate over approximately 2h by the application of a vacuum at 15”Hg. Once the extract was 
dry they were reconstituted with 100µL of 1:1 water to methanol solution. Following reconstitution 
plates were stored at 4°C in the Sample Manager of the mass spectrometer. 
4.4.2.5 Ultra Performance Liquid Chromatography (UPLC) and Mass Spectrometry 
Chromatographic analysis was performed using an Acquity UPLC system (Waters, Manchester, UK). 
Prepared samples and standards were injected onto a HSS T3 UPLC column (100 mm × 1 mm, 1.8 
μm) (Waters, Manchester, UK) at 40 °C with a flow rate of 140 μL/min. The mobile phase A consisted 
of water and 0.1% formic acid and mobile phase B acetonitrile and 0.1% formic acid. The injection 
volume was 5 μL. 
After separation by UPLC, mass spectrometry was performed using a Xevo TQ-S triple quadrupole 
mass spectrometer (Waters, Manchester, UK). In negative ion mode, MS parameters were as 
follows: capillary voltage was set at 2.5 kV, cone voltage was set between 10-40 V depending on the 
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analyte being measured, source temperature 150°C, desolvation temperature 500 °C, desolvation 
gas flow 900 L/h and cone gas flow 150 L/h. All data were collected using MassLynx software 
(Waters, Manchester, UK)  
4.4.2.6 Data Pre-processing 
The same data preprocessing was applied to each 96-well plate and its corresponding calibration 
curves. Peaks were determined and peak area integrated using TargetLynx software (Waters, 
Manchester, UK). All peaks were inspected manually and corrected where necessary. The IS 
response factors were calculated and the analyte peaks were corrected for variation in extraction 
yields depending on the eicosanoid class. For each standard the concentration-response equation 
was established by least-square linear regression of the calibration curve. The calibration curves 
were constructed using the following rules:  
x The response of the lowest concentration point (LLOQ) must be at least 5 times the 
response of the equivalent noise area.  
x The measured concentration of standard must be 85-115% of the nominal value or 80-120% 
if at the lower limit of quantification. 
x At least six standard points should meet these criteria and define the range of linearity 
between the lowest and upper limits of quantification.  
 Finally, sample concentrations were back-calculated from the constructed calibrations curves for 
each analyte. 
4.4.3 Cytokine Measurement 
A panel of 20 human inflammatory cytokines and soluble adhesion molecules were measured using 
the commercially available 20plex FlowCytomix™ kit (eBioscience, San Diego, USA). The kit allowed 
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20 cytokines to be measured using flow cytometry by utilising two bead populations of differing sizes 
(population A 5µm, population B 4µm.) Each population of beads had several sub-populations (size A 
– 11 subpopulations, size B – 9 subpopulations) each with a dedicated cytokine specific antibody and 
a different intensity of an internal fluorescent dye that excited in the far red (700nm) with an Argon 
laser. This allowed the 20 cytokines to be identified based on bead size and intrinsic fluorescence 
intensity, using a single fluorescence channel. All chemicals used were provided with the kits 
(eBioscience, San Diego, USA). 
4.4.3.1 Assay Buffer 
A 1x concentration of assay buffer was prepared from the 10x concentration of assay buffer 
provided with the kits consisting of phosphate buffered saline (PBS) containing 10% N,O-
bis(trimethylsilyl)acetamide (BSA) by the addition of distilled water.  
4.4.3.2 Sample Preparation 
Serum samples were randomised prior to cytokine measurement to limit any batch effect that may 
confound the experimental design. Samples were transported on ice and allowed to thaw at room 
temperature prior to cytokine measurement. The time between samples being removed from the -
80°C freezer and thawing was kept to a minimum and was approximately 30 minutes. All samples 
were run in duplicate. 
4.4.3.3 Standard Curves 
A lyophilized standard mixture of cytokines was included in the kit for preparing a standard curve for 
each cytokine. The standards were spun down for a few seconds in a microcentrifuge before being 
reconstituted in 1x assay buffer to give the concentrations detailed in table 4.1. 
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Table 4.1. Concentrations of cytokine standards on reconstitution per bead population. 
 
 
 
 
 
 
 
A series of seven declining concentrations of these standards were prepared using serial dilution. 
50µL of the reconstituted standard was added to 100µL of assay buffer and mixed. 50µL of this 
mixture was then added to a further 100µL assay buffer and this process was repeated until there 
were seven solutions of diminishing concentration.  
4.4.3.4 Fluorescent Beads 
 For each 96 well plate the provided bead mixture was vortexed for five seconds and mixed by 
repeated pipetting prior to transferring 1500µL into two Eppendorf tubes. These were centrifuged at 
3000g for 5 minutes. The excess liquid was removed and the beads reconstituted to a total volume 
of 3000µL with the reagent dilution buffer provided in the kit. The resulting solution was vortexed 
for five seconds prior to use.  
 
 
Bead size A Bead size B 
Standard  Concentration upon 
reconstitution  
Standard  Concentration upon 
reconstitution  
G-CSF  25000 pg/ml  E-Selectin  3000 ng/ml  
ICAM-1  4000 ng/ml  IFN α  20000 pg/ml  
IFN γ  20000 pg/ml  IL-1α  1000 pg/ml  
IL-6  20000 pg/ml  IL-1ß  20000 pg/ml  
IL-8  10000 pg/ml  IL-4  20000 pg/ml  
IL-10  20000 pg/ml  IL-13  20000 pg/ml  
IL12p70  20000 pg/ml  IL-17A  10000 pg/ml  
LAP  1500 ng/ml  IP-10  12500 pg/ml  
MCP-1  30000 pg/ml  TNF α  20000 pg/ml  
MIP1 α  10000 pg/ml    
MIP1ß  3000 pg/ml    
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4.4.3.5 Preparation of Plates 
Beads for flow cytometry were prepared in a 96-well filter plate prior to transfer to flow cytometry 
tubes. The wells of the plate were pre-wetted with the addition of 50µL of assay buffer to each well. 
The buffer was removed using a vacuum manifold until no fluid remained in the wells. 25µL of 
standard mixtures one to seven were added to the first and second columns, figure 4.1, and 25µL of 
assay buffer was added to the final well of each column as a blank. 25µL of sample were added to 
the remaining wells, each sample being run in duplicate. 25µL of bead mixture was then added to 
each well, including the blanks, followed by 25µL of biotin-conjugate antibody mixture. The biotin 
conjugated mixture contained specific antibodies that bound to the cytokines bound to the beads. 
The plate was then covered with adhesive film and incubated at room temperature for 2h on a plate 
shaker at 250rpm. The plate was protected from light with aluminium foil. 
Figure 4.1. Schematic diagram illustrating the layout of the 96-well plate for sample preparation for 
flow cytometry. (1A-G first set of standard concentrations, 2A-G, second set of standard 
concentrations, H1, H2 blanks, A3 set up beads, green numbered wells represent samples and their 
duplicates in yellow). 
 
 
 
 
After incubation the adhesive film was removed and the wells emptied using the vacuum manifold. 
The wells were washed by the addition of 100µL of assay buffer to each and emptied with the 
vacuum manifold. This step was performed twice.  
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100µL assay buffer and 50µL of streptavidin-PE solution were added to each well before covering 
and incubation at room temperature for one hour on a plate shaker at 250rpm. The plate was 
protected from light with aluminium foil. This incubation step allowed the streptavidin to bind to the 
biotin added in the previous step providing a fluorescent signal to allow cytokine quantification. 
After incubation the wells were emptied on the vacuum manifold and the wells washed twice with 
100µL of assay buffer as before.  
Finally 200µL of assay buffer were added to each well and mixed by repeated aspiration with a 
micropipette. This volume was transferred to tubes ready for measurement on the flow cytometer 
and the volume made up to 500µL with the addition of 300µL assay buffer. The tubes were covered 
in aluminium foil to protect them from light and kept at 4°C overnight prior to data acquisition. 
  4.4.3.6 Flow Cytometry 
Data were acquired on a CyAn flow cytometer (Beckman Coulter, Brea, USA). The forward scatter 
(FS) and side scatter (SS) were adjusted to allow the two bead populations to be discriminated on 
size, figure 4.2. Two gated regions were then created based on the two populations of beads. For 
each region fluorescence was detected at 595nm for Phycoerythrin (PE) emission (x-axis) to quantify 
cytokine concentrations and 700nm (y-axis) to separated cytokine specific bead populations. Voltage 
of the PE emission was adjusted to ensure that the beads with the highest standard cytokine 
concentrations touched the right side of the plot. Voltage of the far red emission was adjusted to 
give clear separation of the individual cytokines. 
The total number of events counted was defined so that there would be approximately 300 gated 
events per analyte.  After cytometer set up samples were run in sequential order and the generated 
files saved. 
 
147 
 
 
 
Figure 4.2. Representative plots from the flow cytometer demonstrating how the cytokines were 
identified and quantified.  a) differentiation of the two bead populations  based on size measured 
with forward scatter (FS, x-axis) and side scatter (SS, y-axis): each dot represents an individual bead, 
Beads marked A 5µm diameter, B 4µm diameter. b, c) Fluorescence channels for the two populations 
of cells, b) population A and c) population B. Far red emission (FL 8 Log) is shown on the y-axis and 
discriminates individual cytokines based on fluorescence intensity. PE emission (FL 2 Log), on the x-
axis, measures cytokine concentration with higher intensity representing higher concentration. 
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4.4.3.7 Data Pre-processing  
Data files were exported into FlowCytomix Pro™ software (eBioscience, San Diego, USA) for initial 
analysis. The software generated standard curves based on the average of the two sets of standard 
cytokine concentrations run on each plate. For each curve the software provided an estimate of the 
goodness of fit to the data points. Points were only removed from the curves on the rare occasions 
when there was clearly an outlier, with a point lying above or below the next point higher or lower 
on the curve. This was only required in a few instances.  
Cytokine concentrations were calculated by comparing the mean fluorescence intensity (MFI) of 
each sample corrected for the MFI of the blank sample to the standard curve. 
All duplicates were examined and where clear discrepancy existed in cytokine concentrations 
between a sample and its duplicate the sample was re-analysed. Similarly samples that saturated the 
concentration curves were rerun using a ten-fold dilution and concentrations calculated from this 
result. Where the calculated concentration failed to exceed the concentration curve, the average 
was taken from the repeated value and the upper limit of quantification from the standard curve.  
Further statistical analysis was carried out using the mean of the cytokine concentrations calculated 
for each sample and its duplicate. Where a sample was re-run the average was taken of the rerun 
pair when these provided concentrations that were consistent.   
4.4.3 Statistical Analysis 
Routine data handling was performed in Excel (Microsoft, USA). Prior to multivariate analysis all 
mediator concentrations were scaled to unit variance. Standardising the variance of variables 
attempts to take into account the potentially enhanced influence on multivariate models of analytes 
with naturally higher concentrations that tend to be associated with higher variance and allows 
variables with generally lower values to be given similar weight within the model. Multivariate 
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statistics were used to analyse the data. Initial exploration with principal component analysis (PCA) 
was performed to look for natural clustering and to detect outliers before supervised multivariate 
analysis using orthogonal partial least squared discriminant analysis (OPLS-DA) was used to generate 
models to optimally separate predefined groups. OPLS-DA models were cross validated using seven 
fold cross-validation using a “leave-one-out” methodology. Permutation testing was used to 
evaluate equivalent partial least squared discriminant analysis PLS-DA models. Important 
metabolites in each model were identified by examining the loadings associated with each model 
and the most important metabolites were selected by picking those that had a Variable Importance 
for the Projection (VIP) of greater than 1.0 (112). All multivariate analysis was performed using the 
SIMCA statistical package (Umetrics, Sweden). Further discussion of multivariate techniques can be 
found in chapter 2. 
Univariate statistical analysis was used to compare individual mediators and characteristics of 
included patients using SPSS (IBM, UK) and Excel (Microsoft, USA).  Student’s T-test was used to 
compare continuous variables between groups of patients and Fisher’s exact test to compare 
categorical variables. Normality of metabolite distributions was determined using Kolmogorov-
Smirnov and Shapiro-Wilk tests of normality. Non-normally distributed metabolites were compared 
using the Mann-Whitney U test and concentrations are given as median and interquartile range. To 
account for multiple comparisons the Benjamini-Hochberg procedure was used to control the false 
discovery rate.  A p-value of 0.05 or less was taken to represent statistical significance.  
4.5 Results 
4.5.1 Patients 
Thirty four patients, that fulfilled the criteria defined in chapter 2, had eicosanoids and cytokines 
measured in their serum. Of these 13 had pneumonia on admission and 21 had brain injuries with no 
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suggestion of pneumonia when the first serum samples were taken. Five brain injured patients went 
on to develop VAP based on CPIS scoring. Clinical features of these patients can be seen in table 4.2. 
As previously described in chapter 2, patients with borderline CPIS scores were reviewed by an 
independent clinical assessor and classified as non-infected, pneumonia or VAP based on clinical 
course. Based on this assessment a further six brain injured patients were classified as not having 
pneumonia on admission, five were defined as pneumonia and three as VAP. All initial comparisons 
were made with the original grouping of patients based on CPIS. 
Patients were similar across the groups with respect to their demographic details. Features that 
identified the pneumonia and VAP groups from those with brain injuries included markers of 
infection such as CRP, use of antibiotics and the higher oxygen requirement as would be expected in 
patients with pulmonary infection. 
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Table 4.2. Clinical features of included patients. Continuous variables are given as mean and 
standard deviation and categorical variables as number and percentage. P-values presented in bold 
text relate to parameters that were significant at the p<0.05 level. The clinical parameters compared 
were taken from the 24h prior to 8:00 am on the day of sampling, for the pneumonia and brain 
injured patients this was time point 0 and for cases of VAP this was the 24h prior to the sample taken 
soonest after the onset of VAP. 
 Pneumonia (P) Brain Injury (BI) p-value 
(BI vs P) 
VAP p-value 
(BI vs VAP) 
N 13 21 - 5 - 
Age (Mean +/- SD) 53.5±16.5 52.3±14.9 0.84 50.8±17.2 0.87 
Sex, Number of males (%)  9 (69.2) 12 (57.1) 0.72 3.0 (60.0) 1.00 
Ethnicity, number  White 
European (%) 
9 (69.2) 15 (71.4) 1.00 4.0 (80.0) 1.00 
Outcome, Number alive (%) 8 (61.5) 16 (76.2) 0.45 3.0 (60.0) 0.59 
APACHIE II Score (Mean +/- SD) 19.6±6.3 17.0±6.0 0.23 17.8±9.4 0.86 
SOFA Score (Mean +/- SD) 10.2±3.2 8.9±2.6 0.23 8.6±3.1 0.87 
CPIS (Mean +/- SD) 5.8±1.0 2.1±1.4 <0.001 7.0±1.58 <0.01 
Lowest WCC (109/L) (Mean +/- 
SD) 
15.8±7.5 10.0±3.8 0.02 10.5±3.2 0.76 
Highest WCC (109/L) (Mean +/- 
SD) 
16.4±7.3 11.2±3.9 0.03 10.5±3.2 0.70 
Lowest CRP (mg/L) (Mean +/- SD) 165.7±98.7 49.4±54.2 <0.01 116.7±28.2 <0.01 
Highest CRP (mg/L)(Mean +/- SD) 184.1±913 62.0±52.5 <0.001 116.7±28.2 <0.01 
Lowest Temperature (°C) (Mean 
+/- SD) 
35.8±0.83 36.0±0.68 0.45 36.0±1.6 0.95 
High Temperature (°C) (Mean +/- 
SD) 
37.7±0.96 37.6±0.68 0.65 38.0±1.3 0.45 
Lowest FiO2 (Mean +/- SD) 0.4±0.15 0.4±0.22 0.47 0.4±0.1 0.51 
Lowest PaO2:FiO2 (Mean +/- SD) 24.0±9.7 41.8±15.5 <0.001 18.6±8.5 <0.001 
Lowest MAP (mmHg) (Mean +/- 
SD) 
71.7±10.4 74.0±11.3 0.54 71.0±12.4 0.65 
Use of noradrenaline, N (%) 9 (69.2) 13 (61.9) 0.73 1.0 (20.0) 0.15 
Use of antibiotics N (%) 13 (100) 10 (47.6) <0.01 5.0 (100) 0.05 
Enteral nutrition, N (%) 12 (92.3) 15 (71.4) 0.21 5.0 (100) 0.3 
Time to sampling from start of 
ventilation (h) (Mean +/- SD) 
42.7±11.5 40.1±16.9 0.61 143.4±44.9 <0.01 
Time of day of sample, Number 
taken in the morning (%) 
8 (61.5) 13 (61.9) 1.0 5.0 (100) 0.28 
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4.5.2 Eicosanoids 
 Of the 48 eicosanoids measured there were 17 where levels were below the lower limit of 
quantification in all samples, table 4.3. These were omitted from any further analysis. This left 31 
quantifiable eicosanoids.  
Table 4.3. The 31 quantified eicosanoids and the 17 that were unquantifiable. 
Measured Eicosanoids Unquantifiable Eicosanoids  
C18:2 (LA) tetranor-PGEM 
C20:3 (DGLA) tetranor-PGFM 
C20:4 (AA) 15(S)-HEPE 
C20:5 (EPA) 5,6-EET 
C22:6 (DHA) 8,9-EET 
9(S)-HODE 11,12-EET 
13(S)-HODE 14,15-EET 
tetranor-PGDM 5-oxo-ETE 
12(S)-HEPE LTD4 
5(S)-HETE LTE4 
8(S)-HETE PGD2 
11(R)-HETE PGF2alpha 
12(R)-HETE 8-iso-PGF2alpha 
15(S)-HETE 15dPGJ2 
16(R)-HETE 11-dehydro TXB2 
5,6-DHET Resolvin D1 
8,9-DHET Resolvin D2 
11,12-DHET  
14,15-DHET  
12-oxo-ETE  
14-HDoHE  
17(S)-HDoHE  
10(S),17(S)-DiHDoHE  
LTB4  
12-oxo-LTB4  
LTC4  
PGE2  
Lipoxin A4  
Lipoxin B4  
6-keto-PGF1alpha  
TXB2  
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4.5.2.1 Evaluation of Batch Effect 
All eicosanoid measurements were carried out over a period of two days in two runs. PCA was used 
to evaluate the presence of any batch effect, figure 4.3. Most of the samples from both batches 
clustered together in the PCA scores plot, although the outliers appear to all arise from the first 
batch. On closer examination many of these appear to be due to patient factors as samples taken 
from the same patient appear together on the plot, regardless of the day of analysis.   Although it is 
possible to construct an OPLS-DA model (R2Y 0.50, Q2Y 0.37, p<0.001) to separate samples based on 
batch, there is a great deal of overlap of the two groups even before cross-validation has been 
applied, suggesting that batch effect, although present, was very small. The eicosanoids most 
susceptible to batch effect were 17(S)-HDoHE, 11,12-DHET, 12(S)-HEPE, 16(R)-HETE, 10(S),17(S)-
DiHDoHE, 14-HDoHE, Lipoxin A4, 15(S)-HETE, TXB2, 14,15-DHET, 5,6-DHET, LA, 12-oxo-LTB4, 12(R)-
HETE, 8(S)-HETE, and AA. In an attempt to establish the degree of effect that batch had on the 
overall variation within the samples the R2X of the model was examined. Whereas the R2Y metric 
quantifies the amount of variation explained by the model between the classification groups the R2X 
quantifies the total amount of variation explained by the model across all samples. In this case 
although the OPLS-DA model was able to explain roughly 50% of the variation between the two 
batches (R2Y 0.5) and was moderately predictive (Q2Y 0.37) the total amount of variation across all 
samples explained was small at only 16% (R2X 0.16) implying that the batch effect had only a small 
effect on the overall variation between samples. In order to examine batch more closely the clinical 
comparisons described below were also re-examined to assess for batch effect. 
4.5.2.2 Brain Injury vs. Pneumonia 
Initial comparison using PCA of the 13 patients with pneumonia at the start of invasive ventilation 
with the 21 brain injured patients who demonstrated no evidence of pneumonia when ventilation  
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Figure 4.3 a. Three component PCA scores plot (R2X 0.49 Q2Y 0.25), showing components 1 and 2. Samples are coloured according to batch, run 1 - 
blue squares, run 2 - green circles, samples marked with the same symbols arise from the same patient at different time points The inability of this 
unsupervised model to find natural separation between the two batches implies minimal batch effect and that most of the variation between 
samples is due to factors other than batch. b. OPLS-DA model (R2Y 0.50, Q2Y 0.37, p<0.001 ) with one component and one orthogonal component, 
shown prior to cross-validation, comparing samples from run 1, blue squares, to those from run 2, green circles. Samples to the far left and right of 
the plot show the greatest difference when variation based on batch effect is actively explored, the overlapping samples in the middle demonstrate 
least difference c. Loading plot for the OPLS-DA model demonstrating the eicosanoids causing the most separation in the OPLS-DA model. 
Eicosanoids distributed at the extremes of the x-axis are responsible for most variation in the first component, x-axis, of the OPLS-DA model and 
those at the extremes of the y-axis are responsible for most variation in the orthogonal component.  
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was commenced showed no innate ability to separate these groups based on the presence or 
absence of pneumonia, figure 4.4. However, there appeared to be some distinct groupings or 
clusters within the data distribution. The group of four brain injured patients in the upper right 
quadrant of the plot had a dominance of almost all fatty acids and their subsequent eicosanoid 
metabolites whereas the bulk of the patients on the left showed a dominance of 6-keto-PGF1alpha, 
LTC4, 12-oxo-LTB4 and Lipoxin B4.  The three patients in the lower right quadrant differentiated 
from the main cluster by the presence of higher levels of TXB2, 11(R)-HETE, 12(R)-HETE, 8(S)-HETE, 
PGE2, 12(S)-HEPE, 12-oxo-ETE, 15(S)-HETE, tetranor-PGDM and 14-HDoHE. Comparison of these 
groups with clinical data showed no clear clinical explanation for this grouping. There was no 
differentiation based on the underlying pathology, the use of drugs known to alter eicosanoid 
metabolism or the development of later infection. 
Use of OPLS-DA, figure 4.5, enabled a model to be constructed with R2Y 0.68, Q2Y 0.40, p=0.02. 
Examination of the loadings for the model showed a predominance of fatty acids, particularly DHA, 
EPA, AA and LA, in the brain injury group along with the metabolites 6-keto-PGF1α, 5,6-DHET, 9(S)-
HODE, 13(S)-HODE, 10(S),17(S)-DiHDoHE and 5(S)-HETE. Lipoxin B4 and tetranor-PGDM were more 
abundant within the pneumonia group. Testing this model with the set of 11 patients with 
borderline scores, that were reclassified blindly by an independent clinician, demonstrated the 
model to have a sensitivity of 0.60, a specificity of 0.67, a positive predictive value of 0.6 and a 
negative predictive value of 0.67. When the same subgroup of patients was used to construct a 
batch model only a much less predictive model could be made (R2Y 0.52, Q2Y 0.15, p=0.30) with less 
of the overall variation described by the batch model compared to the disease classification model 
(R2X 0.42 vs 0.55) implying that disease group had a greater impact on inter sample variation than 
the batch effect. 
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Figure 4.4. a. Three component PCA model (R2X 0.62, Q2X 0.25), showing components 1 and 2, comparing samples taken at the first time point from 
patients admitted with pneumonia (red squares) to those admitted with brain injuries with no evidence of pneumonia when the first sample was 
taken (blue circles). No overall natural separation between pneumonia and brain injured patients is seen, however a group of brain injured patients 
seem to separate out into the right side of the plot, along the first component, and two patients with pneumonia separate from the main group 
along the second component.  b. Loadings plot for the PCA model demonstrating the eicosanoids causing the most separation in the model. 
Eicosanoids distributed at the extremes of the x-axis are responsible for most variation in the first component, x-axis, and those at the extremes of 
the y-axis are responsible for most variation in the second component, y axis, of the PCA model. 
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Figure 4.5 a. OPLS-DA scores plot from a model with one aligned and two orthogonal components, showing the aligned vs. the first orthogonal 
component, before cross validation, (R2X 0.68 Q2Y 0.40, p=0.02) based on eicosanoid analysis from samples taken at the first time point from 
patients admitted with pneumonia (red squares) to those admitted with brain injuries with no evidence of pneumonia when the first sample was 
taken (blue circles). Distribution along the x-axis shows the degree of separation of the two groups along the first component. b. Loadings plot for 
the OPLS-DA model demonstrating the eicosanoids causing the most separation in the model. Eicosanoids distributed at the extremes of the x-axis 
are responsible for most variation in the first component, x-axis, of the OPLS-DA model and those at the extremes of the y axis are responsible for 
most variation in the orthogonal component. 
  a. b. 
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4.5.2.3 Brain Injury vs VAP 
Comparison of serum samples taken from the 21 patients with brain injury without infection at the 
time of ventilation to the samples taken from the five brain injured patients who developed VAP 
based on CPIS scores at the time pneumonia developed failed to demonstrate separation on PCA. 
OPLS-DA modelling had no predictive capacity with a negative Q2Y (R2Y 0.36 Q2Y -0.06). Models 
failed to have any predictive capacity even when VAP was compared to only samples from those 
brain injured patients who did not go on to develop VAP (R2Y 0.56 Q2Y -0.25), their own first time 
point (R2Y 0.29 Q2Y 0.01) or a larger group including the patients assessed by an independent 
assessor (R2Y 0.23 Q2Y -0.16 ). Some of this lack of predictivity may have related to batch effect. 
When a batch effect model was made from the subgroup of brain injured and VAP patients a more 
predictive model could be made (R2Y 0.59, Q2Y 0.35, p=0.05) and explained a greater proportion of 
population variation (R2X 0.47 vs 0.15). This may have been because of the small number of VAP 
patients, especially if they had a tendency to be randomised to one of the batches. 
4.5.3 Cytokines  
4.5.3.1 Evaluation of Batch Effect 
Cytokine measurement was performed in six batches due to the length of the protocol. In order to 
assess for batch effect PCA was performed and each sample was coloured based on the day on 
which it was run. One patient’s samples were excluded from this analysis due to cytokine levels that 
were far in excess of the maximum values of many of the standard curves, even after rerunning the 
samples at a 40 fold dilution. This patient was found to have a lymphoma after enrolment to the 
study, this diagnosis possibly accounts for the pronounced cytokine levels. Interestingly this patient 
was not an outlier when only eicosanoids were considered, possibly a consequence of the difference 
in site of production of cytokines and eicosanoids in relation to lymphoma or the differing timescales 
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of production of the two types of mediators. This patient’s samples were excluded from all other 
comparisons. The PCA, figure 4.6, shows no natural separation based on sample batch and individual 
patients’ time points tended to cluster together, even when run on different days, suggesting inter-
patient variability was greater than either that caused by batch effect or that from time point to time 
point. A two component OPLS-DA model (R2Y 0.14 Q2Y 0.08, p<0.001) could be constructed to try to 
differentiate the batches. The biggest difference appeared to be between batch 2 and 5, 
examination of the loadings suggested most of this difference was accounted for by the levels of IL-
10 and IL-12p70. However, when the R2X of this model was explored the batch model explained 58% 
of the variation across all samples suggesting that batch may be an important contributor to this 
data.  
4.5.3.2 Brain Injury vs Pneumonia 
Comparison of the 13 patients with pneumonia on admission to those 21 with brain injuries, without 
infection, via PCA (R2X 0.46 Q2X 0.23) failed to show any natural groupings but with outliers all 
coming from the pneumonia group, the outliers were associated with elevated levels of almost all 
cytokines compared to the non-outliers suggesting a generalised increase in inflammatory activity. 
Supervised analysis with a single component OPLS-DA model (R2Y 0.18, Q2Y 0.11, p=0.17), figure 4.7, 
only had a low ability on cross validation to discriminate the two groups. Assessment of the model 
with a test set of patients based on the borderline group of patients independently assessed only 
produced a sensitivity 0.6, specificity 0.67 positive predictive value of 0.6 and negative predictive 
value of 0.67, similar to those from the eicosanoid only model. All cytokines other than IL-8 and IL-1α 
had a tendency to increase in the pneumonia patients, the most important cytokines, based on a VIP 
score of >1.0, in this model were ICAM-1, E-selectin , IP-10, MCP-1, IL-13, and TNFα. When this 
subgroup was used to construct a batch model it was impossible to build an OPLS-DA model with a 
+ve Q2Y suggesting that within this group the effects of batch were limited and those of the disease
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Figure 4.6. a. Single component PCA (R2X 0.34 Q2Y 0.25) of all cytokine batches (run 1: red triangles, run 2: green circles, run 3: yellow inverted triangles, run 
4: cyan diamonds, run 5: blue squares, run 6: purple pentagons) showing samples clustering by patient along the first component, direction axis, with no 
batch predominance as shown by the degree of overlap of the six batches. b. Two component supervised OPLS-DA model (R2Y 0.21 Q2Y 0.11, p<0.001) before 
cross validation showing that the greatest difference is between batches 2 and 5, with this difference being driven by IL-10 and IL12p70 being more 
predominant in batch 2 as shown on the loadings plot, c.  The loadings plot demonstrates the cytokines causing the separation in the OPLS-DA model. The 
cytokines at the extremes of the x and y-axes are responsible for the most separation in the same respective directions in the OPLS-DA model.  
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Figure 4.7. a. Single component OPLS-DA model (R2Y 0.18 Q2Y 0.11, p=0.17) based on cytokine analysis comparing samples taken at the first time point from 
patients admitted with pneumonia (red bars) to those admitted with brain injuries with no evidence of pneumonia when the first sample was taken (blue 
bars). Samples from brain injured patients tend to deflect downwards along component 1, y-axis, however, the samples from patients with pneumonia are 
distributed both upwards and downwards with three patients dominating the upward direction.  b. Loadings plot for the OPLS-DA model showing that nearly 
all cytokines tend to dominate in the pneumonia patients whose samples deflect upwards along component 1 in the OPLS-DA model. 
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were more important, this was supported by the larger R2X within the disease model (R2X 0.43 vs 
0.37). 
4.5.3.3 Brain Injury vs VAP 
Comparison of serum samples taken from the 21 patients with brain injuries without infection at the 
time of ventilation to the samples taken from the five brain injured patients who developed VAP 
based on CPIS scores showed no grouping on PCA (R2X 0.492 Q2X 0.17). However, a supervised 
model using OPLS-DA showed an improved predictive capacity (R2Y 0.38 Q2Y 0.16, p=0.13) compared 
to that made from eicosanoid measurements, figure 4.8. The loadings showed a tendency for all 
cytokines except IL-6 to increase in the VAP group, of these TNFα, ICAM-1, IP-10, IL-13, iL-12p70, IL-
17A, INFγ and Il-1beta caused the majority of the separation based on their VIP scores. The 
predictive capacity was only marginally improved (R2Y 0.49 Q2Y 0.22, p=0.18) when only brain 
injured patients who did not develop VAP at any point were used as controls with the same trend,  
including IL-6, of all cytokines increasing with VAP. However, when the samples taken from the time 
that VAP developed were compared to the first samples taken from the same patients, before VAP 
developed, the model lacked any predictive capacity (R2Y 0.44 Q2Y -0.53) and this remained the case 
even with a larger group made up from a combination of VAP diagnosed from CPIS scores and 
classification of borderline cases (R2Y 0.21 Q2Y -0.80). 
The influence of batch on this model appeared greater than when brain injured patients were 
compared to those with pneumonia at admission. When an OPLS-DA model comparing batch was 
constructed from the subgroups of patients with brain injuries or VAP (R2Y 0.19, Q2Y 0.09, p=0.39) 
the predictive capacity was less than that for the model comparing disease classes. However, the 
amount of variation explained in the overall population was greater (R2X 0.46 vs 0.31) again possibly 
relating to the small number of patients in the VAP group.  
166 
 
 
 
Figure 4.8. a. Single component OPLS-DA model (R2Y 0.38, Q2Y 0.16, p=0.13) based on cytokine analysis comparing samples taken at the first time point from 
patients admitted with brain injuries with no evidence of pneumonia at the time of sampling (blue bars) to the time point that VAP developed (green bars). 
VAP samples are all oriented upwards along component 1 and brain injury samples generally deflect downwards, however, a number of brain injury patients 
overlap the VAP group showing positive orientation.  b. Loadings plot for this model showing that nearly all cytokines tend to dominate in patients whose 
samples show upwards orientation along component 1 in the OPLS-DA model. 
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4.5.4 Combining Eicosanoids and Cytokines 
4.5.4.1 Brain Injury vs Pneumonia 
Combining the cytokine and eicosanoids together into one model produced a two component PCA 
which still failed to show any natural separation into pneumonia and non-pneumonia groups. 
Clustering continued to mirror the PCA model using only eicosanoid levels with one group 
demonstrating a predominance of fatty acids. Similarly three of the pneumonia patients naturally 
separated out from the others due to dominant levels of nearly all cytokines. Supervised analysis 
produced an OPLS-DA model (R2Y 0.69, Q2Y 0.35, p=0.01) with a slightly reduced predictive capacity 
compared to that from the eicosanoids alone. The loadings from this model, figure 4.9, 
demonstrated that most of the measured cytokines dominated in the pneumonia group with the 
exception of MIP-1α, MIP-1β, IL-8 and IL-1α. The cytokines dominating the separation based on VIP 
scoring were ICAM-1, E-selectin, IP-10, MCP-1, IL-13, TNFα, INFγ and IL-6. Fatty acids dominated the 
brain injury group, as seen in the eicosanoid model, with 6-keto-PGF1α, 5,6-DHET,DHA, EPA, 9(S)-
HODE, 13(S)-HODE, 10(S),17(S)-DiHDoHE, AA, and 5(S)-HETE   causing most separation.  Tetranor-
PGDM and lipoxin B4 were the eicosanoids differentiating the patients with pneumonia. Validation 
of the model using the classified borderline cases gave a sensitivity 0.6, specificity 0.67, positive 
predictive value 0.6 and negative predictive value 0.67, similar to both the eicosanoid and cytokine 
models. Building a model based only on the most important mediators produced a model with a 
slightly improved predictive capacity to that using all inflammatory molecules (R2Y 0.49, Q2Y 0.43, 
p<0.001), however, although the sensitivity 0.40, and negative predictive value 0.625 reduced the 
specificity 0.83 and positive predictive value 0.67 both increased. 
As it was possible that some of the brain injured patients could be developing VAP earlier than was 
clinically apparent a further model was constructed comparing only those patients who never 
developed VAP with those with pneumonia on admission. This two component model (R2Y 0.78, Q2Y  
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Figure 4.9. a. OPLS-DA model with one orthogonal component (R2Y 0.69 Q2Y 0.35, p=0.01) before cross validation, comparing cytokines and eicosanoids at 
the first time point from patients admitted with pneumonia (red squares) to those admitted with brain injuries with no evidence of pneumonia at sampling 
(blue circles).Pneumonia samples cluster in a positive direction along the first component, x-axis, and brain injury samples in the negative direction. b. 
Loadings plot for the model shown in a, inflammatory molecules to the right of the plot dominate in the pneumonia group and those on the left in the brain 
injury group. 
a. b. 
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0.25, p=0.19), figure 4.10, had an improved sensitivity of 0.8, a specificity 0.67, positive predictive 
value 0,67 and negative predictive value of 0.8. Similarly to the model using all brain injured patients 
ICAM-1, IL-6, MCP-1, E-selectin, IP-10, IL-17A and IL-13 were the cytokines causing most of the 
separation. Fatty acids again dominated in the brain injury group, with 5,6-DHET, 6-keto-PGF1α, 
DHA, 9(S)-HODE, EPA , 13(S)-HODE,  10(S),17(S)-DiHDoHE, 5(S)-HETE, AA, LA and LTB4 , causing most 
separation. Lipoxin B4 and tetranor-PGDM again appeared in the pneumonia group.  
4.5.4.2 Brain Injury vs VAP 
Combining cytokine and eicosanoid data into one model improved the predictive capacity, after 
cross validation, when patients with VAP were compared to the first time point from brain injury 
patients before infection developed (R2Y 0.76 Q2Y 0.27, p=0.14), figure 4.11. In this model the 
separating molecules all dominated in the VAP group and were almost all cytokines, predominantly 
TNFα, ICAM-1, IP-10, IL-13, IL-12p70, IL-17A, INFγ, IL-1beta, IL-10, and IL-4. The eicosanoids causing 
separation also dominated in the VAP group and were LTC4, 14,15-DHET, LTB4, 8,9-DHET, tetranor-
PGDM, 11,12-DHET and Lipoxin A4. LA and DHA both dominated in the brain injury group. 
When samples taken at the time patients developed VAP were compared to those at the start of 
ventilation from brain injured patients who never developed VAP the OPLS-DA model improved (R2Y 
0.90 Q2Y 0.38, p=0.19), figure 4.12. The mediators causing most of the separation in this model were 
IL-12p70, IL-17A,TNFα, IP-10, INFγ,ICAM-1, IL-13, IL-4,  IL-10, , IL-1beta and MCP-1, the eicosanoids 
causing separation, also dominating in the VAP group, were 12-oxo-LTB4, 14,15-DHET, Lipoxin A4, 
LTB4, tetranor-PGDM and LTC4 . In this model DHA, LA, EPA and 14-HDoHe became important in 
identifying the first time point from brain injured patients who never developed VAP.  
However, when the patients diagnosed with VAP based on CPIS were combined with those with 
borderline scores that were independently classified the model lost all predictive capacity on cross- 
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Figure 4.10. a. OPLS-DA model with one orthogonal component (R2Y 0.78 Q2Y 0.25, p=0.19) shown prior to cross validation, comparing cytokines and 
eicosanoids at the first time point from patients admitted with pneumonia (red squares) to those admitted with brain injuries who never developed VAP 
during their stay (blue circles). Pneumonia patients separate from brain injured patients along the first component, x axis. b. Loadings plot for the OPLS-DA 
model. Inflammatory molecules dominating in the pneumonia group are positioned on the right of the plot, predominantly cytokines, and those in the brain 
injury group are to the left, predominantly eicosanoids. 
b. a. 
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Figure 4.11. a. OPLS-DA model with one orthogonal component (R2Y 0.76, Q2Y 0.27, p=0.14), comparing samples taken at the first time point from patients 
admitted with brain injuries (blue circles) to samples taken from those brain injury patients who developed VAP at the time point that VAP developed (green 
triangles). VAP samples separate in the positive direction along the first component. b. Loadings plot for the OPLS-DA model. Inflammatory molecules 
important in the VAP group are positioned on the right of the plot whilst those important in the brain injured group are to the left. 
 
a. b. 
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Figure 4.12. a. OPLS-DA model with one orthogonal component (R2Y 0.90, Q2Y 0.38, p=0.19), comparing samples taken at the first time point from patients 
admitted with brain injuries (blue circles) who never developed VAP to samples taken when VAP developed in those that did (green triangles). VAP samples 
separate in the positive direction along the first component. b. Loadings plot for the OPLS-DA model. Inflammatory molecules important in the VAP group 
are positioned on the right of the plot whilst those important in the brain injured group are to the left. 
a. b. 
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validation (R2Y 0.51 Q2Y-0.42). Also, even when cytokines and eicosanoids were combined, the 
models were still unable to differentiate samples from the time that VAP developed from those at 
the start of ventilation (R2Y 0.60 Q2Y -0.17) in the same patients. 
4.5.4.3 Time Course 
So far samples taken from the start of ventilation have been compared to samples taken at the time 
VAP developed. However, changes seen between these groups may not have been  genuinely due to 
development of VAP and may have represented changes associated with a prolonged stay on 
intensive care. In the majority of cases VAP developed around time point three and four. In order to 
get a sense of the inflammatory changes over this time frame the samples from the first time point 
from brain injured patients who did not develop VAP were compared to samples taken at the fourth 
time point. OPLS-DA modelling (R2Y 0.96, Q2Y 0.66, p=0.05), figure 4.13, suggested that the 
dominance of fatty acids at the first time point shifts towards the metabolites of arachidonic acid, in 
the form of 5,6-DHET, 8,9-DHET and 14,15-DHET and 16(R)-HETE, 12(R)-HETE, 15(S)-HETE and 11(R)-
HETE. Cytokines seemed generally to be at higher concentrations at the beginning of the ICU stay 
but over time the levels of IL-13, IL-4, IL-1β, TNFα and IP-10 increased.     
If samples from patients diagnosed with VAP based on CPIS scoring were compared to the fourth 
time point samples from brain injury patients who did not develop VAP a cross validated OPLS-DA 
model (R2Y 0.98, Q2Y 0.56, p=0.31), figure 4.14, could be made. The loadings from this model 
showed a greater dominance of cytokines in those who developed VAP than in those who did not 
develop infection. The cytokines causing separation of these group were IL-6, MCP-1, IL-12p70, IFNγ,  
IL-17A, IFNα, IL-10, ICAM-1, G-CSF, IL-1beta, IP-10 and TNFα within the VAP group. The eicosanoids 
12-oxo-LTB4 and Lipoxin A4 were the only eicosanoids dominating in the VAP group. Fatty acid 
metabolites continued to dominate in the final time point of the non-VAP group with 5,6-DHET and 
8,9-DHET being responsible for the separation. When only the metabolites causing the greatest   
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Figure 4.13. a. OPLS-DA model with one aligned and two orthogonal components (R2Y 0.96 Q2Y 0.66, p=0.05), comparing samples taken at the first time 
point from patients admitted with brain injuries (blue circles) who never developed VAP to the fourth time point sample (blue squares). Fourth time point 
samples are separated in a positive direction along the first component, x-axis, and first time point samples in a negative direction. b. Loadings plot for the 
OPLS-DA model. Inflammatory mediators that increase over time are on the right of the plot and those that decrease are on the left. 
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Figure 4.14. a. OPLS-DA model with one orthogonal component (R2Y 0.98 Q2Y 0.56, p=0.31), comparing samples taken at the fourth time point from patients 
with brain injuries (blue squares) who never developed VAP to samples taken from those patients with VAP (green triangles). Brain injured patients separate 
in a positive direction along the first component and VAP patients in a negative direction, x-axis b. Loadings plot for the OPLS-DA model. Inflammatory 
mediators that increase in VAP are on the left side of the plot. c and d. Hierarchical dendrograms illustrating, c, the cytokines and eicosanoids involved in 
separating the two groups and, d, the sub-clustering of patients in both groups (group 1 – VAP group 2 – time point 4 from BI patients not developing VAP). 
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separation were used to construct the OPLS-DA model the predictive capacity improved (R2Y 0.90, 
Q2Y 0.78, p<0.01). Univariate statistics were performed on those analytes, figure 4.15, that were 
associated with a VIP of >1.0 and a p(corr) >0.5 in either direction in this model. The non-parametric 
Mann-Whitney U test was used to compare individual markers as none of these followed a normal 
distribution when Kolmogorov-Smirnov or Shapiro-Wilk tests of normality were applied.  Before 
correction for multiple comparisons was applied, table 4.4, Lipoxin A4, IL-12p70, IFNγ, MCP-1 and IL-
6 showed a tendency towards being elevated in those with VAP and 5,6-DHET showed a tendency to 
be increased in those brain injury patients not developing VAP at their final time point. IL-10, IFNα, 
IL-17A, IL-1β and 12-oxo-LTB4 failed to reach statistical significance between the groups. After the 
Benjamini-Hochberg procedure was applied to control the false discovery rate only the differences 
observed for IFNγ (p=0.04), MCP-1 (p=0.04) and IL-6 (p=0.04) remained significant. 
Table 4.4. Univariate comparison of discriminant mediators based on an OPLS-DA model comparing 
brain injury patients at the time point that VAP develops (VAP) to those who do not develop VAP at 
their final time point (BI TP4). Concentrations are given as median and interquartile range. P-values 
are from Mann-Whitney U test prior to correction for false discovery rate. 
Mediator VAP BI TP4 p-value 
Lipoxin A4 (fg/µL) 647.1 (473.6-667.6) 0 (0-183.2 ) 0.04 
IL-12p70 (pg/ml) 23.49 (18.97-27.3) 0.74 (0-1.38) 0.02 
IFNγ (pg/ml) 124.56 (99.76-135.92) 78.55 (26.60-81.96) 0.01 
MCP-1 (pg/ml) 412.78 (405.61-573.24) 207.1 (192.90-207.14) 0.01 
IL-6 (pg/ml) 24.48 (18.55-36.89)  0 (0-0) 0.01 
5,6-DHET (fg/µL) 132.2 (101.9-132.8) 367.3 (266.0-434.2) 0.04 
IL-10 (pg/ml),  15.49 (15.0-22.29) 1.67 (1.31-9.87) 0.14 
IFNα (pg/ml) 220.25 (97.24-253.31) 32.63 (30.71-55.89) 0.06 
IL-17A (pg/ml) 161.01 (127.88-194.05) 60.54 (14.53-72.59) 0.06 
IL-1β (pg/ml) 179.95 (80.26-192.03) 102.26 (56.58-132.70) 0.21 
12-oxo-LTB4 (fg/µL) 23947.1 (5529.9-51405) 6467.6 (5912.2-9771) 0.40 
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Figure  4.15. Univariate comparison of the mediators associated with a p(corr) of >0.5 in either direction from the OPLS-DA  model comparing the final time 
point from brain injured patients who did not develop VAP to the time point VAP developed in those that did. Green bars VAP time point, blue bars final time 
point from brain injured patients who did not develop VAP. Data displayed as median ± inter-quartile range. VAP n =5 Brain Injury n=5. Comparisons marked 
* are significant at p<0.05 after application of the Benjamini-Hochberg procedure. 
  
* 
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Even when both cytokines and eicosanoids were combined it was not possible to distinguish patients 
with brain injuries who went on to develop pneumonia from those who did not at the first sample 
time point, before pneumonia had become clinically apparent (R2Y 0.35, Q2Y -0.191). 
4.5.4.4 Correlation 
The correlation of all inflammatory mediators was checked against each other to produce 
correlation heatmaps, figure 4.16. When all samples were explored together there was clearly a 
trend for the cytokines to broadly correlate in a positive direction and the eicosanoids to do the 
same. Only low level correlation was seen between the two classes of inflammatory mediators. 
Within the eicosanoids the precursor fatty acids such as AA, EPA and LA seemed to correlate 
together and strong correlation was seen between several of their metabolites such as the HETE 
group of metabolites. When only samples taken at the first time point from patients with pneumonia 
were considered the strength of correlation between the cytokines generally increased with strong 
correlation between several of the interleukins with the exception of IL-8 and IL-1α, which 
correlated with each other.  Some correlation between cytokines and eicosanoids became apparent 
within this group. For example, 6-keto-PGF1α, a break down product of prostacycline which 
mediates vasodilation, was seen to correlate with several, mainly pro-inflammatory, cytokines. 
Alternatively when the first time point samples from the brain injured patients who never developed 
pneumonia, including two patients clearly without pneumonia at enrolment but with borderline CPIS 
scores during their ICU stay who were independently assessed and classified as not developing VAP, 
were examined, although correlation still existed between cytokines, the greatest correlation was 
seen between the eicosanoids. This correlation was seen predominantly between families of similar 
molecules, such as the fatty acid precursor molecules, the HETEs and the DHETs. Interestingly the 
cytokine which correlated with the most eicosanoids in this group was ICAM-1, which has previously 
been associated with subarachnoid haemorrhage. 
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4.6 Discussion 
This chapter has explored the potential of a panel approach to eicosanoid, using a MS methodology, 
and cytokine, using a flow cytometry based method, measurement to assist the diagnosis of both 
pneumonia and VAP. Not only has the independent ability of each of these panels to differentiate 
patients with pneumonia from those with brain injuries been examined but also a combined 
approach using both panels together. 
Neither the eicosanoid nor cytokine measurements appeared to suffer from a significant batch 
effect when PCA was used to look for natural separation within all samples. Differences between 
individual patients, especially for the cytokine experiments, seemed to dominate over either an 
effect due to batch or that related to samples taken from different time points during a patient’s 
stay. In both cases, however, it was possible to produce multivariate models that showed some 
ability to separate samples based on batch and thus identify the analytes that may be most affected 
by batch effect.  
Use of only eicosanoid measurements to differentiate pneumonia from brain injuries at the time of 
admission to ICU allowed a model to be constructed that had a moderate predictive capacity at 
cross-validation and both sensitivity and specificity of 60-70% when validated with a small 
independent group of patients. Interestingly the markers that caused most of the separation 
dominated in the brain injured group. These markers were predominantly fatty acids and their direct 
metabolites. Polyunsaturated fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic 
acid (EPA) may inhibit platelet function (285) and increase risk of bleeding and thus subarachnoid 
haemorrhage (SAH), the predominant injury in this brain injury group. In some populations higher 
risk of haemorrhagic stroke has been seen in patients with high levels of these polyunsaturated fatty 
acids in their fat composition (286), however, this has not been seen in all populations (287). 
Although little is written about serum levels of free fatty acids in patients with brain injury, the brain 
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has a high composition of polyunsaturated fatty acids, especially DHA, and all free fatty acids have 
been seen to be elevated in the cerebrospinal fluid of patients with SAH (288) and the F4-
neuroprostanes, the oxidative metabolites of DHA, have also been seen to increase in the CSF of 
both patients with SAH and traumatic brain injury (289). EPA may be involved in brain injury and 
may play an important role in the modulation of cerebral circulation (290-292). Similarly, in an 
experimental model hydroxyeicosatetraenoic acids have been found to be elevated in the CSF, 
haemorrhagic clot and basilar artery following SAH (293) and levels of 6-keto-PGF1α have been seen 
to be elevated in the urine of patients following haemorrhagic stroke (294). As 6-keto-PGF1α 
represents the metabolic product of prostacyclin a possible causal relationship may exist through 
alterations in the regulation of cerebral blood flow associated with brain injury.  
Although the differences in eicosanoids potentially represented both risk factors for and the result of 
cerebral haemorrhage it is also possible that they represented different temporal courses of the two 
diseases in question. Brain injury usually occurs rapidly in patients who were often previously well, 
however, pneumonia takes several days to develop with a prodromal phase when patients may feel 
unwell and have altered or diminished dietary intake. Levels of polyunsaturated fatty acids, such as 
LA, have been seen to fall in states of reduced oral intake such as anorexia nervosa (295) and similar 
changes may be occurring seen in this context.  
Within the pneumonia group lipoxin B4, a metabolic product of lipoxin A4, and tetranor-PGDM, the 
stable degradation product of prostaglandin D2, were the two eicosanoids that were greater than in 
the brain injured patients. The lipoxins have been associated with the resolution phase of 
inflammation and inhibit the actions of the leukotrienes, especially LTB4. Lipoxin A4 has been 
measured in the BAL fluid of patients with several pulmonary diseases including pneumonia (162) 
and PGD2 has been suggested to have an anti-inflammatory role in lung inflammation (296). 
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Interestingly it was not possible to use eicosanoid measurements to predict patients with brain 
injuries who went on to develop VAP either in comparison to all brain injured patients at time point 
one or to only those that were known not to develop infection at any time. This suggests that the 
lack of ability to identify these patients was not due to confounding factors from the patients who 
went on to develop VAP exhibiting important metabolic changes at the time of first sampling. As the 
eicosanoids identified in those patients with pneumonia at admission seemed to be predominantly 
anti-inflammatory it is possible that by looking at the serum samples that were taken when VAP 
seemed to be developing clinically it was too early in disease progression to see these markers in 
VAP patients. The number of patients developing VAP was small in comparison to both the brain 
injury and pneumonia groups and it is possible that with this sample size it was not possible to 
detect subtle changes in eicosanoid levels in this group. 
Use of a cytokine panel to try to differentiate patients with pneumonia from those with brain injury 
performed less well than the model using eicosanoids alone. On the whole all cytokines tended 
towards an increase in the pneumonia group. Of the most predominant cytokines IP-10 and MCP-1 
are involved in chemoattraction for monocytes and IP-10 is secreted in response to INFγ. ICAM-1 
and E-selectin are involved in leucocyte cellular adhesion and TNFα is an acute phase reactant 
associated with several inflammatory conditions. Interestingly out of the most important cytokines 
in this model IL-10 is the only one that has a predominantly anti-inflammatory role.  
In a mouse model of E.Coli pulmonary infection the importance of MCP-1 has been demonstrated 
and it is suggested that it may control production of other cytokines such as TNFα, IL-6 and 
eicosanoids such as LTB4 (297). In humans systemic levels of TNFα, IL-6, IL-10 and IFN-γ were 
significantly higher in severe community acquired pneumonia than in non-severe pneumonia and 
healthy individuals (298, 299), however, TNFα has also been seen to be higher in ARDS than 
severe pneumonia (300). Some of these cytokine changes may act as predisposing factors to CAP 
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as opposed to direct responses to infection as high TNFα and IL-6 levels have been suggested to 
predispose to CAP (301). In another study using stimulated leukocytes from patients who had 
recovered from Gram negative pneumonia, stimulated leukocytes produce less IL12p70 and TNFα 
than healthy controls but more G-CSF, and similar IL-10 levels (302). In paediatric patients with 
influenza and secondary pneumonia both IL-10 and IL-5 were significantly greater in patients with 
pneumonia than in those without. Serum concentrations of INFγ, TNFα, IL-4, and IL-2 were 
significantly lower in pneumonia patients with neutrophilic leukocytosis than in those without (303). 
Elevated levels of IL-6, IL-8, MCP-1 and TNFα  associated with pneumonia have been shown to be 
reduced when patients are given dexamethasone, with the degree of suppression being linked to the 
causative organism  (304). In an animal model the concentration of serum TNFα correlated to that in 
BAL specimens after an interbronchial E.Coli challenge and the serum concentration also appeared 
to be dependent on the degree of bacterial challenge (305). The patients with pneumonia in this 
study not only had community acquired pneumonia but some who had brain injuries possibly had an 
aspiration pneumonia. In models of aspiration MCP-1 and TNFα have been found in BAL fluid and 
used to predict the type of aspiration syndrome (306). Increased levels of IL-1beta and IL-6 have also 
been associated with other forms of lung disease such as those working in phosphate mines (307) 
suggesting a more generalised role  in pulmonary inflammation. 
Slight variations in cytokine levels in previously reported studies and the current study may be due 
to a number of factors, firstly the exact cytokines that are up-regulated may vary between causative 
organisms and in this population there was a range of responsible microorganisms causing 
pneumonia, see chapter 2. Secondly cytokine levels change with the stage and natural history of 
disease. Although an attempt was made to enrol all patients within 48h of the start of mechanical 
ventilation it was impossible to account for the duration of disease prior to enrolment and the phase 
of pulmonary inflammation for each patient, and thus the exact cytokines that may predominate.  
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Cytokine measurements performed better than eicosanoid measurements when trying to 
differentiate brain injured patients at the time of developing VAP from the first sample taken from 
brain injured patients without infection. However, even with these measurements the predictive 
capacity of these models following cross validation was limited.  
When both cytokine and eicosanoid measurements were combined into one model the ability to 
differentiate pneumonia from brain injured patients was marginally reduced after cross-validation 
than with eicosanoids alone. When validated using the independently classified patients the test 
statistics were similar to those from models based on eicosanoids and cytokines alone, sensitivity 
0.6, specificity 0.67, positive predictive value 0.6 and negative predictive value 0.67. As there is no 
gold standard by which to diagnose pneumonia there was no single test or score to which this 
method could be compared. The use of clinical diagnostic criteria in a paediatric population to 
predict radiologically confirmed pneumonia had a sensitivity of 0.45, specificity of 0.66 and positive 
and negative predictive values of 0.25 and 0.82 respectively (12). In adults abnormal vital signs have 
a high degree of sensitivity (14) but lack specificity for pneumonia, however, it is also known that 
features such as respiratory rate may be sensitive but not specific (16) limiting their usefulness.  
Decision aids have been evaluated that use clinical features to determine the likelihood of a 
radiological diagnosis of pneumonia. In a single study clinicians judgement was found to have a 
sensitivity of  0.74, a specificity of 0.84, a positive predictive value of 0.27 and a negative predictive 
value of 0.97 in primary care (18) and in another clinical diagnosis had a sensitivity of 0.29, a 
specificity of 0.99, positive predictive value of 0.57 and a negative predictive value of 0.96 (19).  
No biomarker has been found to be a gold standard test for pneumonia, the most studied are C-
reactive protein (CRP) and procalcitonin (PCT). In studies of CRP with and without clinical features of 
pneumonia sensitivity varied from 0.36-1.0 and specificity from 0.52-0.96 depending on the cut off 
of used (22-24), however, if an infiltrate was present on the x-ray then these values changed to 
sensitivity 0.36-0.89 and specificity 0.17-0.91 (24). In another primary care study a CRP>20mg/l had 
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a sensitivity of 0.73, a specificity of 0.65, a positive predictive value of 0.24 and a negative predictive 
value of 0.94 to diagnose pneumonia in patients already suspected of having lower respiratory tract 
infections (25). PCT may have sensitivities of 0.17-0.90, specificities of 0.59-1.0, positive predictive 
values of 0.24-1.0 and negative predictive values of 0.89-0.94 depending on the cut off levels used in 
the absence of radiology, however, if an infiltrate was already present on the CXR then these values 
changed to sensitivity 0.43-0.90 and specificity 0.39-0.87. In comparison blood cultures only had a 
sensitivity of 0.11 (24, 25). 
Many of these studies used radiological findings as confirmation of pneumonia, however, depending 
on the frequency of bacterial infection infiltrates on chest radiograph have been found to have a 
positive predictive value of only 0.46-0.85 in one study (26) and lack sensitivity, with around 21% of 
radiographs being negative initially, in another (27).   
The model described above using cytokine and eicosanoid measurement performed at least similarly 
to some of the clinical models outlined above. However, it must be remembered that the group of 
patients in this study were much more unwell than those in the primary care studies so the 
performance of clinical variables may be very different in this group. Also many of these studies used 
radiological findings as an end point where as the diagnosis of pneumonia in this model took 
radiology and all laboratory results into account when patients were classified as pneumonia. Clearly 
evaluating any new test to make a diagnosis of pneumonia is potentially limited when no gold 
standard exists, the calculated test performance statistics are based on patient classifications that 
have their own limited sensitivities and specificities as such it would be impossible to know if a new 
test outperformed the criteria used as the basis of study classification.   
  
The inflammatory molecules that were of most importance in this model were almost identical to 
those identified with either eicosanoids or cytokines alone with the exception that in this model IL-6 
assumed a new degree of importance.  
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Due to concerns that the differences between VAP and brain injured patients sampled at the first 
time point may have represented the effect of a prolonged stay on ICU, rather than the 
development of infection, a further model was constructed comparing an equivalent time point from 
those brain injury patients not developing VAP. This allowed a model to be constructed with 
reasonable predictive capacity on cross validation. Again cytokines dominated in the VAP group. As 
well as cytokines seen in previous models G-CSF, IL-1beta, IL-12p70 and IL-17A become important 
along with the eicosanoids 12-oxo-LTB4 and lipoxin A4. 12-oxo-LTB4 is a metabolite of LTB4 which 
has been associated with pneumonia in a number of ways. It has been seen to increase IL-6 levels 
(159), has been linked to pulmonary complications following trauma (160) and has been associated 
with an increase with both Klebsiella  (308) and Pneumococcus (309) infections. LTB4 has also been 
measured in the EBC of children with CAP (310), in the pleural effusions of patients with pneumonia 
(311) and in BAL fluid from an animal model of brain trauma  which was associated with a non-
significant rise in serum LTB4,  IL-1β and IL-6 (312). In patients with severe head injuries IL-6, IL-10, 
IL-1α, TNFα, and IL-8 have been associated with poor prognosis (313, 314) whilst TNFα, IL-8 and IL-
10 were associated with longer mechanical ventilation and the development of VAP (314). Similarly 
in trauma patients who develop VAP IL-6 and 8 may be associated with antibiotic non-
responders (315). Interestingly previous studies failed to find that serum or plasma cytokines 
were able to identify VAP but within  BALF several cytokines have been noted to increase 
including IL-1α, IL-1β, IL-8, G-CSF, MIP1α and TNFα (316, 317). 
Cytokine production may not only be a response to infection but may result from the act of 
mechanical ventilation its-self, for example  increased tidal volumes may cause increase in plasma 
cytokines (318) and following lung injury in animal models  TNFα, IL-6 and IL-1B have been 
seen to act in combination to cause airway IgA secretion (319). 
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A limited amount of work exists examining the correlations of cytokines and eicosanoids especially 
between such an extensive number of inflammatory mediators. Looking at the correlation between 
all of the inflammatory mediators measured showed some interesting results. The most striking 
difference was that when all patients at time point one were taken very little correlation was seen 
between cytokines and eicosanoids, where as strong correlations existed between molecules from 
within the same families of mediators. However, when either patients with pneumonia or those with 
brain injury who did not develop pneumonia were taken alone new patterns of correlation became 
apparent.  In pneumonia negative correlation was seen between lipoxin B4 and almost all the 
cytokines whereas this was less marked when the brain injured patients were considered and was 
not apparent when all patients were combined. Similarly lipoxin A4 shows only weak correlation 
with cytokines in pneumonia patients but strong positive correlations with IL-12p70, MIP1b, GCSF, 
IL-8, ICAM-1 and IL-1α in brain injured patients. 10(S)17(S)DiHDoHE and 17(S)-HDoHE both 
demonstrated similar patterns of correlation in pneumonia patients with positive correlation being 
seen with all cytokines except MIP-1b, IL-8 and IL-1α where negative correlation was seen. These 
patterns were not the same in the brain injured patients. These two eicosanoids are both anti-
inflammatory in nature and oppose the actions of the cytokines they showed negative corrolation 
with.  
Within the pneumonia patients DHA and EPA had strong positive correlation with IL-12p70, LAP, 
INFγ, IL-13 and IL-17A whereas AA and DGLA had predominantly negative correlation with almost all 
cytokines. In the brain injury cohort this pattern was less clear-cut, in this group there were similar 
patterns with all fatty acid precursors with negative correlations with MIP-1b, GCSF, MP-1 and IL-6. 
EPA and DHA have previously been shown to inhibit IL-6 and IL-8 production from endotoxin 
stimulated endothelial cells (320) and in this data set, negative correlation was seen between both 
EPA and DHA and IL-6 across all three clinical groups which is consistent with the previously reported 
data (320). EPA and DHA have also been seen to reduce TNFα, IL-1β and IL-8 levels although this was 
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less clearly seen in these data. Adhesion molecule expression, including ICAM-1, have been reduced 
by both EPA and DHA (320), however, the correlation data from all three groups in this current data 
set did not support these previous finding with low levels of positive correlation seen.  
In pneumonia tetranor-PGDM had a positive correlation with all cytokines, consistent with its action 
as a mediator of inflammation and vasodilation, but in the brain injury group there were several 
strong negative correlations including LAP, IFNγ, MIP1α, IFNα, IL-13, IP-10, IL-4, IL-17A, IL-1β and E-
selectin. PGD2 is a predominant prostaglandin in the brain and in this organ is synthesized via an 
alternative pathway to that in the systemic circulation. It is possible that a difference in the 
expression of this prostaglandin exists between patients with brain injuries and pneumonia 
explaining the variation in correlation in these two conditions.  Similarly 6-keto-PGF1α correlated 
with all cytokines except ICAM-1 in pneumonia but in the brain injured group negative correlation 
with ICAM-1, IL-6, MCP-1, MIP1a and E-selectin was seen. 6-keto-PGF1α is the more stable 
metabolite of prostacycline, a potent vasodilator, so correlation with cytokines in the infected group 
makes biological sense. In the pneumonia patients IL-8 had a positive correlation with the family of 
HETE metabolites but negative correlation with the DHET family 
In a group of patients with severe sepsis IL-1β was seen to correlate with both TNFα and IL-6 (321). 
In this data set the strongest correlations between these markers were also seen in the infected, 
pneumonia, patients.  
A previous study has correlated phospholipase A2 activity with concentrations of IL-6, IL-8, TNFα, 6-
keto-PGF1α, LTB4 and TXB2 in patients with burns (322). Although we did not measure 
phospholipase 2 activity we measured the concentration of arachidonic acid (AA), the direct result of 
activity of this enzyme. However, only in the BI group did we see positive correlation between TXB2 
and LTB4 with AA. With the other inflammatory markers and in the other groups the relationships 
often showed either a negative correlation or only a weak positive correlation. This may represent 
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downstream enzyme activity in our cohort converting AA into other eicosanoids thereby reducing AA 
levels. Notably in severe sepsis (321) other investigators failed to find significant correlation 
between phospholipase A2 activity and inflammatory mediator levels. 
During cardiopulmonary bypass several positive inflammatory mediator correlations have been 
documented;  IL-6 with IL-8; TXB2 with LTC4 and PGE2; LTB4 with PGE2  and 6-keto-PGF1α and PGE2 
with 6-keto-PGF1α (323). Some of these observations are preserved in this data set. Local 
correlation of IL-1α and PGE2 has been seen in the blister fluid of capsasin induced skin irritation 
(324) with similar finding in our pneumonia patients where inflammation was prominent. IL-8 and 
PGE2 have previously been positively correlated in astrocytomas (325), however, in our brain injured 
patients this correlation was in fact negative. 
The complexity of the relationship between eicosanoids and cytokines can be seen in the following 
example. Negative correlation of PGE2 and TNFα from LPS stimulated human macrophages in the 
plasma of decompensated liver disease has been observed (326), however, the same mediators have 
been seen to be positively correlated in the plasma of children with febrile convulsions  (327). In the 
cohort of patients described above in both the analysis of all patients and when only brain injured 
patients were considered TNFα and PGE2 showed positive correlation, however, when those 
patients with pneumonia at admission were isolated this degree of correlation was no longer 
apparent. This may represent the regulatory effect of PGE2 on TNFα during infection (305).  
Despite some promising findings it is important to note the limitations of this study. Firstly the small 
number of patients, especially in the VAP group, limited the interpretation that could be made of the 
multivariate models and the possibility of over-fitting had to be borne in mind. The optimal way to 
test for this would have been with a validation set of data, however, the low numbers in the VAP 
group meant there were insufficient patients to allow a validation set. We were able to add the few 
reclassified, borderline, patients to the model to explore if a slightly larger data set made a 
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difference to the predictive capacity or the inflammatory mediators of importance compared to the 
original models based on the original patients based on CPIS classification, however this potentially 
lead to new problems. These patients were likely to be different to those diagnosed based on CPIS as 
by being borderline ran a higher risk of having been misclassified before being put into the model. 
Although extensive effort was made to recruit groups of patients that were similar in most respects, 
including time from admission, time and methods of sampling, the inherent heterogeneity of ICU 
patients meant that even within a relatively defined group, such as patients admitted with brain 
injuries, a great deal of variation was likely to exist between individual patients which limiting the 
ability of multivariate models to define specific differences within the population. 
4.7 Conclusion 
Both eicosanoid and cytokine profiling demonstrated an ability to differentiate patients with 
pneumonia from those admitted to ICU with brain injuries. Models based on cytokines highlighted 
inflammatory changes present in the serum of pneumonia patients, whereas models based on 
eicosanoid profiling had a tendency to highlight fatty acids and their metabolites present in the 
serum of patients with brain injuries. Neither type of profiling was particularly able to identify those 
brain injured patients who went on to develop VAP. However, by combining both profiling methods 
a more predictive model of VAP could be created. A combined approach using a combination of both 
cytokines and eicosanoids shows promise for aiding the diagnosis of pneumonia and specifically VAP. 
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5. EXHALED BREATH CONDENSATE 
 
5.1 Summary 
Exhaled breath condensate (EBC) has been investigated using a number of modalities in a range of 
diseases. Some previous work has been done in relatively stable diseases using both NMR 
spectroscopy and mass spectrometry (MS). However, very little work has been done addressing 
pneumonia or metabolic profiling of EBC from ventilated patients. This chapter explores profiling of 
EBC with both NMR spectroscopy and MS to distinguish patients admitted for ventilation with 
pneumonia from those with brain injuries and also to identify those patients who develop ventilator 
associated pneumonia (VAP). NMR spectroscopy was only able to identify a limited number of, 
mainly volatile, metabolites, whereas MS was able to detect a greater number of metabolites, 
however, this was limited by a significant batch effect. Untargeted MS analysis showed some ability 
to distinguish pneumonia from brain injury. However, the biggest metabolic changes seen appeared 
to be those that occurred over time with the duration of mechanical ventilation. 
5.2 Background 
Volatile organic compounds (VOCs) in breath give signatures that are familiar to us from several 
disease processes, from the ketones associated with diabetic complications to the compounds that 
produce the recognisable hepatic fetor. Formalised breath analysis is used widely in law 
enforcement and in some diagnostic clinical tests such as for Helicobacter pylori.  
Technology exists to perform online metabolic profiling of exhaled breath using selected ion flow 
tube mass spectrometry (SIFT-MS) and gas chromatography mass spectrometry (GC-MS) (170-172). 
Work in healthy volunteers has allowed metabolites such as acetone, ammonia and methane to be 
quantified (173, 174) and the repeatability of the technique has been demonstrated (175). Levels of 
exhaled nitric oxide (NO) have shown potential for detecting airway inflammation in asthma and 
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chronic obstructive pulmonary disease (COPD) (176) and carbon monoxide levels increase in 
systemic sepsis (178).  
Trace gas analysis has detected elevated NO levels in patients suffering from pneumonia (177) and 
techniques such as SIFT-MS have shown a potential ability to detect of a range of micro-organisms 
by examining headspace gas of cultures (179-181) including from broncheoalveolar lavage fluid from 
patients with pneumonia (182). Specifically pseudomonas has been investigated from cultures from 
patients with cystic fibrosis (183, 184) and breath has been analysed in an attempt to determine 
colonisation status (185-187). It is thus suspected that analysis of exhaled breath may allow 
detection of specific organisms causing pneumonia by differentiating metabolic profiles.  
Along-side the gaseous phase of breath it is possible to condense and collect the water vapour 
contained in breath, known as exhaled breath condensate (EBC). EBC is 99% evaporated water but 
also contains droplets of fluid from the airway linings allowing non-volatile compounds to be 
detected. Many substances have been detected in EBC including interleukins (188), leukotrienes 
(189) and soluble triggering receptor expressed on myeloid cells (sTREM-1)(89). One of the most 
extensively investigated substances is hydrogen peroxide which is elevated in many inflammatory 
conditions including ARDS (190), asthma (191) and may correlate with treatment response in 
patients with cystic fibrosis treated with antibiotics (192). Similarly EBC isoprostanes have been 
noted to be increased  in COPD (193), asthma (194) and ARDS (195). EBC pH also appears to 
decrease with lung inflammation and has been seen to fall in bronchiectasis, COPD and lung injury 
(196, 197). Limited work has been done in the field of pneumonia but thiobarbituric acid and 
hydrogen peroxide can been seen to increase in CAP (198, 199). 
Limited work has been carried out applying metabonomic techniques to breath. Small scale studies 
with EBC have used NMR analysis to distinguish asthmatics from controls (201-203), stable from 
unstable patients with cystic fibrosis (200) and to investigate smoking related diseases (204). Studies 
196 
 
 
 
have made attempts at metabolite assignment based on NMR spectra (99, 200, 204, 205) identifying 
26 compounds between them, table 5.1.  
Table 5.1. Metabolites identified by H1NMR analysis of EBC across all diseases studied 
Metabolites 
1-methylimidazole ^ 
2-Propanol (Isopropanol) †^ 
Acetate *†‡^ 
Acetoin ^ 
Acetone † 
Alanine *‡ 
Choline * 
Ethanol †‡^ 
Formate †‡^ 
Glutamate *† 
Glutamine *† 
Isobutyrate ^ 
Lactate *†‡ 
Leucine ‡ 
Lysine * 
Methanol * †‡^ 
N-Butyrate ‡ 
Phosphorylcholine * 
Phenylalanine ‡ 
Propionate *†‡^ 
Pyruvate *‡ 
Succinate *‡ 
Saturated Fatty Acids † 
Taurine * 
Trimethylamine *‡ 
Threonine *‡ 
*de Laurentiis et al (205) † Montuschi et al (200) ‡ Sofia et al (99) ^ de Laurentiis et al (204) 
 
Concern has been raised regarding the risk of contamination of EBC with disinfectant when reusable 
collection devices are used and some conflicting work has been done to investigate this (328, 329). 
As yet there is no experience of collecting EBC from ventilated patients for the purpose of 
metabolite analysis. As with the gaseous phase of breath the optimal methods for sample collection, 
processing and analysis are not known.  
Although it is known that changes in respiratory parameters, especially minute ventilation, alter the 
volume of EBC obtained for a given time period of collection (330) it is unknown what effect this has 
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on metabolite concentrations. In the literature using NMR to analyse EBC, samples have been both 
freeze dried and used unaltered prior to spectral acquisition. It is debatable as to which method is 
better, although freeze drying may allow concentration of metabolites leading to improved 
detection it is conceivable that volatile compounds may be lost with this approach.  
With its greater sensitivity mass spectrometry (MS) has potential advantages over NMR 
spectroscopy for the analysis of EBC given the very low concentrations of metabolites within this 
biofluid. Very little work has been done ustilising MS as a profiling tool (206, 207), more work has 
focused on specific markers or panels of markers. Examples of markers that have been explored 
using MS modalities include  glucose (208), urea (209, 210), volatile organic compounds (211, 212), 
aldehydes (213-216),  isoprostanes (195, 217-226), markers of oxidative stress (218), cystinyl 
leukotrienes (218, 227, 228), leukotrienes (189, 227, 229-233), eicosanoids (234-239), 12-HETE (240), 
lysophosphatidic acid (241), asymmetric dimethylarginine (ADMA) (242, 243), adenosine (209), 
phenylalanine (209), lysine (244), tyrosine (245), hydroxyproline (245), proline (245),  purines (246-
249), metallic elements(250), 3-nitrotyrosine (245, 251-254), and proteins (255). In order to measure 
this number of markers a  number of chromatographic techniques have been coupled to MS to 
analyse EBC including Liquid Chromatography – Mass Spectrometry  (206-208, 218), Liquid 
Chromatography Tandem Mass Spectrometry (217, 241, 255), Gas Chromatography - Mass 
Spectrometry (211) and Ultra Performance Liquid Chromatography Tandem Mass Spectrometry 
(227, 243). 
As was the case with NMR analysis of EBC, the majority of work with MS has focussed on relatively 
stable diseases including healthy subjects (215, 238, 256), asthma (189, 206, 218, 227, 232, 234-236, 
239, 242, 248), COPD (216, 247, 250, 255), pulmonary fibrosis (223, 224, 241), cystic fibrosis (208, 
209), pulmonary hypertension (211), brochopulmonary dysplasia (207), pneumoconiosis (229), 
silicosis (221), asbestosis (226), ARDS (195), Churg Strauss (240) and seasonal rhinitis (233). Almost 
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all of the studies so far have been performed in spontaneously ventilating patients with only two in 
those requiring mechanical ventilation (195, 210). No studies have been carried out utilising this 
approach in patients with pneumonia either with or without the need for mechanical ventilation.  
Analysis of EBC is an appealing tool for the diagnosis of pneumonia in ventilated patients as it 
provides a non-invasive method to directly sample form the site of pathology so may be able to 
provide early diagnostic markers and allow for repeated sampling. 
In this chapter I outline an attempt to use a metabonomic profiling approach using 1H-NMR and MS 
methods to analyse EBC collected from ventilated patients with and without pneumonia. 
5.3 Aims 
The overall aim of this study was to investigate the usefulness of metabonomic analysis of EBC in an 
attempt to improve the diagnosis of pneumonia in patients requiring ventilation, specifically those 
going on to develop VAP.  The following questions were addressed: 
1. Can 1H-NMR and MS be used as methods for analysing EBC collected from ventilated 
patients? 
2. Can metabolic profiling of EBC have the potential to aid in the diagnosis of pneumonia in 
ventilated patients? 
5.4 Protocols 
5.4.1 Patient Recruitment and Sample Collection 
Patients were recruited and samples taken as described in chapter 2. Patients were defined as either 
having pneumonia or a brain injury as described earlier. All patients were followed up over time and 
those brain injured patients developing VAP were defined based on CPIS scoring. For a breakdown of 
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the CPIS score used see chapter 2. Patients with borderline scores were assessed and classified as 
VAP or no VAP by an independent assessor. 
Where healthy volunteer EBC was required for method development, samples were taken from a 
single investigator, DA. In order to simulate collection of samples from a ventilated patient as far as 
possible samples were collected using the same equipment as described in chapter 2. The volunteer 
breathed through a non-invasive ventilation mask connected to a Servo-I ventilator set up to provide 
non-invasive ventilation. EBC samples were collected from the expiratory limb of the ventilator for 
15 minutes as described previously, aliquotted into 500µl aliquots and immediately frozen at -80°C. 
To explore the potential contribution of the collection equipment to the metabolic profiles obtained 
from samples of EBC, blanks were prepared with distilled and sterile water to simulate the EBC 
collection. Approximately 2ml of distilled water was placed into an RTube™ and left for 15 minutes, 
the water was then collected using the aluminium plunger and aliquotted into 500µl aliquots before 
being frozen at -80°C. When these blanks were processed similar samples of the distilled and sterile 
water, that had not been through and RTube™, were also run in an attempt to determine whether 
additional signals originated from the water or the RTube™.   
5.4.2 1H-NMR Spectroscopy 
 5.4.2.1 1H-NMR Experiments 
As EBC is >99% water initial assessment was of different methods of water supression. Samples from 
both a healthy subject and a ventilated patient were prepared by the addition of 100µl of D2O to 
500µl of EBC. 550µl were then transferred to a 5mm NMR tube. Four different 1D NMR experiments 
using different pulse sequences were acquired for comparison on an 800MHz spectrometer,  a 
standard one-dimensional experiment using the first increment of a Nuclear Overhauser Effect pulse 
sequence to achieve pre-saturation of the water resonance (110), water suppression using excitation 
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sculpting with gradients, water suppression using excitation sculpting with gradients with a flip back 
pulse and a water gated experiment using water suppression with a 3-9-19 pulse sequence with 
gradients.  All experiments were run at a constant temperature of 300 K. 128 FIDs were accumulated 
for each experiment using a 20 ppm spectral width centred at δ 4.75. The relaxation delay was set at 
2s and a water pre-saturation pulse was applied during this period to cancel the water signal and the 
receiver gain was kept constant.  
For both the volunteer sample, figure 5.1, and that from the patient, figure 5.2, water suppression 
using excitation sculpting without the flip back pulse provided the optimal water suppression. 
However, few new metabolites became apparent with the different pulse sequences. Although more 
spectral peaks were apparent in the patient sample when compared to that from the volunteer, 
there remained relatively few metabolites apparent in these spectra. 
 5.4.2.2 Freeze Drying 
In some of the previously published work EBC has been freeze dried and reconstituted in an attempt 
to improve the yield of metabolites at low concentrations. To explore this method the EBC samples 
were processed as follows. 500µl aliquots were left to dry in the freeze drier overnight. The samples 
were then reconstituted with either 500µl D2O and 100µl 0.1mM TSP with 550µl being placed in a 
5mm NMR tube or with 167µl D2O and 33mcl 0.1mM TSP with 180µl being placed into a 3mm NMR 
tube. 1D NMR experiments using excitation sculpting for water suppression were then performed as 
described above. 
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When samples obtained from a healthy volunteer were compared with and without freeze drying, 
figure 5.3, loss of several of the metabolites was seen, especially those which were volatile such as 
methanol, acetone and acetic acid. When the same experiments were performed on a sample 
obtained from a ventilated patient, figure 5.4, the results were less clear cut.  Many signals appeared 
to be enhanced when samples were freeze dried, with little difference between samples 
reconstituted into 5mm and 3mm tubes. 
5.4.2.3 Effect of Collection Equipment. 
In order to assess the potential for the observed metabolites to originate, not from the samples, but 
from the D2O, the TSP or the RTube™ collecting equipment several blanks were run of the added 
chemicals, figure 5.5, and of D2O instilled into the RTube™, figure 5.6. The spectrum obtained from 
the TSP demonstrated many of the peaks also seen in the freeze dried patient sample, figure 5.5, 
suggesting that much of what was seen did not represent endogenous metabolites but additive 
peaks from the TSP, however, when the spectra from D2O instilled into the RTube™ was compared 
to that from the TSP very few additional signals were seen suggesting that the RTube™ itself had 
minimal effect on the NMR spectra from EBC samples collected using this device. 
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 5.4.2.4 Summary of 1H-NMR 
Only a small number of metabolites were recovered from the EBC using NMR without a freeze drying 
step. Although the use of freeze drying could potentially make metabolites apparent that could not 
otherwise be seen, some of the volatile metabolites were lost in this process and it was unclear how 
reproducible this step may be. Also as there was limited capacity for freeze drying samples would 
have had to be processed in batches making this process unsuitable for either large sample sets or a 
high throughput methodology and adding an additional, time consuming, step that would be 
unwanted in a clinical test. For these reasons, the risk of the additive batch effect with freeze drying 
and the limited number of metabolites recovered without this step it was decided to shift focus from 
NMR analysis of EBC to a method based on MS with the greater sensitivity offered by this method.  
5.4.3 Mass Spectrometry 
EBC samples were randomised and thawed at room temperature prior to preparation. Methanol was 
added to the samples as a solvent prior to MS analysis. In order to optimise the method a range of 
methanol to sample ratios were tested using a sample of healthy control EBC, the best signal 
acquisition was found to be obtained using a ratio of 1:5 sample to methanol. 40µl of EBC was 
placed into each well of a 96 well plate and then 200µl of methanol was added to each well. The 
plate was then heat sealed with foil prior to mixing in an ultrasonic bath for 5 minutes and then a 
plate shaker of a further 5 minutes. For each 96 well plate a number of blanks were run consisting of 
methanol only. Also blanks to examine the RTube™ collecting system were made with distilled water 
as described earlier, along with these blanks samples of the distilled water that had not been 
through the RTube™ were also run to ensure detected metabolites were not from the water itself.  
 A high-throughput screening method was used using an Exactive Instrument equipped with TriVersa 
NanoMate ion source (Advion, Ithaca, NY, USA). Chip-based infusion mode measurements were 
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performed using 5μm nominal internal diameter nozzle chips, and a sample volume of 5μL was 
injected. Total data acquisition time was 2 min, 1 min in negative ion mode and 1 min in positive ion 
mode with automatic polarity switching. EBC samples were run in three batches. 
5.4.3.1 Data processing 
Following data acquisition spectral data were imported into MatLab 2013 (MathWorks, 
Massachusetts, USA) using in-house scripts for all processing steps. Firstly peak picking using a 
threshold of 0.7 was performed to reduce the size of the data matrix and remove noise from the 
data. Probabilistic quotient normalisation was performed to counter for intensity multiplier effects 
such as concentration. Finally data were scaled to reduce the influence of a small number of intense 
peaks that dominate the variance of the un-scaled dataset.  Log scaling was used with an offset of 
the median of all values greater than zero. 
 5.4.3.2 Statistical Analysis 
Processed data were imported into the SIMCA 13.0 statistical package (Umetrics, Sweden) and 
multivariate statistics were used for analysis. Initial exploration with principal component analysis 
(PCA) was performed to look for natural clustering and to detect outliers before supervised 
multivariate analysis using orthogonal partial least squared discriminant analysis (OPLS-DA) was used 
to generate models to optimally separate predefined groups. OPLS-DA models were cross validated 
using seven fold cross-validation using a “leave-one-out” methodology. Important ions within the 
OPLS-DA models were identified by examining the ‘s-plots’ for the models. The ‘s-plots’ show the 
covariance plotted against the correlation with the model for each variable. Variables that are likely 
to be important have a high covariance, indicating a real biological effect on the model and not just 
one driven by analytical variation or noise, and a high correlation, suggesting greater reliability (112, 
331). Such variables lie at the extreme tips of the ‘S’ formed in this plot. 
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An attempt was made to assign potential metabolites to the m/z ratios that appeared in multiple 
comparisons by comparing them with entries in both the Human Metabolome Database, Canada 
(332) and the Scripps Center for Metabolomics METLIN database, USA (333). 
5.5 Results 
5.5.1 Patients 
Thirty four patients, that fulfilled the criteria defined in chapter 2, had samples of EBC taken and 
analysed with MS. Of these 13 had pneumonia on admission and 21 had brain injuries with no 
suggestion of pneumonia when the first samples were taken. Five brain injured patients went on to 
develop VAP based on CPIS scoring. Clinical features of these patients can be seen in table 5.2. As 
previously described in chapter 2, patients with borderline CPIS scores were reviewed by an 
independent clinical assessor and classified as non-infected, pneumonia or VAP based on clinical 
course. Based on this assessment a further six brain injured patients were classified as not having 
pneumonia on admission, five were defined as pneumonia and three as VAP. All initial comparisons 
were made with the original grouping of patients based on CPIS. 
Patients were similar across the groups with respect to their demographic details. Features that 
identified the pneumonia and VAP groups from those with brain injuries included markers of 
infection such as CRP, use of antibiotics and the higher oxygen requirement as would be expected in 
patients with pulmonary infection. 
5.5.2 Evaluation of Batch Effect 
The EBC was run on three separate occasions so a PCA was performed to look for natural separation 
of the samples by batch, figure 5.7. Clear separation could be seen between the three batches along 
the first component. The methanol blanks run at the same time as the samples were seen to cluster 
with the samples as were those blanks prepared from the RTubes™ and distilled water. Separation of  
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Table 5.2. Clinical features of included patients with EBC for MS analysis. Continuous variables are 
given as mean and standard deviation and categorical variables as number and percentage. P-values 
presented in bold text relate to parameters that were significant at the p<0.05 level. 
 Pneumonia (P) Brain Injury (BI) p-value 
(BI vs P) 
VAP p-value 
(BI vs VAP) 
n 13 21 - 5 - 
Age (Mean +/- SD) 55.4±17.7 52.3±14.9 0.60 50.8±17.2 0.87 
Sex, Number of males (%)  9 (69) 12 (57) 0.72 3 (60) 1.00 
Ethnicity, number  White 
European (%) 
11 (84) 15 (71) 0.44 4 (80) 1.00 
Outcome, Number alive (%) 10 (77) 16 (76) 1.00 3 (60) 0.59 
APACHIE II Score (Mean +/- 
SD) 
18.9±5.3 17.0±6.0 0.32 17.8±9.4 0.86 
SOFA Score (Mean +/- SD) 9.9±2.8 8.9±2.6 0.28 8.6±3.1 0.87 
CPIS (Mean +/- SD) 5.8±1.1 2.1±1.4 <0.001 7.0±1.6 <0.01 
Lowest WCC (109/L) (Mean 
+/- SD) 
14.3±5.4 10.0±3.8 0.02 10.5±3.2 0.76 
Highest WCC (109/L) (Mean 
+/- SD) 
14.9±5.2 11.2±3.9 0.04 10.5±3.2 0.70 
Lowest CRP (mg/L) (Mean 
+/- SD) 
174.8±109.8 49.4±54.2 <0.01 116.7±28.2 <0.01 
Highest CRP (mg/L)(Mean 
+/- SD) 
192.8±101.0 62.0±52.5 <0.001 116.7±28.2 <0.01 
Lowest Temperature (°C) 
(Mean +/- SD) 
36.0±0.6 36.0±0.7 0.96 36.0±1.6 0.95 
High Temperature (°C) 
(Mean +/- SD) 
37.5±0.9 37.6±0.7 0.93 38.0±1.3 0.45 
Lowest FiO2 (Mean +/- SD) 0.43±0.15 0.40±0.22 0.57 0.36±0.07 0.51 
Lowest PaO2:FiO2 (Mean +/- 
SD) 
26.2±8.4 41.8±15.5 <0.001 18.6±8.5 <0.001 
Lowest MAP (mmHg) (Mean 
+/- SD) 
70.4±9.8 74.0±11.3 0.33 71.0±12.4 0.64 
Use of noradrenaline, N (%) 9 (69) 13 (62) 0.72 1 (20) 0.15 
Use of antibiotics N (%) 13 (100) 10 (48) <0.01 5 (100) 0.05 
Enteral nutrition, N (%) 11 (85) 15 (71) 0.44 5 (100) 0.30 
Time to sampling from start 
of ventilation (h) (Mean +/- 
SD) 
39.4±8.6 40.4±16.7 0.82 143.6±45.2 <0.01 
Time of day of sample, 
Number taken in the 
morning (%) 
10 (77) 13 (62) 0.47 5 (100) 0.28 
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Figure 5.7. PCA (R2X 0.86, Q2X 0.66) showing separation of batch 1, blue, batch 2, red, and batch 3, 
green. The blanks, triangles, RTube™ blanks, squares, and distilled water blanks, stars, cluster with 
the samples run at the same time point. Separation between the batches is seen along the first 
component, horizontal axis, indicating that the variation caused by batch is of much greater 
magnitude than biological or sample preparation variance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the blanks by batch could also be seen when a PCA using only the blank samples was constructed, 
figure 5.8. The spectra obtained from the blanks can be seen in figure 5.8 with most of the difference 
being seen between batch 3 and both batch 1 and 2. As much of the separation between batches 
seemed to be accounted for by signals originating from the methanol, the average spectral signal 
from each set of blanks was calculated then subtracted from each of the sample spectra from the 
same run. After subtraction from the raw spectra normalisation and scaling was re-applied as 
detailed above. PCA of the resulting spectra, figure 5.9 showed a reduction in batch effect especially  
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Figure 5.8. a. PCA (R2X 0.61, Q2X 0.35) showing separation of blanks run with each batch. Batch 1, 
blue, batch 2, red, and batch 3, green. The greatest separation is seen between batch 3 and batches 
1 and 2. b. MS spectra of blanks run with batch 1 and c. MS spectra of blanks run with batch 3.  
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Figure 5.9. PCA (R2X 0.77, Q2X 0.48) showing separation of batch 1, blue, batch 2, red, and batch 3, 
green after subtraction of average signal from the blanks run simultaneously. The RTube™ blanks, 
squares, and distilled water blanks, stars, cluster with the samples run at the same time point. Less 
separation between the batches is seen than from the previous PCA although batch 3 still shows 
some separation along the second component, y- axis. 
  
218 
 
 
 
between the first and second batch, some separation of batch 3 was still observed along the second 
component.  
5.5.3 Collection Equipment 
After attempting to correct for the batch effect the blanks created to simulate sample collection in 
the RTube™ device could be seen to cluster together away from most of the samples on PCA 
analysis, figure 5.9. However, alongside the RTube™ blanks the blanks made up of only distilled 
water that had not been through an RTube™ could be seen to cluster in the same area. In fact it was 
impossible to construct an OPLS-DA model to separate the RTube™ blanks from the distilled water 
blanks. This implied that almost all of the signals coming from the RTube™ were due to the water 
that had been used to prepare them and not from the tubes themselves. As no water was used in 
any stage of sample preparation these signals could be discounted from interfering with the 
separation of samples based on clinical comparisons. 
5.5.4 Brain Injury vs Pneumonia 
When the 13 patients with pneumonia at admission were compared to the 21 with brain injuries and 
no evidence of pneumonia no natural separation on PCA could be seen (R2X 0.33, Q2X 0.12), figure 
5.10. One outlier could be seen who seemed to have a generally greater intensity of metabolites, 
especially in negative mode. However, there were no technical issues either in the patient’s care or 
sample collection that suggested they should be excluded from further analysis. An OPLS-DA model 
(R2Y 0.90, Q2Y 0.20, p=0.64), figure 5.11, could be constructed to separate the cases of pneumonia 
from those with brain injuries, however, the first orthogonal component is required to obtain a 
positive Q2Y. When the set of patients who were classified by an independent assessor were used to 
validate this model, seven with pneumonia and six with brain injuries, this model had a sensitivity of 
0.43, a specificity of 0.83, positive predictive value of 0.75 and a negative predictive  
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value of 0.56. The ions that were most significant in determining the difference between groups 
were determined by observing the s-plot for the model, figure 5.11 and table 5.3. If a group of brain 
injured patients were used who never went on to develop pneumonia during their stay as the 
control group it became impossible to construct an OPLS-DA model to separate brain injury from 
pneumonia. 
 
Figure 5.10.  PCA scores plot (R2X 0.33, Q2X 0.12) comparing samples taken at the first time point 
from patients admitted with pneumonia (red squares) to those admitted with brain injuries with no 
evidence of pneumonia at sampling (blue circles). No natural separation can be seen between groups 
on the first and second component with only a single outlier being identified.   
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Figure 5.11.  OPLS-DA model with three orthogonal components (R2Y 0.90, Q2Y 0.20, p=0.64) a. 
before and b. after cross validation, comparing samples taken at the first time point from patients 
admitted with pneumonia (red squares) to those admitted with brain injuries with no evidence of 
pneumonia at sampling (blue circles). c. demonstrates the s-plot for the model. This plot compares 
the covariance with the correlation co-efficient for each metabolite. Important metabolites appear at 
the extreme ends of the ‘S’ and are associated with the highest of both the correlation co-efficients 
and the covariance. Metabolites in the top right hand corner are associated with pneumonia and 
those in the bottom left are associated with brain injury. Important ions, labelled are those within the 
circles. 
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Table 5.3. m/z descriptors that were most important in separating patients with pneumonia from 
those with brain injuries at the start of ventilation, the arrows indicate in which of the two groups the 
m/z showed a predominance. Highlighted rows represent ions also identified in other comparisons. 
m/z Brain Injury Pneumonia Possible Assignments 
-221.155  ↑  
-92.015  ↑ Cefuroxime 
-78.995  ↑  
-77.995  ↑  
-76.995  ↑  
371.105  ↑ - 
415.215 ↑  Dexamethasone, Histidine, Lysine, Methionine 
421.225 ↑   
432.245 ↑  Alanine, Arginine, Glutamine, Lysine, Tryptophan 
 433.245 ↑  Lysophosphatidic acid 
437.195 ↑   
 
5.5.5 Brain Injury vs VAP 
When the five patients who developed VAP based on CPIS were compared with those with BI with 
no infection at the start of ventilation PCA (R2X 0.18, Q2X 0.03) failed to separate the two groups. In 
fact it was not possible to build OPLS-DA models with either the original patients based on CPIS or 
with a combined group utilising patients classified with CPIS and those borderline patients classified 
by the independent assessor. However, if only those BI patients who never developed VAP were 
used from the original group an OPLS-DA model with weak classification ability could be constructed 
(R2Y 0.58, Q2Y 0.09, p=0.54) but this did not remain true of when the combined group was used. The 
ions that were important in this model can be seen in table 5.4. 
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Table 5.4. m/z descriptors that were most important in separating samples taken from patients as 
they developed  VAP from those taken from patients with brain injuries, who never developed VAP,  
at the start of ventilation, the arrows indicate in which of the two groups the m/z showed a 
predominance. Highlighted rows represent ions also identified in other comparisons. 
m/z Brain Injury VAP Possible Assignments 
135.054 ↑   
358.205 ↑   
371.105  ↑ - 
432.285 ↑   
433.285 ↑   
 
5.5.6 Time Course 
To investigate whether with time there was a change in the metabolites present in EBC the samples 
taken from the first time point were compared to those taken at the fourth for those brain injured 
patients who did not develop VAP. OPLS-DA models were similar for both the original group based 
only on CPIS (R2Y 0.93, Q2Y 0.53, p=0.05)(TP1 n=12 and TP4 n=5), figure 5.12, and with a combined 
group (R2Y 0.91, Q2Y 0.59, p<0.01)(TP1 n=16 and TP4 n=5). When the samples were paired so that 
only those patients who had both a time point one and four sample were used the Q2Y of the model 
was similar although the p-value fell to below significance due to the small number of subjects (R2Y 
0.96, Q2Y 0.59, p=0.26)(n=5 for each time point). The metabolites that were important in separating 
the time points can be seen in table 5.5 below. 
When the time course of patients with pneumonia was examined an OPLS-DA model from the 
original group (R2Y 0.52, Q2Y 0.20, p=0.89) (TP1 n=13 and TP2 n=5) and the combined group could be 
made (R2Y 0.49, Q2Y 0.19, p=0.08) (TP1 n=20 and TP2 n=7). However, if only paired samples were 
used it was impossible to build a discriminant model. Table 5.6 shows the ions that were important 
in these models. 
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Figure 5.12.  OPLS-DA model with one orthogonal component (R2Y 0.93, Q2Y 0.53, p=0.05) a. before 
and b. after cross validation, comparing samples taken at the first time point from patients admitted 
with brain injuries (blue circles) who never developed pneumonia to the fourth (blue squares). c. 
demonstrates the s-plot for the model. This plot compares the covariance with the correlation co-
efficient for each metabolite. Important metabolites appear at the extreme ends of the ‘S’ and are 
associated with the highest of both the correlation coefficients and the covariance. Metabolites in 
the top right hand corner are associated with pneumonia and those in the bottom left are associated 
with brain injury. Important ions, labelled are those within the circles. 
 
 
  
a. b. 
c. 
432.245 
433.245 
415.215 
265.115 
416.215 
371.105 
372.105 
388.135 
373.105 
-101.065 
393.085 
226.065 
224 
 
 
 
Table 5.5. m/z descriptors that were most important in separating samples taken from brain injured 
patients who never developed VAP comparing time point 1 (TP1) with time point 4 (TP4), the arrows 
indicate in which of the two groups the m/z showed a predominance. Results from the models based 
on both the original groups based on CPIS and the combined group including patients categorised by 
and independent assessor are shown Highlighted rows represent ions also identified in other 
comparisons. 
 Group based on CPIS Combined group Possible Assignments 
m/z TP1 TP4 TP1 TP4  
-92.015   ↑  Cefuroxime 
-101.065  ↑  ↑  
226.065  ↑   Alanine, Asparagine, Cysteine 
265.115 ↑  ↑   
371.105  ↑  ↑ - 
372.105  ↑  ↑  
373.105  ↑  ↑  
388.135  ↑  ↑ Cysteine, Glutamate, Glutamine, 
Histidine, Phenylalanine 
393.085  ↑  ↑ - 
395.085    ↑  
415.215 ↑  ↑  Dexamethasone, Histidine, Lysine, 
Methionine 
416.215 ↑  ↑   
432.245 ↑  ↑  Alanine, Arginine, Glutamine, 
Lysine, Tryptophan 
432.265   ↑   
433.245 ↑  ↑  Lysophosphatidic acid 
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Table 5.6. m/z descriptors that were most important in separating samples taken from patients with 
pneumonia at time point 1 (TP1) from time point 4 (TP4), the arrows indicate in which of the two 
groups the m/z showed a predominance. Results from the models based on both the original groups 
based on CPIS and the combined group including patients categorised by and independent assessor 
are shown. Highlighted rows represent ions also identified in other comparisons. 
 Group Based on CPIS Combined Group Possible Assignments 
m/z TP1 TP4 TP1 TP4  
-302.225  ↑    
-299.205  ↑    
-199.175 ↑     
82.045  ↑    
89.065 ↑    25-Hydroxycholesterol, Alanine, 
Aspartate, Cysteine, Glutamate, Histidine 
111.555  ↑  ↑  
119.055  ↑  ↑  
135.045   ↑  Noradrenaline, Prostaglandin G2,  
Arginine, Asparagine, Glutamine, Glycine,  
Isoleucine, Tyrosine 
144.085  ↑  ↑  
207.165 ↑  ↑   
210.175   ↑   
212.155 ↑    - 
214.095   ↑   
279.165 ↑  ↑   
355.285  ↑    
358.252 ↑     
361.335  ↑    
364.345  ↑    
369.305  ↑    
  
In order to establish if changes over time were different between those brain injured patients who 
did and did not go on to develop VAP the time point four samples were compared to those samples 
taken when VAP developed. Using the original group based on CPIS a discriminant OPLS-DA model 
could be built (R2Y 0.93, Q2Y 0.23, p=0.82)(BI n=5 and VAP n=5), figure 5.13. The predictive capacity 
improved when a combined group was used (R2Y 0.93, Q2Y 0.57, p=0.11) (BI n=5 and VAP n=8). The 
important metabolites in these models can be seen in table 5.7.   
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Figure 5.13.  OPLS-DA model with one orthogonal component (R2Y 0.93, Q2Y 0.23, p=0.82) a. before 
and b. after cross validation, comparing samples taken from patients admitted with brain injuries 
(blue squares) at the fourth time point who never developed pneumonia to those with VAP (green 
triangles). c. demonstrates the s-plot for the model. This plot compares the covariance with the 
correlation coefficient for each metabolite. Important metabolites appear at the extreme ends of the 
‘S’ and are associated with the highest of both the correlation coefficients and the covariance. 
Metabolites in the top right hand corner are associated with pneumonia and those in the bottom left 
are associated with brain injury. Important ions, labelled are those within the circles. 
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Table 5.7. m/z descriptors that were most important in separating samples taken from patients with 
VAP from time point 4 (TP4) samples taken from patients with brain injuries who never went on to 
develop VAP, the arrows indicate in which of the two groups the m/z showed a predominance. 
Results from the models based on both the original groups based on CPIS and the combined group 
including patients categorised by and independent assessor are shown. Highlighted rows represent 
ions also identified in other comparisons. 
 Group based on CPIS Combined group Possible Assignments 
m/z VAP TP4 VAP TP4  
115.575  ↑  ↑  
135.045  ↑   Noradrenaline, Prostaglandin G2,  
Arginine, Asparagine, Glutamine, 
Glycine, Isoleucine, Tyrosine 
135.085 ↑   ↑  
191.115  ↑    
194.125  ↑    
212.155 ↑  ↑  - 
222.175 ↑     
226.065    ↑ Alanine, Asparagine, Cysteine 
226.565    ↑  
303.295 ↑     
306.305 ↑     
325.275 ↑     
371.105    ↑ - 
388.135    ↑ Cysteine, Glutamate, Glutamine, 
Histidine, Phenylalanine 
415.215 ↑  ↑  Dexamethasone, Histidine, Lysine, 
Methionine 
432.245 ↑  ↑  Alanine, Arginine, Glutamine, 
Lysine, Tryptophan 
433.245 ↑  ↑  Lysophosphatidic acid 
445.125 ↑     
520.055  ↑    
548.505 ↑     
589.405 ↑     
590.405 ↑     
 
When only those patients who developed VAP were examined it was impossible to build a model 
that would separate the first time point sample from the sample taken at the time that VAP 
developed. 
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Using the first time point samples from the brain injured patients it was possible to build a weakly 
predictive model to separate those patients who went on to develop VAP from those who did not 
from the group based on CPIS scoring (R2Y 0.90, Q2Y 0.20, p=0.61), however, when the combined 
group was used this failed to be the case. The metabolites that cause this separation can be seen in 
table 5.8 below. 
Table 5.8. m/z that were most important in separating patients who did and did not go on to develop 
VAP using samples taken from patients with brain injuries at time point 1 (TP1), the arrows indicate 
in which of the two groups the m/z showed a predominance. Results from the models based on both 
the original groups based on CPIS and the combined group including patients categorised by and 
independent assessor are shown. Highlighted rows represent ions also identified in other 
comparisons. 
m/z VAP  No VAP Possible Assignments 
81.035 ↑   
89.065  ↑ 25-Hydroxycholesterol, Alanine, Aspartate, 
Cysteine, Glutamate, Histidine 
124.035  ↑  
212.155  ↑ - 
246.175  ↑  
277.185  ↑  
393.085  ↑ - 
419.325 ↑   
420.325 ↑   
441.305 ↑   
442.305 ↑   
467.105 ↑   
468.105 ↑   
 
5.6 Discussion 
In this chapter I have investigated the possibility of using a metabonomic approach to EBC to assist 
in the diagnosis of pneumonia in ventilated patients. The initial approach using 1H-NMR 
spectroscopy found only a handful of metabolites in the samples that were run. An attempt to 
improve metabolite recovery by freeze drying the samples was made. 
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The majority of the identified metabolites within the EBC were volatile metabolites such as ethanol, 
methanol and acetone, such metabolites would be poor candidates for quantitation due to their 
volatility and instability. Similar metabolites have been identified before in the literature (99, 200, 
204, 205), however, it is notable that the number of metabolites seen in this sample set is lower 
than that previously documented. There are a number of potential reasons for this, firstly this group 
of patients were clinically quite different from those studied previously, in none of the previous 
studies have patients who are critically ill been investigated. It is very possible that differences in 
disease processes account for some of the differences. In this study all samples were collected from 
intubated patients, where a tube lies in the patient’s trachea, avoiding the potential for 
contamination of the EBC from metabolites originating in the oral cavity, from saliva, or from the 
digestive tract. For example trimethylamine, a noted cause of halitosis, originating from the 
gastrointestinal tract (334) has been found with NMR in samples of EBC collected from 
spontaneously breathing patients (200, 205). This raises the possibility that some of the metabolites 
within EBC that were identified with NMR that have previously been attributed to the respiratory 
tract may actually originate from other parts of the oropharynx.  Finally, although no work has been 
done specifically examining the effect of different collection techniques on metabolic profiling, 
different equipment used to collect EBC has been seen to alter levels of other markers measured 
(335, 336). The majority of the NMR based metabonomic EBC studies to date have used the 
Ecoscreen collection device to collect samples (200, 201, 204, 205, 328, 329). This device has several 
reusable components and so needs cleaning between samples. There have previously been 
controversies regarding contamination of NMR spectra with metabolites originating from the 
disinfectant used to clean the reusable equipment (205, 328). The use of the disposable RTube™ in 
this study avoided the potential for such artefacts and may also account for the number of 
metabolites being observed appearing lower. The best method in which to handle the samples prior 
to NMR analysis is unclear. In the previous literature both methods involving drying (202) and using 
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samples with only the addition of deuterium have been used (200, 201, 204, 205, 328, 329). No 
studies exist comparing the two techniques. In this study an attempt was made to freeze dry 
samples to enhance metabolite recovery.  However, during the freeze drying process volatile 
compounds could be easily lost and this method showed only a limited ability to improve the 
number of metabolites seen in the spectra. Due to the difficulty in standardising this technique and 
the possibility of both losing important volatile metabolites and adding in metabolites during the 
freeze drying process, this was judged to be an unappealing solution. Also the extra time needed to 
process the samples was unfeasible for large sample sets so this was not pursued further. 
In an attempt to improve metabolite recovery from the EBC an approach using a direct injection MS 
methodology was used.  This method initially demonstrated significant batch effects. The batch 
effect was reduced, although not entirely eliminated, when the peaks found in the methanol blanks 
were removed from the sample spectra.  
When spectra obtained using MS were compared for patients at the start of ventilation who did and 
did not have pneumonia it was possible to build a model that had limited predictive value. As 
described earlier there is no gold standard by which to diagnose pneumonia. Use of vital signs, 
biomarkers and radiographs in differing combinations have all had varying performance 
characteristics in different patient groups (12-16, 18, 20, 22-24, 26, 27) and as such it  is difficult to 
compare the current findings with what is known about currently available tests. However, a 
sensitivity of only 43% would make this test perform less well than many of those described in the 
literature. 
EBC analysis did not perform well when VAP was compared to brain injured patients at the start of 
ventilation. However, although it was not possible to validate the models, EBC seemed to perform 
better after cross-validation when metabolic changes over time were considered for both brain 
injured patients and patients with pneumonia. In both cases a number of potential metabolites 
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could be seen to both increase and decrease over time. It is interesting to observe that the set of 
metabolites that changed over time for pneumonia and brain injured patients were different 
suggesting that what was being observed was not just an accumulation of metabolites from the 
plastic of the endotracheal tube and ventilator circuit. Differences in the changes in airway 
inflammation such as those caused by infection with pneumonia, patterns of airway micro-organism 
colonisation or airway stress from the differences in mechanics involved in the different approaches 
to ventilation in the two groups could all account for the differences seen over time. 
Some of the best models seen could be made when EBC samples taken from similar time points 
were compared between brain injured patients with and without VAP suggesting important 
metabolic differences  may develop as  infection takes hold in the lower respiratory tract. However, 
it is notable that even at the first time point there was a suggestion that there may be some 
potential to distinguish patients before VAP became clinically apparent potentially representing 
metabolic predisposition to infection or the early development of infection itself. 
Because of the nature of MS and the multiple ions that can be produced from the fragmentation of a 
given metabolite and the potential for two metabolites to produce fragmentation ions with similar 
mass/change ratios metabolite identification is much more challenging with this modality than with 
NMR. An attempt was made to make some preliminary assignments of the ion fragments that 
appeared in multiple clinical models by comparison with published databases. Because of the 
overlap of m/z ratios firm assignment was not possible within the scope of this project. However, 
some interesting metabolites were potentially detected. Amino acid species seemed to be candidate 
metabolites for many of the detected ion fragments. Amino acids, especially adenosine (209), 
phenylalanine (209), lysine (244) and tyrosine (245), have been measured previously in EBC. Of note, 
alanine and glutamine were potentially identified in the breath of those patients with brain injuries, 
in keeping with the abundance of these amino acids seen in the serum of this group of patients, in 
chapter 3. Similarly phenylalanine may have been detected in samples taken from those with brain 
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injuries at time point four, again, in keeping with findings from serum. More detailed conclusions 
regarding the amino acids detected in EBC are difficult to make due to the great deal of overlap in 
the ion fragments of these species.   Lysophosphatidic acid, a signalling molecule derived from 
phospholipids that has been implicated in increasing vascular permeability, promoting epithelial cell 
death and the development of fibrosis, was also potentially identified in the samples studied here and 
has also been previously reported in EBC of patients with pulmonary fibrosis (241). Although it may 
have been expected that lysophosphatidic acid was more abundant in those with pneumonia, due to 
its role in inflammation, it was generally found in the breath of those with brain injuries especially at 
the start of the ICU stay, the only case where this was not so was with VAP when it was more 
abundant than in those with brain injuries ventilated for a similar time. Other biological markers 
possibly detected included prostaglandin G2 at the start of ventilation in those with pneumonia and 
towards the end of ICU stay in those with brain injuries and 25-hydroxycholesterol in those with 
pneumonia, however, without further information these assignments are very tentative. Along with 
biological substances a number of drugs were potentially present. Breath analysis has been used 
before to detect the presence of drugs, for example to the anaesthetic agent propofol in the gaseous 
phase of breath (337). In this study cefuroxime, noradrenaline and dexamethasone were tentatively 
identified in the EBC. Dexamethasone was seen as a possible differentiating substance in those with 
brain injuries compared to those with pneumonia and was detected in the breath of those with brain 
injuries at the start of ventilation compared to the final time point. These findings make sense as 
dexamethasone was used in a number of the brain injured patients as an anti-inflammatory drug in 
certain diseases and as such was more likely to administered at the start of the ICU stay. 
Dexamethasone was also more likely to be associated with VAP than those brain injured patients who 
were ventilated for a similar amount of time, perhaps because of the immunosuppressive properties of 
steroids predisposing to infection. The antibiotic cefuroxime seemed to be more abundant in those 
with pneumonia compared to those with brain injuries, however, this seems unlikely as 
cephalosporins were more widely administered to those with brain injuries than to those with 
pneumonia suggesting that this is not a true assignment. This drug may have also been able to 
distinguish time point one from time point four samples from patients with brain injuries which makes 
much more sense as this antibiotic was more likely to be given around the time of admission to 
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intensive care than during a patient’s stay. Noradrenaline is a vasopressor frequently given to patients 
on intensive care, and although no statistical significant differences existed in the use of this drug 
between the pneumonia, brain injured and VAP groups it was interesting that it may be associated 
with some capacity to help separate some of the groups with multivariate analysis. The fact that some 
drug metabolite may have been detected in these samples raises the concern that some of the 
predictive models were basing prediction not on genuine biological differences but treatment effect. In 
order to address this fully more detailed metabolite assignment would need to be performed. 
 
This study represents the first attempt to investigate pneumonia using a metabonomic approach to 
the analysis of EBC and is one of only a few studies looking at ventilated patients with such 
techniques (195, 210). Almost all of the previous work has focused on relatively stable diseases in a 
clinic setting. Also although MS has been used to study EBC in a number of previous studies few have 
approached the problem with an entirely non-targeted, profiling, approach (206, 207) and this is the 
only one to use a direct-injection non-hyphenated technology. 
The current study has a number of limitations. Firstly as no gold standard exists for the diagnosis of 
pneumonia any method used to define the clinical groups will lead to some misclassification so 
building a model with 100% accuracy is unlikely. Also this study used a limited number of patients, of 
all of those that were recruited only those with the clearest diagnosis of pneumonia were used in 
order to ensure the best clinical separation between comparison groups. This will limit the ability to 
build models to correctly classify patients. EBC itself poses a particular challenge with the 
metabolites it contains being present in very low concentrations thus requiring very sensitive 
equipment to detect them. This also leads to the problem that exogenous metabolites contained 
within solvents, collecting equipment and introduced by any laboratory equipment will also be more 
easily detected. Care had to be taken to minimise the potential for contamination in any of the 
assays. Despite extensive efforts to eliminate such confounders a great number of metabolites were 
still detected within the methanol used for MS analysis. Even after these were addressed batch 
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effect could still be observed between samples run at different times. Although when individual 
models were examined it was not apparent that the batch effect was having an influence on the 
models themselves this issue needs to be addressed when considering this approach as a clinical 
test. For this to be a useful approach in the clinical environment it would have to be reproducible 
day to day and location to location in order to provide accurate results that could influence clinical 
decision making. To further address the clinical importance of the MS based models further 
metabolite identification needs to be undertaken to address the biological importance of the ions 
identified as being discriminant in the models 
 
5.7 Conclusion 
Analysis of EBC using a metabonomic approach with either NMR spectroscopy or MS poses a 
number of challenges due to the low concentration of metabolites within this fluid. In this sample 
set NMR provided only a limited number of metabolites and freeze drying the sample prior to 
preparation failed to produce a feasible solution to the low metabolite count. 
Analysis of EBC with a direct-injection MS methodology shows some possibility to assist with 
diagnosis of both pneumonia and VAP, however, this method has limitations with regard to its 
reproducibility and further work needs to be done in order to identify the metabolites that seem to 
differentiate the clinical groups in order to assess their clinical relevance.  
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6. MULTIVARIATE ANALYSIS OF CLINICAL DATA 
 
6.1 Summary 
Clinical data are typically analysed using simple statistics such as Student’s t-test, ANOVA or Fishers 
exact teat. There are relatively few examples of studies that have used multivariate techniques, 
usually associated with ‘omics’ data processing, to analyse routinely collected clinical data. In this 
chapter multivariate analysis was applied to a set of clinical data in an attempt to differentiate those 
patients with pneumonia and VAP from those with brain injuries. Several interesting differences 
were found between these groups that were not confined to typical clinical features that would have 
been expected to be different in those with and without pneumonia. 
Within this chapter an attempt was made to combine clinical, inflammatory and metabolic data sets. 
Clinical data was important in all comparisons but the significance of inflammatory and metabolic 
data varied depending on the comparison being made. Overall there seemed to be an advantage to 
combining some or all data sets to improve discrimination of the models. Discrimination between 
clinical groups could be improved further by selecting the most important variables. 
6.2 Background 
For patients on the ICU there is an enormous amount of clinical data available from bedside clinical 
observations, for example blood pressure, heart rate and temperature, laboratory tests, such as 
haematological and clinical chemistry parameters, point of care tests, for example blood gas analysis 
and blood glucose measurement, to specific measureable parameters for particular interventions 
such as those associated with mechanical ventilation. Interpreting clinical data is clearly one of the 
skills of the physician. However, in some situations clinical judgement may be unable to detect some 
of the subtle changes in these parameters. In some conditions clinical features can overlap with 
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other medical conditions such as pulmonary oedema, ARDS and lobar collapse, this becomes 
especially problematic when the diagnosis, such as VAP, does not have a gold standard diagnostic 
test.  
Clinical feature have been found to have a variable ability to diagnose pneumonia (11, 14, 18, 19, 21) 
in the primary care setting and the addition of biomarkers such as CRP and PCT have a limited effect 
on improving diagnostic potential (22-25). Despite the greater amount of clinical information 
available on the ICU making the diagnosis of VAP is potentially more challenging than when 
pneumonia is the presenting diagnosis (72-74). This probably represents the greater complexity of 
ICU patients where several clinical conditions can exist simultaneously and the features of each can 
overlap. None of the features that are important in making the diagnosis of pneumonia are specific 
to this condition, a white cell count and temperature increase can be seen in any condition where 
there is a SIRS response; radiological changes of consolidation can be difficult to distinguish from 
lobar collapse or ARDS (73, 75) and similarly oxygen requirements can increase due to these other 
lung conditions.  
The integration of clinical data on ICU has mainly been focused on outcome scores such as the Acute 
Physiology and Chronic Health Evaluation II score (APACHEII) (338) and the Simplified Acute 
Physiology Score II (SAPS II) (339) to predict the risk of death and organ dysfunction scores such as 
the Logistic Organ Dysfunction Score (LODS) (340), Multiple Organ Dysfunction Score (MODS) (341), 
and the Sequential Organ Failure Assessment (SOFA) (342). These scores are generally derived from 
logistic regression models of clinical variables and then validated in large ICU populations. However, 
on the whole these scores have little impact on an individual patient and are used predominantly in 
the context of clinical research to compare patient groups or as a marker of ICU performance (343). 
So far the only attempt to combine clinical data into a model to diagnose VAP has been the CPIS  
developed by Pugin et al based on six clinical parameters, temperature, white cell count, secretion 
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load, radiological changes, oxygen requirement and microbiology, which gives a score from 0-12 (83) 
with a score of greater than six correlating with high bacterial load on broncheoalveolar lavage. This 
score has been used to guide prescribing with a significant reduction in antibiotic prescribing without 
increase in mortality (84).  However, CPIS doesn’t work well in all clinical scenarios such as burn and 
trauma patients (86) and it is plausible that the addition of further parameters available on the ICU 
may be able to strengthen this score. 
There have been a few attempts to use the multivariate statistical methods used previously in this 
study to analyse clinical data. For example, PLS has been used to predict survival in patients with 
multiple myeloma following treatment (344), to predict outcome in children following surgery for 
tuberous sclerosis (345) and using specific measurements of dental disease to predict outcome 
following dental intervention (346). No studies exist that attempt to apply these methods to either 
intensive care patients or to those with pneumonia. 
Further, despite the number of studies that exist using ‘omics’ sciences there is little available 
attempting to combine ‘omics’ data with clinical features. A few studies exist that attempt to 
combine different ‘omics’ data sets. For example, an animal study looking at liver toxicity combined 
NMR, microarray and clinical chemistry data (347). 
6.3 Aims 
The overall aim of this study was to use multivariate techniques with clinical data to attempt to 
improve the diagnosis of pneumonia in patients requiring ventilation, specifically those going on to 
develop VAP. The following questions were addressed: 
1. Can multivariate methods applied to routinely collected clinical data produced 
discriminant models to differentiate those with and without pneumonia? 
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2. Can combining clinical data with metabolic and inflammatory data more accurately 
differentiate pneumonia than any one set of data alone? 
6.4 Protocols 
6.4.1 Patient Recruitment 
Patients were recruited as described in chapter 2. Patients were defined as either having pneumonia 
or a brain injury as described earlier. All patients were followed up over time and those brain injured 
patients developing VAP were defined based on CPIS scoring, for a breakdown of the CPIS score used 
see chapter 2. Patients with borderline scores were assessed and classified as VAP or no VAP by an 
independent assessor. 
6.4.2 Clinical Data 
A comprehensive set of clinical data was recorded for each day of a patient’s ICU stay. Data included 
all physiological variables, laboratory test results, radiology results, arterial blood gas results, 
microbiology results and administered drugs, fluid and feed. Data were collected at 8:00am every 
morning and covered the preceding 24h period. For all variables the minimum and maximum values 
were recorded for the 24h period. Where data were not recorded or had not been measured the 
relevant data point was left blank. Where patients were spontaneously breathing and receiving 
oxygen via nasal cannula or facemask the number of litres of oxygen was converted into an FiO2 
using the conversion in table 6.1 to allow comparison to patients receiving titrated oxygen therapy 
either through the ventilator or via a face mask such as a venturi or humidified system. 
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Table 6.1. Conversion table for litres of oxygen to FiO2. 
Method O2 Flow (l/min) Estimated FiO2 
Nasal Cannula 1 0.24 
 2 0.28 
 3 0.32 
 4 0.36 
 5 0.40 
 6 0.44 
Facemask 5 0.40 
 6-7 0.50 
 7-8 0.60 
 
All clinical data were checked by hand to ensure that recorded values fell within physiological 
ranges. Numerical data were selected to build multivariate models to compare pneumonia to brain 
injured patients leaving a data set made of continuous variables that could be objectively measured. 
The complete list of variables acquired can be seen in table 6.2, giving 106 variables for multivariate 
analysis. 
6.4.3 Metabolic and Inflammatory Data 
The two most reliable data sets from the earlier analysis, the metabonomic and inflammasome data 
from serum samples, were chosen to combine with the clinical data in an attempt to build an all-
encompassing model taking into account clinical, inflammatory and metabolic data. Because of the 
much larger data set that was the metabonomic data this data set was handled in two ways, first the 
entire spectral data was combined with the two other data sets and then a smaller data set using 
only the integrals of the identified peaks. The integrals were calculated using an in-house Matlab 
script and reduced this data set from thousands of data points to just over 200. 
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Table 6.2. Clinical variables used for multivariate analysis, for all values other than those which are 
averages over 24h (*) the minimum and maximum values for each variable for the 24h period prior 
to sampling were taken. Some variables (ǂ) were only available for certain ventilation modes. 
 
  
Bedside Variables Laboratory Variables 
Ventilator Settings Laboratory Parameters 
Peak end expiratory pressure (PEEP) (cmH2O)ǂ White Blood Cell Count (x10^9/L) 
FiO2 Haemoglobin (g/dl) 
Respiratory rate set (breaths/min)ǂ Haematocrit (%)  
Respiratory rate measured (breaths/min) Platelet Count (x10^9/L) 
Set tidal volume (ml)ǂ Prothrombin Time (s) 
Expiratory tidal volume (ml) Activated Partial Thromboplastin Time (s) 
Pressure support (cmH2O)ǂ Fibrinogen (g/L) 
Pressure control (cmH2O)ǂ Sodium (mmol/L)  
Expiratory minute volume (L) Potassium (mmol/L)  
Peak airway pressure (cmH2O) Creatinine (µmol/L)  
 Urea (mmol/L)  
Physiological Parameters Chloride (mmol/L) 
Glasgow Coma Scale  Magnesium (mmol/L)  
Heart rate (beats/min) C-Reactive Protein (mg/l)  
Systolic blood pressure (mmHg) Alanine Transaminase (IU/L) 
Diastolic blood pressure (mmHg) Alkaline Phosphatase (IU/L) 
Mean arterial pressure (mmHg) Bilirubin (µmol/L)  
Temperature (°C) Albumin (g/L)  
Oxygen saturations (SpO2) (%) with associated FiO2 Corrected Calcium (mmol/L)  
Ratio of saturation (SpO2) to FiO2 Phosphate (mmol/L) 
Hourly urine output (ml/h)  
Total urine output over 24 hours (ml) Blood Gas Parameters 
Average hourly urine output (ml)* PaO2  with associated FiO2 
Total fluid input over 24 hours (ml) PaO2:FiO2 ratio (kPa) 
Average hourly fluid input (ml)* PaCO2 (kPa) 
Fluid balance over previous 24h (ml) pH 
Number of tracheal secretions over 24h Bicarbonate (mmol/L) 
Central Venous Pressure (CVP)(cmH2O) Base excess 
 Lactate (mmol/L) 
 Glucose (mmol/L) 
241 
 
 
 
6.4.4 Statistical Analysis  
Prior to multivariate analysis all data were scaled to unit variance. Standardising the variance 
attempts to take into account the influence on multivariate models of variables with naturally higher 
values that tend to be associated with higher variance and allows smaller parameters to have similar 
weight within the model. This technique also allows parameters measured with different units to be 
combined without other manipulation. Multivariate statistics were used to analyse the data. Initial 
exploration with principal component analysis (PCA) was performed to look for natural clustering 
and to detect outliers before supervised multivariate analysis using orthogonal partial least squared 
discriminant analysis (OPLS-DA) was used to generate models to optimally separate predefined 
groups. OPLS-DA models were cross validated using seven fold cross-validation using a “leave-one-
out” methodology. Important variables in each model were identified by examining the loadings 
associated with each model and the variable importance, VIP, scores. VIP is a parameter which 
summarizes the influence on Y, the defined groups, of each variable in the model. It is a sum over all 
model dimensions of the variable contributions. Variables important in the models were defined as 
those with VIP greater than 1.0 (112). All multivariate analysis was performed using the SIMCA 13.0 
statistical package (Umetrics, Sweden). Where it was necessary to compare models constructed with 
clinical data combined with inflammatory and metabolic data with those using only metabolic or 
inflammatory data new models were constructed with the inflammatory or metabolic data utilizing 
only those patients who had both sets of data. This was done to ensure that the same patients were 
being compared to avoid bias based on the slightly differences in the patient groups who had both 
types of data. Univariate analysis was performed using the Student’s t-test with the Benjamini-
Hochberg procedure to correct for false discovery rate from multiple comparisons. 
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6.5 Results 
6.5.1 Patients 
21 patients with brain injuries, 12 with pneumonia and 5 who developed VAP had all three of sets of 
data: clinical, inflammatory and serum metabonomic, to allow combined models to be built.  
Overall from these patients 6.1% of the clinical data was missing, however, the majority of the 
‘missing data’ originated from certain ventilator parameters that were only applicable when some 
ventilator modes were used, for example pressure support and set tidal volume. Excluding these 
parameters the rate of missing data was only 3.2%. Excluding ventilation parameters, rates of 
missing data varied from 0-60.5%. The parameter with the largest proportion of missing data was 
the central venous pressure which was missing in over 60% of cases. Selected models were 
examined with and without this parameter and little difference was found when it was included or 
excluded, therefor to simulate the clinical environment, where not all data is necessarily available, it 
was left in for initial comparisons. After CVP the next most common missing variable was ALT which 
was missing 9.3% of the time. 31 parameters had no missing data and a further 51 had only 2% 
missing data, representing data missing from only a single patient. Fourteen variables had 4% 
missing data representing only 2 missed data points. 
6.5.2 Clinical Data Models 
6.5.2.1 Brain Injuries vs Pneumonia 
Principal component analysis of the clinical variables demonstrated natural separation of the brain 
injured and pneumonia patients (R2X 0.27, Q2X 0.05), figure 6.1, but the predictive value for this 
model was only 5% implying that the data set was very heterogeneous. Three of the pneumonia 
patients were outliers, the first lying to the left of the plot was distinguished by having a marked   
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Figure 6.1 a. Three component PCA comparing samples taken from patients with brain injuries, blue circles, and patients with pneumonia, red squares, at the 
start of ventilation (R2X 0.27, Q2X 0.05) with all clinical parameters and b. excluding those used in the CPIS (R2X 0.31, Q2X 0.12). The ellipse represents 
Hotelling’s T2 at p=0.05. Some natural separation can be seen between the two groups in the first and second components, in figure 6.1a two of the 
pneumonia patients are outliers as demonstrated by lying outside the Hotelling’s ellipse, numbered. c. Loadings plot for the first PCA, showing the clinical 
variables causing most of the separation. 
  a. 
1 
2 3 
b. 
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inflammatory response with a higher white cell count and CRP along with renal failure as suggested 
by high urea,  also for this patient several respiratory parameters were not available as they had 
both of their lungs independently ventilated at the start of recruitment so a single set of parameters 
were impossible to obtain. The second two patients presenting as outliers at the bottom of the plot 
were characterised by the high carbon dioxide, bicarbonate and base excess values. This is not 
unexpected as these individual had compensated chronic respiratory failure secondary to previous 
brain injuries. All of these patients were retained for further analysis as ideally a good clinical model 
would be able provide discrimination across a range of patients with various associated 
comorbidities. The natural separation between the pneumonia and brain injured groups was not 
entirely surprising as the classification of pneumonia was based on an adaption of the CPIS score 
which is based on several of the clinical parameters here. When the model was rebuilt excluding 
temperature, secretion load, white cell count and markers of oxygenation there was still a 
suggestion of separation along the first two components (R2X 0.31, Q2X 0.12), figure 6.1b. When the 
loadings from the first PCA were examined, figure 6.1c, the features that caused the separation were 
not those from the CPIS but parameters such as haemoglobin, PEEP, CRP, fibrinogen and PaCO2. 
When a supervised model was constructed using OPLS-DA then good separation was achieved on 
cross validation (R2Y 0.71, Q2Y 0.53, p<0.001), figure 6.2, and this predictive capacity was only slightly 
reduced when features from the CPIS were excluded (R2Y 0.62, Q2Y 0.43, p<0.001). The clinical 
features that were most important in building this model can be seen in table 6.3. 
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Figure 6.2. OPLS-DA model based on clinical data with one component comparing patients admitted with brain injuries, blue bars, to those with pneumonia, 
red bars, at the start of ventilation (R2Y 0.70, Q2Y 0.53, p< 0.001) a. before and b. after cross validation. Before cross validation the groups can be seen to be 
separated with pneumonia samples separated in the positive direction along the first component. After cross validation this separation is less with some of 
the pneumonia patients crossing between groups.   
 
a. b. 
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Table 6.3 Clinical features with VIP>1.0 for the OPLS-DA model (R2Y 0.71, Q2Y 0.53, p<0.001) 
comparing patients with pneumonia to those with brain injuries, including features making up the 
CPIS. 
 
When only those variables with VIP >1.0 were used to construct the model, including features used 
in the CPIS then predictive capacity improved (R2Y 0.72, Q2Y 0.65, p<0.001) and when the nine 
independently classified patients were used as a small validation cohort then the model had a 
sensitivity of 0.75, specificity of 0.80, positive predictive value of 0.75 and negative predictive value 
of 0.80. 
 
Variables Increased in Pneumonia Variables Reduced in Pneumonia 
Variable VIP Direction of 
Change in 
Pneumonia 
Variable VIP Direction of 
Change in 
Pneumonia 
Highest PEEP 2.68 ↑ Highest Albumin 2.08 ↓ 
Highest CRP 2.10 ↑ Lowest Albumin 2.04 ↓ 
Lowest CRP 1.95 ↑ Highest PaO2:FiO2 ratio 1.75 ↓ 
Lowest PEEP 1.82 ↑ Lowest PaO2:FiO2 ratio 1.70 ↓ 
Highest Peak Airway Pressure 1.68 ↑ Highest SpO2:FiO2 Ratio 1.58 ↓ 
Highest Respiratory Rate 1.62 ↑ Highest pH 1.55 ↓ 
Highest Fibrinogen 1.59 ↑ Highest Haemoglobin 1.40 ↓ 
Highest PaCO2 1.53 ↑ Lowest pH 1.30 ↓ 
Lowest Fibrinogen  1.53 ↑ Lowest SpO2:FiO2 Ratio 1.25 ↓ 
Lowest White Cell Count 1.51 ↑ Lowest PaO2  1.12 ↓ 
Lowest Glasgow Coma Score 1.43 ↑ Lowest Expiratory Tidal 
Volume 
1.07 ↓ 
Total Secretions 1.40 ↑ Lowest Haemoglobin 1.06 ↓ 
Highest White Cell Count 1.39 ↑    
Lowest FiO2 1.38 ↑    
FiO2 for highest SpO2 1.38 ↑    
Highest Haematocrit 1.27 ↑    
Lowest PaCO2 1.26 ↑    
FiO2 to get the highest PaO2 1.20 ↑    
Highest Heart Rate 1.20 ↑    
Lowest Heart Rate 1.14 ↑    
Lowest Peak Airway Pressure 1.11 ↑    
Lowest ALP 1.10 ↑    
Highest Prothrombin Time 1.09 ↑    
Lowest Urea 1.08 ↑    
Lowest APTT 1.07 ↑    
Highest Expiratory Minute Volume 1.02 ↑    
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6.5.2.2 Brain Injury vs VAP 
OPLS-DA models comparing the five patients who developed VAP to those admitted with brain 
injuries continued to have good predictive capacity both when all clinical data was used (R2Y 0.69, 
Q2Y 0.52, p<0.001), figure 6.3, and when the features in the CPIS were excluded (R2Y 0.71, Q2Y 0.50, 
p<0.001). Table 6.4 gives the most important parameters in this model. When the patients with VAP 
were compared to those brain injured patients who never developed VAP but who had data for an 
equivalent time point then the model remained good (R2Y 0.83, Q2Y 0.54, p=0.08)with oxygenation 
and associated parameters having a much greater influence than in previous models, table 6.5. 
When the CPIS variables were removed the predictive capacity fell (R2Y 0.75, Q2Y 0.26, p=0.44). 
Table 6.4 Clinical features with VIP>1.0 for the OPLS-DA model used (R2Y 0.69, Q2Y 0.52, p<0.001) 
comparing patients with VAP to those with brain injuries, including features making up the CPIS. 
Variables increased in VAP Variables decreased in VAP 
Variable VIP Direction of 
Change in VAP 
Variable VIP Direction of 
Change in VAP 
Lowest ALP 2.32 ↑ Highest SpO2:FiO2 Ratio 1.66 ↓ 
Highest ALP 2.28 ↑ Lowest PaO2:FiO2 ratio 1.65 ↓ 
Lowest Fibrinogen  2.23 ↑ Lowest SpO2 1.59 ↓ 
Highest Expiratory Tidal Volume 2.23 ↑ Highest Albumin 1.46 ↓ 
Highest Fibrinogen 2.16 ↑ Lowest Albumin 1.32 ↓ 
FiO2 to give highest SpO2 1.78 ↑ Highest PaO2:FiO2 ratio 1.30 ↓ 
Total Secretions 1.74 ↑ Lowest PaO2  1.08 ↓ 
Lowest ALT 1.74 ↑ Lowest SpO2:FiO2 Ratio 1.06 ↓ 
Highest ALT 1.71 ↑    
Highest Respiratory Rate 1.70 ↑    
Lowest Expiratory Tidal Volume 1.67 ↑    
Lowest Respiratory Rate 1.66 ↑    
Lowest Urea 1.63 ↑    
Highest Peak Airway pressure 1.56 ↑    
Lowest CRP 1.51 ↑    
Highest Expiratory Tidal Volume 1.51 ↑    
Lowest FiO2 1.49 ↑    
Highest PEEP 1.41 ↑    
Highest Urea 1.39 ↑    
Highest Systolic Blood Pressure 1.38 ↑    
Highest CRP 1.32 ↑    
Lowest PEEP 1.27 ↑    
FiO2 to give lowest PaO2 1.09 ↑    
Lowest Bilirubin 1.08 ↑    
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Figure 6.3. OPLS-DA model, with one component, based on clinical data comparing patients admitted with brain injuries, blue bars, to those who developed 
VAP, green bars, a) with all clinical variables (R2Y 0.69, Q2Y 0.52, p< 0.001) and b) without those used in the CPIS (R2Y 0.71, Q2Y 0.50, p< 0.001). Before cross 
validation the groups can be seen to be separated with pneumonia samples separated in the positive direction along the first component.  
  
a. b. 
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Table 6.5 Clinical features with VIP>1.0 for the OPLS-DA model (R2Y 0.83, Q2Y 0.54, p=0.08) 
comparing patients with VAP to those with brain injuries at an equivalent time point, including 
features making up the CPIS. 
Variables Increased in VAP Variables Decreased in VAP 
Variable VIP Direction 
of Change 
in VAP 
Variable VIP Direction 
of Change 
in VAP 
Lowest FiO2 1.81 ↑ Lowest PaO2:FiO2 ratio 1.99 ↓ 
Highest FiO2 1.71 ↑ Highest SpO2:FiO2 ratio 1.93 ↓ 
FiO2 to give highest SpO2 1.69 ↑ Lowest SpO2:FiO2 ratio 1.92 ↓ 
FiO2 to give highest PaO2 1.65 ↑ Highest PaO2:FiO2 ratio 1.61 ↓ 
Lowest CRP 1.61 ↑ Lowest PaO2 1.58 ↓ 
Highest CRP 1.61 ↑ Lowest SpO2 1.58 ↓ 
FiO2 to give lowest PaO2 1.61 ↑ Lowest Platelet Count 1.48 ↓ 
Lowest Creatinine 1.54 ↑ Highest Platelet Count 1.48 ↓ 
Highest Creatinine 1.54 ↑ Lowest Urine Output 1.37 ↓ 
Lowest Inspired Tidal Volume 1.51 ↑ Lowest pH 1.27 ↓ 
FiO2 to give lowest SpO2 1.37 ↑ Total Urine Output in 24h 1.25 ↓ 
Highest PaCO2 1.36 ↑ Average Hourly Urine Output 1.25 ↓ 
Highest Central Venous Pressure 1.36 ↑ Lowest Diastolic Blood Pressure 1.18 ↓ 
Highest PEEP 1.28 ↑ Total Fluid Input in 24h 1.13 ↓ 
Highest Systolic Blood Pressure 1.26 ↑ Average Fluid Intake per Hour 1.12 ↓ 
Highest Inspired Tidal Volume 1.24 ↑ Lowest Mean Arterial Pressure 1.05 ↓ 
Highest Peak Airway Pressure 1.24 ↑    
Lowest Bilirubin 1.15 ↑    
Highest Bilirubin 1.15 ↑    
Lowest ALP 1.13 ↑    
Highest ALP 1.13 ↑    
Lowest Sodium 1.11 ↑    
Highest Sodium 1.11 ↑    
Highest Expiratory Minute 
Volume 
1.05 ↑    
Highest Pressure Support 1.00 ↑    
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6.5.3 Combining Clinical Variables with Metabonomic and Inflammasome Data 
6.5.3.1 Brain Injury vs Pneumonia 
6.5.3.1.1 Clinical and Metabonomic Data 
Combining clinical data with full spectral serum data provided an OPLS-DA model with a reasonable 
Q2Y (R2Y 0.95, Q2Y 0.42, p=0.003) although slightly lower than that using clinical data alone but 
identical to a model using only the spectral data for this patient set (R2Y 0.95, Q2Y 0.42, p=0.003). 
From this model the variables with the highest VIP were metabolites corresponding to lipids at 0.81-
0.74ppm, lipids at 1.18-1.11ppm, alanine at 1.49-1.46ppm, lipids at 1.558-1.51, Glycoproteins at 
2.04, lipids at 2.21-2.17, glutamine at 2.49-2.42ppm, an unidentified metabolite at 3.07, 
phospholipids at 3.20ppm, glycerol at 3.57ppm, phenylalanine at 7.45-7.41ppm and formate at 
8.45ppm. Clinical variables of importance were maximum and minimum PEEP, highest and lowest 
CRP, highest and lowest albumin and highest PaO2:FiO2 ratio.  
Due to concerns that the vastly overwhelming number of data points contributed by the metabolic 
data may dominate these models similar analysis was carried out using the integrals of all of the 
NMR peaks. When clinical data were combined with the integrals of the metabolic peaks via OPLS-
DA a model could be created that was similar to that using the entire spectral data (R2Y 0.86, Q2Y 
0.43, p=0.003) and was better than using only the integrals of the metabolic data alone (R2Y 0.72, 
Q2Y 0.29, p=0.04). Using this method the metabolites that were most important can be seen in table 
6.6. They were similar to those that were seen when the entire spectrum was utilised, with formate, 
alanine, glycoprotein and phospholipids being some of the most important metabolites 
differentiating between patients with brain injury and pneumonia. Univariate comparison of these 
integrals found all but one of the unidentified metabolites to be significantly different between the 
two groups even after correction for false discovery rate, table 6.6.  Many of the lipid species seen to 
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be important when brain injured patients were compared to those with pneumonia using only 
metabolic data, in chapter 3, appeared no longer to differentiate the groups when spectral integrals 
were used.  
Table 6.6. Integrals of metabolites with the most influence on the OPLS-DA model comparing 
pneumonia with brain injuries. p-values represent comparisons between groups of individual 
integrals using the Student’s t-test corrected for the false discovery rate using the Benjamini-
Hochberg procedure.  
Metabolite Integral ppm Range VIP p-value Direction of Change in Pneumonia 
Phospholipids 3.196 3.188 2.89 0.02 ↓ 
Glycoproteins 2.046 2.022 2.69 0.02 ↑ 
Formate 8.455 8.450 2.58 0.03 ↑ 
Unknown 3.074 3.059 2.40 0.03 ↑ 
Unknown 2.057 2.052 2.34 0.02 ↑ 
Unknown 2.063 2.057 2.32 0.03 ↑ 
Unknown 3.016 3.01 2.29 0.02 ↓ 
Glutamine 2.453 2.449 2.25 0.02 ↓ 
Alanine 1.489 1.461 2.24 0.02 ↓ 
Unknown 7.812 7.805 2.15 0.07 ↑ 
Unknown 2.052 2.046 2.06 0.03 ↑ 
Glutamine 2.470 2.460 2.02 0.03 ↓ 
 
6.5.3.1.2 Clinical and Inflammatory Data 
Combining clinical and inflammasome data provided an OPLS-DA model with a good predictive 
capacity (R2Y 0.68 Q2Y 0.49, p<0.001) which was better than that using the inflammatory data alone, 
from these patients (R2Y 0.45 Q2Y 0.26, p=0.012). The variables that were most important in this 
model can be seen in table 6.7, the most important variables in this model were predominantly 
clinical. 
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Table 6.7. Variables with VIP>1.0 in the OPLS-DA model (R2Y 0.68, Q2Y 0.49, p<0.001) combining 
inflammatory and clinical data comparing patients with pneumonia and brain injuries. Clinical 
variables are in black and inflammatory variables blue. 
Variables Increased in Pneumonia Variables Decreased in Pneumonia 
Variable VIP Direction of 
Change in 
Pneumonia 
Variable VIP Direction of 
Change in 
Pneumonia 
Highest PEEP 2.84 ↑ Highest Albumin 2.20 ↓ 
Highest CRP 2.22 ↑ Lowest Albumin 2.16 ↓ 
Lowest CRP 2.06 ↑ Highest PaO2:FiO2 ratio 1.86 ↓ 
Lowest PEEP 1.97 ↑ Lowest PaO2:FiO2 ratio 1.80 ↓ 
Highest Peak Airway pressure 1.76 ↑ Highest SpO2:FiO2 ratio 1.68 ↓ 
Highest Respiratory Rate 1.72 ↑ Highest pH 1.64 ↓ 
Highest Fibrinogen 1.69 ↑ 6-keto-PGF1α 1.58 ↓ 
Highest PaCO2 1.62 ↑ Highest Haemoglobin 1.48 ↓ 
Lowest Fibrinogen  1.61 ↑ 5,6-DHET 1.41 ↓ 
Lowest White Cell Count 1.60 ↑ Lowest pH 1.37 ↓ 
Lipoxin B4  1.52 ↑ Highest Haematocrit 1.34 ↓ 
Lowest Glasgow Coma Score 1.52 ↑ Lowest SpO2:FiO2 ratio 1.33 ↓ 
Total Secretions 1.48 ↑ C22:6 (DHA) 1.32 ↓ 
Highest White Cell Count 1.47 ↑ Lowest PaO2 1.18 ↓ 
Lowest FiO2 1.46 ↑ Lowest Expiratory Tidal 
Volume 
1.13 ↓ 
FiO2 to get the highest  SpO2 1.46 ↑ Lowest Haemoglobin 1.12 ↓ 
E-Selectin 1.38 ↑ C20:5 (EPA) 1.07 ↓ 
MCP-1 1.38 ↑ 10(S),17(S)-DiHDoHE 1.04 ↓ 
ICAM-1 1.35 ↑ 9(S)-HODE 1.00 ↓ 
IP-10 1.34 ↑    
Lowest PaCO2 1.34 ↑    
FiO2 to get the highest  PaO2 1.28 ↑    
Highest Heart Rate 1.27 ↑    
Tetranor-PGDM 1.26 ↑    
TNFα 1.26 ↑    
Lowest Heart Rate 1.21 ↑    
IL-13 1.19 ↑    
Lowest ALP 1.17 ↑    
Lowest Peak Airway Pressure 1.16 ↑    
Highest Prothrombin Time 1.15 ↑    
Lowest Urea 1.15 ↑    
Lowest APTT 1.13 ↑    
Highest Expiratory Minute 
Volume 
1.07 ↑    
Lowest Creatinine 1.05 ↑    
Highest APTT 1.05 ↑    
Highest Urea 1.05 ↑    
Lowest Magnesium 1.04 ↑    
Highest ALP 1.04 ↑    
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6.5.3.1.3 Clinical, Metabonomic and Inflammatory Data 
Combining the clinical variables, metabolic spectral data and the inflammatory data yielded an OPLS-
DA model (R2Y 0.95, Q2Y 0.42, p=0.003) ,figure 6.4, which had a Q2Y similar to that from the 
metabolic data alone but not as good as that seen when only the clinical data were used. However, 
when the model was constructed using only variables that had a VIP greater than 1.0 the model 
improved, figure 6.5, (R2Y 0.95, Q2Y 0.73, p<0.001) but when variables with a VIP greater than 2.0 
were used no further improvement in Q2Y was gained (R2Y 0.91, Q2Y 0.71, p<0.001). 
When the integrals of the metabolite peaks were used instead of the full spectral data the model 
was similar to that using the whole spectral data (R2Y 0.69, Q2Y 0.38, p<0.001) and when only 
features with VIP greater than 1.0 (R2Y 0.70, Q2Y 0.60, p<0.001) or greater than 2.0 (R2Y 0.66, Q2Y 
0.63, p<0.001) were used the models were no better than using the full spectra. 
Although the best model was found when clinical and metabolic spectral data were combined, 
without the addition of inflammatory data, and features with a VIP greater than 2.0 were selected 
(R2Y 0.91, Q2Y 0.75, p<0.001) many of the areas of spectral data included appeared to be associated 
with baseline noise.  Much of this was removed by using a VIP cut off of 2.5 (R2Y 0.77, Q2Y 0.66, 
p<0.001), without the loss of metabolic information, which was similar to the models produced 
when only the clinical and metabolic integral data were used, with a VIP cut off of 2.0 (R2Y 0.70, Q2Y 
0.68, p<0.001). This model was made up of 15 variables: Minimum and maximum PEEP, highest 
respiratory rate, highest peak pressure, minimum and maximum CRP, minimum and maximum 
albumin, glycoproteins, formate, minimum and maximum PaO2:FiO2 ratio and three unidentified 
metabolites. When the independently classified patients were used to validate the model it had a 
sensitivity of 0.50, specificity of 1.0, positive predictive value of 1.0 and negative predictive value of 
0.71. As there was a great deal of, seemingly, duplicate information within this model, for example 
with the inclusion of both minimum and maximum PEEP, the model was reconstructed using only  
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Figure 6.4. OPLS-DA model based on clinical, metabolic and inflammatory data with one component and one orthogonal component comparing patients 
admitted with brain injuries, blue circles, to those with pneumonia, red squares, at the start of ventilation (R2Y 0.95, Q2Y 0.42, p= 0.003) a. before and b. 
after cross validation. Before cross validation the groups can be seen to be separated with pneumonia samples separated in the positive direction along the 
first component. After cross validation this separation is less with several samples crossing between groups. 
 
  
a. b. 
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Figure 6.5. OPLS-DA model based on clinical, metabolic and inflammatory data using only variables with a VIP>1.0 with one component and one orthogonal 
component comparing patients admitted with brain injuries, blue circles, to those with pneumonia, red squares, at the start of ventilation (R2Y 0.95, Q2Y 
0.73, p< 0.001) a. before and b. after cross validation. Before cross validation the groups can be seen to be separated with pneumonia cases separated in the 
positive direction along the first component. After cross validation this separation remains good with only a few patients crossing between groups. 
 
  
a. b. 
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the variable from each pair with the highest VIP. In this case there was no change to the model 
parameters (R2Y 0.70, Q2Y 0.68, p<0.001). 
6.5.3.2 Brain Injury vs VAP 
6.5.3.2.1 Clinical and Metabonomic Data 
When the brain injured patients who developed VAP were compared to the brain injured patients 
without infection at the start of ventilation using OPLS-DA, combining metabolic and clinical data 
was only just able to produce a model with discriminant capacity (R2Y 0.94, Q2Y 0.16, p=0.45) which 
was almost identical to that using only the metabolic data (R2Y 0.94, Q2Y 0.15, p=0.46) for this 
patient group.  
When metabolite integrals were used instead of the entire spectrum the OPLS-DA model was more 
predictive (R2Y 0.77, Q2Y 0.37, p=0.04) and functioned better than that based only on metabolic data 
(R2Y 0.64, Q2Y 0.15, p=0.47) for this set of patients. However, this model was not as good as that 
using clinical data alone (R2Y 0.69, Q2Y 0.52, p<0.001). Metabolites that were important in this model 
can be seen in table 6.8. The most important variables were those from the clinical data but the 
metabolites causing the largest effect on the model were phenylalanine, glycoproteins, and 
phospholipids as previously seen, along with a number of metabolites that have not previously been 
identified in this work. 
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Table 6.8. features important, VIP>1.0, in an OPLS-DA model (R2Y 0.77, Q2Y 0.37, p=0.04)  comparing 
patients admitted with brain injuries to those developing VAP using a combination of clinical data 
and the integrals of the metabolic spectral data. Clinical variables are in black and metabolic 
variables in red. 
Variables increased in VAP Variables decreased in VAP 
Variable VIP Direction of 
change in VAP 
Variable VIP Direction of 
change in VAP 
Highest Expiratory Minute 
Volume 
2.91 ↑ Highest SpO2:FiO2 ratio 2.16 ↓ 
Lowest ALP 2.85 ↑ Lowest PaO2:FiO2 ratio 2.15 ↓ 
Highest ALP 2.80 ↑ Lowest SpO2 2.07 ↓ 
Lowest Fibrinogen  2.72 ↑ Highest Expiratory Tidal Volume 1.97 ↓ 
Highest Fibrinogen 2.62 ↑ Highest Albumin 1.86 ↓ 
Phenylalanine (7.446-7.404) 2.34 ↑ Highest PaO2:FiO2 ratio 1.70 ↓ 
FiO2 to give highest SpO2 2.32 ↑ Lowest Albumin 1.68 ↓ 
Total Secretions 2.27 ↑ Unknown (3.196-3.188) 1.51 ↓ 
Highest Respiratory Rate 2.20 ↑ Lactate (4.120-4.084) 1.46 ↓ 
Lowest Expiratory Minute 
Volume 
2.18 ↑ Lowest PaO2 1.41 ↓ 
Lowest Respiratory Rate 2.14 ↑ Unknown (3.016-3.01) 1.41 ↓ 
Unknown (2.063-2.057) 2.12 ↑ Alanine (1.489-1.461) 1.38 ↓ 
Lowest ALT 2.04 ↑ Lowest SpO2:FiO2 ratio 1.38 ↓ 
Highest Peak Airway 
Pressure 
2.04 ↑ Citrate (2.521-2.511) 1.30 ↓ 
Highest ALT 2.00 ↑ Phospholipids (3.225-3.213) 1.30 ↓ 
Lowest Urea 1.99 ↑ Unknown (2.370-2.363) 1.27 ↓ 
Lowest FiO2 1.94 ↑ Glutamine (2.470-2.460) 1.26 ↓ 
Unknown (2.078-2.063) 1.92 ↑ Citrate (2.547-2.537) 1.24 ↓ 
Unknown (2.052-2.046) 1.91 ↑ Phospholipids (3.213-3.196) 1.24 ↓ 
Lowest CRP 1.88 ↑ Highest PaO2 1.23 ↓ 
Highest PEEP 1.84 ↑ Unknown (2.899-2.894) 1.22 ↓ 
Glycoproteins (2.046-2.022) 1.80 ↑ Average Fluid Intake per Hour 1.18 ↓ 
Highest Systolic Blood 
Pressure 
1.80 ↑ Unknown (2.970-2.960) 1.16 ↓ 
Phenylalanine (7.340-7.313) 1.75 ↑ Unknown (3.443-3.438) 1.15 ↓ 
Unknown (1.052-1.045) 1.73 ↑ Glutamine (2.460-2.453) 1.12 ↓ 
Highest Urea 1.69 ↑ Unknown (2.912-2.907) 1.10 ↓ 
Lowest PEEP 1.65 ↑ Glutamine (2.449-2.444) 1.09 ↓ 
Unknown (2.057-2.052) 1.64 ↑ Lowest Expiratory Tidal Volume 1.07 ↓ 
Tyrosine (7.201-7.176) 1.63 ↑ Glutamine (2.453-2.449) 1.06 ↓ 
Highest CRP 1.62 ↑ Fluid Balance 1.05 ↓ 
Unknown (7.497-7.471) 1.60 ↑    
Unknown (8.127-8.12) 1.60 ↑    
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Unknown (5.474-5.457) 1.60 ↑    
Unknown (8.078-8.071) 1.60 ↑    
Unknown (7.857-7.850) 1.60 ↑    
Tyrosine (6.907-6.882) 1.58 ↑    
Unknown (1.037-1.032) 1.54 ↑    
Unknown (1.18-1.174) 1.47 ↑    
Unknown (1.168-1.163) 1.46 ↑    
Unknown (7.670-7.664) 1.44 ↑    
Unknown (1.025-1.019) 1.43 ↑    
FiO2 to give lowest PaO2 1.42 ↑    
Unknown (2.356-2.342) 1.40 ↑    
Unknown (1.062-1.057) 1.38 ↑    
Lowest Bilirubin 1.36 ↑    
Unknown (5.101-5.080) 1.34 ↑    
Unknown (7.79-7.756) 1.31 ↑    
Unknown (1.074-1.068) 1.31 ↑    
Highest Inspired Tidal 
Volume 
1.30 ↑    
Lowest Magnesium 1.29 ↑    
Unknown (1.174-1.168) 1.25 ↑    
Unknown (1.458-1.443) 1.23 ↑    
FiO2 to give lowest SpO2 1.21 ↑    
Unknown (1.113-1.107) 1.21 ↑    
Unknown (5.454-5.445) 1.20 ↑    
Highest Mean Arterial 
Pressure 
1.19 ↑    
Unknown (4.901-4.894) 1.18 ↑    
Highest Central Venous 
Pressure 
1.16 ↑    
Formate (8.488-8.484) 1.10 ↑    
Highest FiO2 1.08 ↑    
Lowest Potassium 1.06 ↑    
Highest Diastolic Blood 
Pressure 
1.05 ↑    
Highest Base Excess 1.04 ↑    
Unknown (5.501-5.495) 1.04 ↑    
Unknown (2.342-2.331) 1.03 ↑    
Highest Pressure Support 1.01 ↑    
 
6.5.3.2.2 Clinical and Inflammatory Data 
Combining clinical and inflammatory data into a single OPLS-DA model (R2Y 0.74, Q2Y 0.50, p<0.001) 
performed better than those detailed above with metabolic data and better than the inflammatory 
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data used alone (R2Y 0.76, Q2Y 0.27, p=0.14) for this patient group. The features contributing most to 
this combined model can be seen in table 6.9. The model was similar, although not quite as good, as 
that using only the clinical data (R2Y 0.69, Q2Y 0.52, p<0.001). 
6.5.3.2.3 Clinical, Metabonomic and Inflammatory Data 
Combining all three data types into a single OPLS-DA model performed only as well as the metabolic 
data alone (R2Y 0.94, Q2Y 0.16, p=0.44). If integrals of the metabolites were used instead of the 
whole spectra the model was better (R2Y 0.82, Q2Y 0.4, p=0.03) and could be improved further by 
taking either those features with a VIP greater than 1.0 (R2Y 0.70, Q2Y 0.56, p<0.001) or with VIP 
greater than 2.0 (R2Y 0.72, Q2Y 0.68, p<0.001), figure 6.6. The features that made up the last of these 
models can be seen in table 6.10. 
This model could only be improved upon by using the full metabolic spectra when only metabolites 
with VIP greater than 2.0 were used (R2Y 0.94, Q2Y 0.73, p<0.001), figure 6.7. This model had the 
same features as that in table 6.10 with the addition of maximum and minimum PEEP, Highest 
PaO2:FiO2, IP-10, IL-17A, IL-13, Il-12p70, ICAM-1, highest systolic blood pressure, minimum FiO2 and 
maximum expiratory tidal volume. However, within the metabolic component of this model were 
areas of the spectrum that corresponded to the baseline and not specific metabolic features. This 
was not improved by taking VIP>2.5. 
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Table 6.9. Variables with VIP>1.0 in the OPLS-DA model (R2Y 0.74, Q2Y 0.50, p<0.001) combining 
inflammatory and clinical data comparing patients with VAP and brain injuries before infection 
developed. Clinical variables are in black and inflammatory variables blue. 
Variables Increased in VAP Variables Decreased in VAP 
Variable VIP Direction of 
Change in VAP 
Variable VIP Direction of 
Change in VAP 
Lowest ALP 2.50 ↑ Highest SpO2:FiO2 ratio 1.83 ↓ 
Highest ALP 2.46 ↑ Lowest PaO2:FiO2 ratio 1.82 ↓ 
Highest Expiratory Minute Volume 2.45 ↑ Lowest SpO2 1.75 ↓ 
Lowest Fibrinogen  2.37 ↑ Highest Albumin 1.55 ↓ 
Highest Fibrinogen 2.29 ↑ Highest PaO2:FiO2 ratio 1.43 ↓ 
FiO2 to give highest SpO2 1.96 ↑ Lowest Albumin 1.42 ↓ 
Total Secretions 1.92 ↑ Lowest PaO2 1.19 ↓ 
TNFα 1.91 ↑ Lowest SpO2:FiO2 ratio 1.17 ↓ 
Highest Respiratory Rate 1.87 ↑ Highest PaO2 1.03 ↓ 
Lowest Expiratory Minute Volume 1.84 ↑    
Lowest ALT 1.82 ↑    
Lowest Respiratory Rate 1.82 ↑    
Highest ALT 1.79 ↑    
Lowest Urea 1.73 ↑    
Highest Peak Airway Pressure 1.73 ↑    
Highest Expiratory Tidal Volume 1.66 ↑    
Lowest FiO2 1.64 ↑    
Lowest CRP 1.61 ↑    
Highest PEEP 1.55 ↑    
ICAM-1 1.53 ↑    
IP-10 1.52 ↑    
Highest Systolic Blood Pressure 1.52 ↑    
IL-13 1.48 ↑    
IL-12p70 1.47 ↑    
Highest Urea 1.47 ↑    
IL-17A 1.47 ↑    
Highest CRP 1.40 ↑    
Lowest PEEP 1.39 ↑    
IFNγ 1.25 ↑    
FiO2 to give lowest PaO2 1.20 ↑    
LTC4 1.16 ↑    
Lowest Bilirubin 1.14 ↑    
Highest Inspired Tidal Volume 1.12 ↑    
Lowest Magnesium 1.08 ↑    
IL-1β 1.05 ↑    
FiO2 to give lowest SpO2 1.02 ↑    
Highest Central Venous Pressure 1.02 ↑    
Highest Mean Arterial Pressure 1.01 ↑    
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Figure 6.6. OPLS-DA model with one component comparing patients admitted with brain injuries, blue bars, to those with VAP, green bars, based on clinical 
data , inflammatory data and integrals of metabolic spectral features using only variables with a VIP>2.0 . (R2Y 0.72, Q2Y 0.68, p<0.001) a. before and b. 
after cross validation. VAP cases can be seen to separate in a positive direction along the first component, there is little change after cross validation.  
a. b. 
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Figure 6.7. OPLS-DA model with one component and one orthogonal component comparing patients admitted with brain injuries, blue circles, to those with 
VAP, green triangles, based on clinical data , inflammatory data and full metabolic spectral features using only variables with a VIP>2.0 . (R2Y 0.94, Q2Y 0.73, 
p<0.001) a. before and b. after cross validation. VAP cases can be seen to separate along the first component and after cross validation this separation 
remains good. 
 
a. b. 
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Table 6.10. Features comprising an OPLS-DA model (R2Y 0.72, Q2Y 0.68, p<0.001) comparing patients 
with brain injuries to those with VAP using only features with VIP>2.0, combining clinical, 
inflammatory and integrals of metabolic data. Clinical variables are in black, metabolic variables in 
red and inflammatory variables blue. 
Variable 
Lowest ALP 
Highest ALP 
Lowest Fibrinogen  
Highest Expiratory Minute Volume 
Highest Fibrinogen 
Phenylalanine (7.446-7.404) 
FiO2 to give highest SpO2 
Lowest ALT 
Total Secretions 
TNFα 
Highest ALT 
Highest Respiratory Rate 
Lowest Expiratory Minute Volume 
Highest SpO2:FiO2 ratio 
Lowest Respiratory Rate 
Lowest PaO2:FiO2 ratio 
Unknown (2.063-2.057) 
Lowest SpO2 
Highest Peak Airway Pressure 
 
When the patients with VAP were compared to those with brain injuries who did not develop 
infection, but spent a similar time on ICU, combining clinical with metabolic data and combining all 
data types failed to produce OPLS-DA models with any predictive capacity with negative Q2 in all 
cases. Combining clinical and Inflammatory data (R2Y 0.88, Q2Y 0.55, p=0.07) produced a model that 
was similar to that with clinical data alone, however, using only the inflammatory data for this group 
of patients produced a more predictive model (R2Y 0.98, Q2Y 0.56, p=0.31). Combining clinical data 
and metabolite integrals (R2Y 0.86, Q2Y 0.18, p=0.9) and using all data with metabolite integrals (R2Y 
0.69 Q2Y 0.16, p=0.59) generated predictive models, although, not as good as those with only 
inflammatory data. The most predictive model was made when all data were combined using 
metabolite integrals selecting those features with VIP>2.0, figure 6.8, (R2Y 0.87, Q2Y 0.84, p=0.001). 
The features that were important in this model can be seen in table 6.11. Many of the variables used 
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in this model represented oxygenation so the model was reconstructed only using the one with the 
highest VIP, the lowest PaO2:FiO2 ratio, the other markers of oxygenation and the duplicate CRP 
value with the lowest VIP were omitted. When this was performed the model (R2Y 0.92, Q2Y 0.86, 
p=0.001) performed similarly. 
Table 6.11. Features used in an OPLS-DA model (R2Y 0.87, Q2Y 0.84, p=0.001) comparing patients 
with VAP to those with brain injuries without infection at a similar time point to that when VAP 
developed. Using a combination of clinical, inflammatory and metabolite integral data but only 
selecting features with VIP>2.0. Clinical variables are in black, metabolic variables in red and 
inflammatory variables blue. 
 
  
Variable 
Lowest PaO2:FiO2 ratio 
IL-6 
Highest SpO2:FiO2 ratio 
Lowest SpO2:FiO2 ratio 
MCP-1 
IL-12p70 
Lowest FiO2 
Highest FiO2 
5,6-DHET 
FiO2 to give highest SpO2 
IFNγ 
FiO2 to give highest PaO2 
Highest PaO2:FiO2 ratio 
Lowest CRP 
Highest CRP 
FiO2 to give lowest PaO2 
Unknown (6.938-6.911) 
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Figure 6.8. OPLS-DA model with one component comparing patients admitted with brain injuries without infection at time point 4, blue bars, to those with 
VAP, green bars, based on clinical data , inflammatory data and metabolic integrals using only variables with a VIP>2.0 (R2Y 0.87, Q2Y 0.84, p=0.001) . a. 
before and b. after cross validation.  VAP cases can be seen to separate along the first component and after cross validation this separation remains good. 
 
a. b. 
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6.6 Discussion 
This chapter focused on the application of multivariate analysis in the form of PCA and OPLS-DA to 
clinical data and the combination of clinical data with metabonomic and inflammatory data. Few 
attempts have been made previously to use these techniques with clinical data sets (344-346) and 
no studies exist using either data sets from patients on ICU or from those with pneumonia.  
The use of multivariate techniques with clinical data produced both PCA and OPLS-DA models that 
were able to separate patients with brain injuries from those with either pneumonia or VAP. This 
was not entirely unexpected as some of the clinical data, oxygenation, secretions, temperature and 
white blood cell count were part of the CPIS that was used to define both VAP and pneumonia. 
However, even when these and closely related features were removed from the models they 
retained a great deal of their predictive capacity. The clinical variables that were important in the 
comparison of patients admitted with pneumonia or VAP to those with brain injuries were not the 
same. Comparing pneumonia to brain injury the features that were most important was the amount 
of PEEP which was highest in the pneumonia group and was likely to represent the difficulty with 
oxygenation that occurs with pneumonia. CRP was also higher in the pneumonia group as may be 
expected as CRP has previously been used as an aid to the diagnosis of this condition (22-25).  
Patients with pneumonia had higher airway pressures, respiratory rate, PaCO2, and minute 
ventilation and lower pH and lowest expiratory tidal volume than those with brain injuries 
suggesting a greater difficulty with ventilation and CO2 clearance in this group (348-350). All 
variables that reflected oxygen requirement for example, PaO2:FiO2 ratio, SpO2:FiO2 ratio and lowest 
PaO2 demonstrated the greater degree of hypoxaemia in those with pneumonia as expected from 
both the natural history of the condition and the CPIS. Similarly white cell count and volume of 
secretions were predictably higher in those with pneumonia as expected as both are components of 
the CPIS. Of note temperature did not appear in the multivariate model comparing brain injury with 
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pneumonia, perhaps reflecting the disregulated temperature control that often occurs in brain 
injury. Of the other variables to appear important albumin levels were higher in those with brain 
injuries. Low albumin has previously been associated with poorer outcomes and worse severity with 
pneumonia (351-354) and may reflect the longer duration of disease, poorer nutritional status in 
patients with pneumonia or the effect on albumin of having a pro-inflammatory state such as 
infection, other pro-inflammatory conditions such as a surgical insult are known to lower albumin. 
Similarly haemoglobin levels were lower in those with pneumonia, although haematocrit was higher 
in this group, and may represent a combination of anaemia associated with a more prolonged 
disease and a degree of dehydration occurring in pneumonia. Anaemia (355, 356) with an increased 
red cell distribution width (357) has been associated with a complicated hospital course in those 
with pneumonia so it is not surprising that anaemic patients with pneumonia find themselves on 
ICU. Although there is no work looking at anaemia as a risk factor for pneumonia in adults it has 
been recognised as such in children in certain populations (358, 359) with anaemia being associated 
with two to five times the risk of pneumonia, potentially as a result of underlying iron deficiency in 
the majority of cases. 
Fibrinogen levels were also found to be higher in those with pneumonia which likely reflects the way 
in which it acts as an acute phase reactant, activates pro-inflammatory processes (360, 361) by 
activating cytokines such as TNFα and IL-1β and possibly has a role in promoting certain bacterial 
survival (362). However, other clotting features, prothrombin time and activated partial 
thromboplastin time, were found to be elevated in those with pneumonia suggesting that there may 
be either a predisposition to coagulopathy (363) in this group or that in the brain injury group there 
was more aggressive correction of coagulopathy due to the risk of bleeding. Tachycardia in those 
with pneumonia was a useful marker in building a model to separate pneumonia from brain injury 
and pneumonia patients had a higher level of consciousness than the brain injury cohort as may be 
expected either from the underlying pathology in the brain injury group rendering the patients 
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unconscious or because of the use of sedative drugs to ensure deep sedation, as a neuroprotective 
measure, in this group. Alkaline phosphatase and urea levels both had VIP scores of just over 1. Urea 
has previously been recognised as a marker of severity in pneumonia (364-366) and is likely to 
represent relative dehydration in this group of patients. The higher ALP in pneumonia patients is 
interesting as although it has not been specifically described in pneumonia, elevated ALP can be 
associated with sepsis (367-369) through sepsis induced cholestasis.  
When brain injured patients were compared to those with VAP the pattern of clinical variables that 
were important in separating the two groups were quite different from those separating pneumonia 
from brain injuries. Although features representing the degree of hypoxaemia were important in the 
model, including the level of set PEEP, suggesting a greater degree of hypoxaemia in the VAP group, 
as would be expected, they were not the most important variables. The levels of ALP in the VAP 
patients were higher than in those admitted with brain injuries. The reason for this may be either 
because of sepsis related cholestasis (367-369) or that the VAP group had a greater time to be 
exposed to drugs increasing the chances of drug induced cholestasis and liver dysfunction, either of 
these explanations may also account for the appearance of bilirubin as a distinguishing variable in 
this model. Fibrinogen was again important in this model acting as an acute phase reactant (360, 
361). Variables relating to higher tidal volumes, respiratory rates and minute ventilation were 
greater in the VAP group suggesting greater difficulty in CO2 control. Secretion burden was greater in 
the VAP group, again as would be expected from the CPIS. Other than hypoxaemia and secretion 
burden the other features of the CPIS, temperature and white cell count, did not appear in the 
multivariate model implying that within this group these are not important features to differentiate 
VAP. Similar results have been reported previously in a group of brain injured patients (370). 
Other features that formed the most important variables to differentiate VAP from brain injuries 
included albumin levels that were lower in those with VAP, probably representing the greater 
duration of ICU stay of these patients and their heightened catabolism. Similar to the ALP levels 
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alanine transaminase levels were also greater in the VAP group but were not as important in the 
model. High CRP was also a variable that played a part in identifying those with VAP, although not to 
such a degree as for pneumonia. CRP has previously been seen to have use in identifying VAP (92, 
371) and to track its response to antibiotics and predict survival (372-374) although this has not 
always been the case and the importance of CRP has been controversial (370, 375). Urea was again 
seen to be higher in the VAP than brain injury group. 
When VAP was compared with brain injury patients without infection who had spent a similar time 
on intensive care parameters associated with oxygenation dominated the model. However, the next 
most important variables were CRP as discussed above. In this model creatinine and sodium became 
important, with higher levels being present in those with VAP, implying a trend towards relatively 
higher rates of renal failure within those who developed VAP, this was also supported by the fact 
that urine output was lower in those with VAP. Within this model hourly fluid input and total fluid 
input over 24h were lower in those with VAP than in those with brain injuries which may have 
accounted for the other renal parameter trends. However, when the data were inspected the 
absolute sodium and creatinine levels were all within the normal range suggesting only a relative 
impairment in renal function, not one generally recognised as renal failure, but these may represent 
subtle changes occurring in those developing infection that may not be apparent to a bedside 
clinician.  Again features suggesting greater difficulty with ventilation, including tidal volume, arterial 
PaCO2, minute ventilation and peak airway pressure were higher in those with VAP implying a 
greater difficulty in achieving neuroprotective CO2 targets in patients with VAP. Platelet count was 
higher in those who did not develop VAP but on closer inspection of the raw data this difference 
could be seen to reflect variations within the normal range for all participants except one of the 
patients without VAP whose result lay above the upper level of normal. This may reflect slight 
reduction of platelet count in the context of sepsis or the elevated platelet count in a single patient 
may reflect ongoing systemic inflammation as a response to intracerebral blood. The influence of 
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blood pressure measurements on the differentiation of VAP from those without infection was a little 
contradictory. The lowest recorded mean arterial and diastolic blood pressures where greater in 
those without VAP, which may represent the lack of sepsis in this group. However, highest recorded 
systolic pressures where higher in those with VAP. As with the model comparing VAP to patients 
with brain injuries at admission to ICU, ALP and bilirubin are higher in those with VAP than those 
without, although these features were not as important in constructing this model as in the other 
models. This added support to the idea that these results may represent cholestasis in the context of 
infection as opposed to results relating to duration of ICU stay, such as exposure to drugs. Results 
from the comparisons of those with VAP to other groups have to be interpreted with care as the 
small number of patients in this group meant that small changes in the variables of one patient 
potentially had a great impact on the models and variables’ apparent importance. Also of note is 
that fact that in some of the models, especially when brain injured patients were compared to those 
with VAP, the number of patients in each group were unbalanced which may have had an impact on 
the statistical analysis. 
Combining clinical data with data from the inflammasome was more straight forward than 
combining clinical data with metabonomic data. This was because the inflammatory data consisted 
of individually measured variables that could be considered as parameters similar to those 
laboratory variables contained within the clinical data set. However, combining clinical data with 
spectral metabolic data was more of a challenge. The metabonomic data set was made up of a 
continuum of variables with each metabolite being comprised of a collection of many data points. As 
little work has been done combining these two types of data before there was little precedent by 
which to proceed. In order to try to account for the potential problem that the sheer number of 
variables contained within the metabolic data may have saturated the data set, models were made 
using both the metabolic spectral data and a simpler data set using integrals of all the peaks in the 
spectral data. On the whole, similar metabolites were seen to be important with both methods. 
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However, the importance of lipids was under represented when integral data was used. This 
probably reflected the fact that several lipid species occupy similar spectral regions. Subtleties in the 
spectral waveform pattern could be elucidated, when the entire spectral data set was used, that 
represent changes in these different species. When only integrals were used these subtleties were 
lost and the lipids seemed to be unimportant. For example, a typical lipid peak may contain around 
350 data points from the spectral data set whereas a metabolite such as formate only around 20, 
leading to lipids being over represented in the spectral data.  Similarly when the integrals were used 
some metabolites that had previously not seemed important and thus not identified appeared 
prominent in the models, which may have reflected slight differences in alignment of the different 
spectra with some spectra having part of the metabolite missed in the integral region. Finally, when 
VIP scores of 1.0 or 2.0 were used as a threshold for important variables in combined models this 
method failed to be of value for the spectral data as several areas of baseline variation were 
detected as important, although baseline variation was not apparent when the spectra were 
examined manually this differences may suggest differences in the protein content of the two 
sample sets. This issue was solved by using a higher threshold of 2.5 for models with these data sets. 
Previously when metabolic data were used this problem was not identified as the spectral data, 
when analysed alone, could be displayed on the OPLS-DA regression co-efficient plots where the 
colour of the peaks represented the significance of the variable and in these cases baseline variation 
never appeared to be a problem. When the data sets were combined these figures could no longer 
be used as not all the data was spectral in nature. 
Combining clinical data with either the metabolic or inflammatory data to compare pneumonia with 
brain injury at admission produced models that were better than models based on either of these 
‘omics’ data sets alone although not quite as good as when only clinical data were used. This may be 
because the initial diagnosis of pneumonia was based firstly on clinicians’ opinion and then refined 
using the CPIS. It may have been expected that the most predictive variables would be those that 
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the physician had access to when making their judgement. Importantly, however, even when 
variables that were related to the CPIS score were omitted from the models only a little predictive 
capacity was lost, similarly when the most important variables were examined for these models 
those from the CPIS were not the most important and some did not feature in these models at all.  
When combining clinical and metabolic data both data types appeared important in the models to 
differentiate pneumonia from brain injuries, when the whole spectra were used important 
metabolites appeared similar to those identified in chapter 3 with lipid species, alanine, 
glycoproteins, phospholipids, phenylalanine and formate appearing important. Of these formate, 
glycoproteins, phospholipids and alanine were significantly different, after correction for the false 
discovery rate, when the metabolite integrals were compared using univariate methods. The clinical 
features were those described when clinical variables alone were used. When the inflammatory data 
set was combined with clinical variables, the clinical data dominated the models. The only 
inflammatory molecules that appeared important in the model were lipoxin B4, E-selectin, MCP-1, 
ICAM-1, IP-10, tetranor-PGDM and TNF-α, IL-13,  which were higher in those with pneumonia and 6-
keto-PGF1alpha, 5,6-DHET, DHA, EPA, 10(S),17(S)-DiHDoHE and 9(S)-HODE in those with brain 
injuries. These were almost identical to the most important inflammatory mediators seen in chapter 
4, with the exception of 13(S)HODE, which was previously seen to be useful in separating patients 
with pneumonia from those with brain injuries. In the model combining clinical and inflammatory 
data this substance only just missed out on being important with a VIP of 0.98. There was a slight 
difference in the order in which some of these inflammatory mediators appeared in the models 
between those made here and those constructed in chapter 4. This may reflect slight differences in 
the total number of patients included in the two chapters, as here only patients who had all three 
sets of clinical, metabolic and inflammatory data were used. 
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Combining all three data types failed to improve the model to a degree that outperformed using 
clinical data alone. The best model based on the Q2Y from cross validation was that made using a 
combination of metabolic and clinical data using either the entire spectral data or the integrals of 
the peaks using only features with a VIP>2.0. It is of note that inflammatory data were not involved 
in the best model. This may have been because many of these inflammatory mediators are known to 
have a transient role in the inflammatory processes in infection. The variable amount of time 
between patients with pneumonia becoming unwell and being admitted to ICU may have meant that 
this group of patients were captured at different stages in there inflammatory cascades, lessening 
the apparent importance of these markers. The factors that made up the best model made clinical 
sense. The important clinical variables were PEEP and PaO2:FiO2 ratio reflecting the increased 
difficulty in oxygenating patients with pneumonia, CRP as has been used previously as an aid to 
pneumonia diagnosis (22-25) indicating the inflammatory processes ongoing in this group and 
albumin which may be a marker of either the more prolonged duration of illness in patients with 
pneumonia prior to critical care admission, poorer nutritional status or an ongoing inflammatory 
process and maybe a marker of severity of disease (351-354). The metabolites that formed part of 
this model were lipid species which may reflect either a response to inflection (269, 270) or risk 
factor for brain injury (276, 278) as described earlier. Alanine was again seen to be reduced in those 
with pneumonia as previously described (145, 281), potentially reflecting either alterations in 
nutritional status or release of amino-acids from muscle. Formate was once again seen to be higher 
in those with pneumonia than in those without as described in chapter 3 as were acetylated 
glycoproteins that may represent acute phase reactants, such as immunoglobulins, often raised in 
infection and inflammation (376). On validation with the independently classified patients this model 
performed well with sensitivity of 50%, specificity of 100%, positive predictive value of 100% and 
negative predictive value of 71%. This is similar, if not better than reports of the performance of 
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clinical variables (12, 13, 16-19), CRP and PCT (22-24) or radiographs (26, 27) to aid in the diagnosis 
of primary pneumonia.   
When data sets were combined to compare VAP to brain injured patients combining clinical and 
metabolic data failed to perform as well as clinical data alone. However, a combination of clinical 
and inflammatory variables performed better than when clinical and metabolic data were combined 
and similarly to when only clinical data were used. This model contained a number of inflammatory 
mediators along with a similar pattern of clinical variables as described earlier. All of the most 
discriminant inflammatory mediators occurred in the VAP group and these included TNFα, ICAM-1, 
IP-10, IL-13, IL-12p70, IL-17A, INFγ, LTC4 and IL-1beta, as described in chapter 4, most of which are 
pro-inflammatory. The best model to distinguish patients with VAP from those with brain injuries at 
the start of ventilation was made when combining all three data types and taking variables with a 
VIP greater than 2.0. In this model clinical features appeared most important and were made up of 
ALP suggesting cholestasis, fibrinogen as an acute phase reactant, markers of oxygenation and 
ventilation and the burden of secretions as previously identified in the CPIS, metabolic data formed 
only a small component of this model with the only positively identified metabolites being part of 
phenylalanine, possibly representing changes in its metabolism in sepsis to activate the immune 
system or because of increased oxidative stress (282-284), phospholipids, acetyl groups of 
glycoproteins and some lipid species. Several inflammatory mediators formed part of this model 
with TNFα, a well-known mediator of inflammation, being the most important as has been noted 
before in pneumonia (163, 299). Other inflammatory mediators were predominantly cytokines 
including the chemotractant IP-10 and adhesion molecule ICAM-1 along with the interleukins IL-13, 
IL-12p70 and IL-17A, all of which have pro-inflammatory actions. IL-13 has been associated with 
airways inflammation. Interestingly several of these inflammatory mediators work synergistically 
supporting the fact that they are found to be important together. The fact that inflammatory 
mediators were much more important in this model than in the model comparing patients with 
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pneumonia at admission is interesting. This may be because the subtlety of the changes in the 
inflammasome are lost in the pneumonia cohort who present at different stages of their disease 
where as we were able to track the VAP patients, allowing sampling at more similar times during the 
disease process possibly meaning that their cytokine swings were more in alignment. 
When patients with VAP were compared to brain injured patients without infection who had spent a 
similar amount of time on the intensive care unit several of the models were unable to differentiate 
the two groups which may reflect the small number of patients in each group. The best model was 
made using a combination of clinical, inflammatory and metabolic data where integrals of the 
metabolic spectra were used and only those variables with a VIP greater than 2.0 were selectively 
used. In this model metabolic data played only a very limited part with only a single, previously 
unidentified metabolite being important. The majority of variables in this model were clinical, mainly 
representing the worse oxygenation in those developing VAP, and higher CRP levels. A combination 
of cytokines and eicosanoids formed part of this model. IL-6, MCP-1, IL-12p70 and IFNγ were all 
higher in those with VAP compared to those without whilst 5,6-DHET was higher in those without. IL-
6 is an important pro-inflammatory mediator in sepsis and has been seen to be higher in VAP (377) 
and pneumonia (298, 299) as has IFNγ (298). 
The use of multivariate methods with clinical and combinations of clinical and ‘omics’ data showed 
promise in building models comparing patients with brain injuries to those with either pneumonia at 
admission or VAP. Combining clinical and ‘omics’ data may also have other advantages beyond 
improving diagnostics by helping to improve understanding of underlying mechanisms of disease 
and the interaction of metabonomics, inflammatory state and easily measured clinical parameters. 
However, there are several limitations to this study. Firstly there was some missing data within the 
clinical data set, which was not a problem with either the metabolic or inflammatory data sets. 
However, on the whole the rate of missing parameters was low. Where rates were higher it was 
usually because certain parameters were only applicable in some situations such as with some 
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modes of ventilation. Missing clinical data is unfortunately not uncommon in the clinical 
environment. It was decided to include all variables within the models, even those with a significant 
proportion of missing data. However, this may become problematic when the number of patients is 
very small. For example when the VAP group was examined there was one patient with VAP who did 
not have a set of laboratory tests sent during the 24h period of interest, it is possible that this 
missing data has a significant impact on the model when there are only five such patients in the 
group. 
Another concern with clinical data is that it was recorded manually at the bedside and is therefore 
open to error or potential subjective assessment. All the bedside clinical data were recorded by hand 
on an hourly basis by the nurses caring for the patients. This meant that for each hour a single value 
for each parameter was taken to represent the clinical situation during that time. Inaccuracy could 
have occurred either if a non-representative value was chosen or if there was a transcription error. 
Further error may have then occurred where this data was transcribed onto the study data sheets 
where the minimum and maximum values for each variable were taken for each 24h period. To 
attempt to detect errors all the clinical data were inspected to find non-physiological values that 
would imply transcription error, very few of these were found suggesting a good rate of 
transcription accuracy.  
Patients were selected for inclusion based on either clinical opinion or CPIS all of which are based on 
clinical data. It was therefore not entirely surprising that clinical data performs well in differentiating 
the groups. However, in the absence of a gold standard test to diagnose either pneumonia or VAP 
clinical features are all that were available by which to allocate groups. The fact that components of 
the CPIS were frequently either not present or not the most important variables in these models 
supports the validity of looking at the clinical data in this fashion. Similarly the fact that predictive 
models could be built even when CPIS components were omitted implies that other discriminant 
features exist in the data set than were initially used to define the groups. 
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Unlike either the metabolic or inflammatory data, clinical data has the added problem that many of 
the measured variables that make up the models also serve as targets or triggers for intervention 
that may not be the same for each group in question. Differentiating variables may then in fact 
represent confounding based on treatment targets and not genuine clinical differences. An example 
of this may be both blood pressure and arterial carbon dioxide tensions. Although vasopressors and 
inotropes would be routinely started to ensure adequate perfusion pressures in both brain injured 
and pneumonia patients, blood pressure targets may be higher in those with brain injuries where 
cerebral perfusion pressure needs to be maintained. Similarly, in patients with brain injuries tight 
carbon dioxide control is desirable to prevent exacerbation of cerebral injury this may lead to more 
aggressive ventilation strategies than may be used in those with pneumonia. It is conceivable that in 
both of these situations blood pressure, carbon dioxide or ventilation parameters may appear as 
differentiating factors in a model when in fact they are confounders brought about by the different 
clinical requirements of the two groups under investigation. In this data set, however, it seemed 
unlikely that confounding was a significant issue. Firstly, when the comparison of pneumonia and 
brain injuries was examined most of the variables that were important either make clinical sense, 
such as the predominance of features suggesting impaired oxygenation, or are laboratory tests that 
are not specifically manipulated such as albumin and CRP levels. Secondly, when the patients with 
VAP were used in comparisons they were compared to other patients with brain injuries where 
similar clinical targets would have been employed. Some features, however, were present in these 
models that could imply confounding. Firstly PEEP was an important feature when those with 
pneumonia were examined. This may be a result of the treating doctor being aware of radiological 
changes thus influencing their decision for a higher PEEP setting in an attempt to re-expand 
consolidated or collapsed lung and may not then be an independent predictor of pneumonia. Also 
higher carbon dioxide levels were seen in those with pneumonia which may represent a more 
relaxed carbon dioxide target as part of a long protective ventilation strategy in this group. 
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This data set was limited to only those clinical variables that were routinely recorded in the unit 
where these patients were recruited. It may be possible to build more predictive models by 
incorporating other clinical variables. For example, pro-calcitonin has been used as a diagnostic aid 
in both pneumonia (24, 25) and VAP (91, 93) and it is conceivable that an improved model could be 
made with its incorporation. In the models described here clinical data were confined to 
measureable, numerical variables. This meant that other potentially important variables such as 
secretion colour, radiograph appearances and microbiology data were omitted. The models may 
well be improved if these data could be incorporated. 
Finally these models were made using a slightly smaller group of patients than had been used when 
either the metabolic or inflammatory data were examined alone as only those patients with all three 
sets of data were selected. However, it appears that the slightly reduced number of patients had 
little impact on the models as the features that were important using the inflammatory and 
metabolic data were relatively consistent between the models.  
 
6.7 Conclusions 
Using multivariate techniques, usually applied to ‘omics’ data sets, with clinical data showed promise 
in separating those with both pneumonia and those with VAP from those with brain injuries. The 
features found were not only those used to group the patients in the first place but other variables 
that may not have otherwise been thought of as discriminant. Combining clinical data with both 
metabolic and inflammatory data may have a greater ability to differentiate pneumonia and VAP 
from brain injured patients than using any one data set alone. This seems especially true when only 
the most important variables are used to construct the models. 
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7. FINAL CONLUSIONS 
Pneumonia is a common cause for admission to the critical care unit and development of VAP is the 
most common nosocomial infection occurring whilst patients are ventilated. Clinical features and 
laboratory tests lack sensitivity and specificity for this diagnosis and chest radiographs can be 
abnormal for a number of reasons other than infection. Although microbiological confirmation of 
infection is often sought, these results can take several days to return from the laboratory and are 
not able to distinguish infection from colonisation of the respiratory tract. Often patients with 
severe pneumonia are too unwell to undergo more invasive sampling techniques, such as 
bronchoscopy, which themselves are not without risks. The inability to make an accurate diagnosis 
of pneumonia and specifically VAP leads to both the under and over prescription of antibiotics both 
of which are associated with an increase in morbidity and mortality. New tests are required to 
improve the diagnosis of pneumonia in critically unwell patients and allow more targeted antibiotic 
therapy. This programme of study was an attempt to assess the potential of various profiling 
techniques applied to serum, urine and exhaled breath condensate to aid in the diagnosis of 
pneumonia in a prospectively recruited group of critically unwell patients. 
Metabonomics, the study of global metabolic changes in the context of disease states, has been 
used in a number of clinical conditions with a range of biofluids, however, little work has been done 
previously focusing on either pneumonia or the critically ill. Application of 1H-NMR spectroscopy to 
the serum of patients with pneumonia allowed them to be successfully distinguished from a similar 
cohort of ventilated patients admitted with brain injuries. The metabolites allowing these patients to 
be identified fell into four main classes: lipids, glycoproteins, amino acids and formate. Amino acid 
changes followed previously described patterns with alanine and glutamine being reduced (145, 148, 
281) in those with infection and phenylalanine being increased (145, 148, 281). Explanations for such 
amino acid changes may be many. They may reflect changes in oxidative metabolism, nutritional 
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state, release from skeletal muscle or direct immune activation. The finding that formate was more 
abundant in those with pneumonia has not previously been described.  
Glycoproteins are a non-specific class of molecule that include members of a range of mediator 
classes from hormones to antibodies and major histocompatibility complex molecules so their 
increase in those with pneumonia may have represented immune activation. However, to 
understand these changes more fully and understand the exact glycoproteins involved in class 
differentiation further targeted analysis would have to be performed.  Lipid changes have been 
previously recognised in both infection (149, 265, 267, 269, 270) and brain injury (274-278) so it was 
unsurprising that there was a change in the balance of these species between the two groups in this 
study. However, NMR is unable to differentiate individual lipid species so further lipid identification 
was not possible. 
In order to explore the role of both immune activation and one class of lipids, experiments were 
conducted to measure fatty acids and their metabolites, the eicosanoids, as well as a panel of 
cytokine and soluble adhesion molecules giving a panel of over fifty inflammatory mediators. Results 
from comparing inflammatory profiles showed that the use of a panel of eicosanoids was able to 
differentiate pneumonia from brain injury with a similar predictive capacity to that using an 
untargeted metabonomic approach. Cytokines alone performed less well but when cytokines and 
eicosanoids were combined predictive capacity was better. The overall pattern of inflammatory 
changes seen showed that the fatty acids and their metabolites were more abundant in those 
patients with brain injuries than pneumonia whereas the converse was true for cytokine species. 
Specifically arachidonic acid, eicosapentanoic acid, 6-keto-PGF1α, 5,6-DHET, docosahexaenoic acid, 
9(S)-HODE, 13(S)-HODE, 10(S),17(S)-DiHDoHE, and 5(S)-HETE were the most important species in 
those with brain injuries and ICAM-1, E-selectin, IP-10, MCP-1, IL-13, TNFα, INFγ and IL-6 in those 
with pneumonia. The greater levels of eicosanoids in those with brain injuries may have arisen as a 
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predisposition to brain injury in these patients (285, 286) or may have been a direct result from the 
injury (290-294) via mechanisms modulating cerebral circulation. It was perhaps not a surprise that 
that cytokines were abundant in those with infection. The most important cytokines were those 
involved in chemoattraction and those recognised to play an active role in inflammation confirming 
the inflammatory nature of this group. 
Unfortunately the application of metabonomic methods to both urine and exhaled breath 
condensate performed less well than serum. Metabolite presence in urine was much more 
heterogeneous from patient to patient than those in serum with a greater degree of peak 
misalignment. This made metabolite identification much more challenging. The patients in intensive 
care were subject to treatment with a large number of therapeutic drugs, with over 200 being 
documented across all recruits, many of which would be excreted either unchanged or as 
metabolites in the urine. This was compounded by the fact that drug metabolism would be altered 
depending patient factors, such as enzyme activity, concomitant use of other drugs that may interact 
or alter metabolisms and potentially different disease states. This made detecting drugs within the 
urine difficult and raised the concern that many of the models that could differentiate clinical groups 
were in fact finding treatment differences and not genuine metabolic differences. 
Exhaled breath condensate was an attractive biofluid to study as it originates directly from the site 
of infection, however, it posed its own challenges with the metabolites it contained being at very 
low concentrations. This meant that NMR had insufficient sensitivity to detect a large enough 
number of metabolites to allow statistical comparison. When a more sensitive MS based 
methodology was applied to these samples it was overly sensitive to both the effects of batch and 
impurities within the solvents used and thus the data required adjustment to attempt to limit these 
effects. Although models could be made that had some ability to differentiate pneumonia from brain 
injury they performed less well than those using metabolic and inflammatory profiling of serum. 
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When only those brain injured patients who did not go on to develop VAP were used as controls it 
became impossible to build a predictive model raising concerns over the validity of the original 
models. In order for EBC to be clinically useful much more work will need to be done, that was 
outside the scope of this project, to establish the best collection and analytical methods for this type 
of sample in this patient group. Technological advances, such as those being used to develop 
intelligent surgical instruments (378) that can analyse vapour in real time, may prove beneficial in 
improving the analysis of EBC. Once these technical issues are resolved this biofluid may still have 
potential to give useful diagnostic information for the critically ill, however, from the data presented 
here its use remains uncertain. 
As clinical tests are rarely used in isolation and are usually combined with clinical data and clinical 
opinion the same multivariate techniques were applied to a large set of clinical data. As may be 
expected, for a diagnosis which is based predominantly on clinical features, the clinical data 
performed well when comparing pneumonia to brain injuries, even when components of the CPIS 
were removed. Many of the discriminating features were expected, including ventilation parameters 
such as PEEP, peak airway pressures and respiratory rate along with general markers of infection, 
such as CRP, and markers of nutritional state including albumin. When clinical data were combined 
with both metabolic and inflammatory data the best model (R2Y 0.70, Q2 0.68, p<0.001) could be 
made by taking the fifteen most important features including minimum and maximum PEEP, 
minimum and maximum CRP, minimum and maximum albumin, glycoproteins, formate, minimum 
and maximum PaO2:FiO2 ratio, maximum Peak airway pressure, maximum respiratory rate and two 
unidentified metabolites. Of note this model only contained clinical and metabolic data, addition of 
inflammasome data were not able to improve classification. 
Across all profiling methodologies prediction of brain injured patients developing VAP from other 
brain injured patients was more difficult than differentiating patients with pneumonia on admission. 
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There were a number of reasons to explain this. Firstly those admitted with pneumonia were likely 
to have been unwell for longer in the community prior to hospital admission having implications for 
their nutritional and inflammatory state. Also the number of patients developing VAP was small 
compared to both those with brain injuries and those admitted with pneumonia, making any 
changes potentially more difficult to detect. Finally it may be expected that the clinical difference 
between a patient with only pneumonia compared to one with only a brain injury may be much 
greater than that between one with both a brain injury and VAP and a brain injury alone and this 
may have been reflected in the limited differences in the inflammatory and metabolic profiles. 
Serum metabolic data had only a week ability to differentiate patients with VAP from those without 
and the metabolites that showed the most discriminant potential were similar to those when a 
primary diagnosis of pneumonia was considered with lipids, glycoproteins and phenylalanine 
showing a small amount of discriminant potential. When the inflammatory data were considered, 
eicosanoids showed no ability to differentiate VAP and cytokines only a weak ability. However, when 
these modalities were combined the predictive capacity improved, although still with a non-
significant p-value, perhaps a reflection on the small number of patients involved. In this comparison 
important inflammatory mediators were again most abundant in the VAP patients, this time being a 
combination of the cytokines and soluble adhesion molecules. The differences between those with 
VAP and brain injuries were more pronounced, although again with a non-significant p-value, when 
samples were compared from similar time points. Most mediators were more abundant in those 
with VAP and included IL-6, MCP-1, IL-12p70, IFNγ,  IL-17A, IFNα, IL-10, ICAM-1, G-CSF, IL-1beta, IP-
10, TNFα, 12-oxo-LTB4 and lipoxin A4 demonstrating the inflammatory nature of pneumonia. 
Clinical variables once again performed well to differentiate those with VAP from those with brain 
injuries, however, in this comparison some unsuspected clinical features including alkaline 
phosphatase, perhaps relating to cholestasis relating to sepsis (367-369), and fibrinogen, acting as an 
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acute phase reactant (360, 361), levels were important in those with VAP. The best models could be 
made to either distinguish VAP from brain injured patients at the start of ventilation (R2Y 0.72, Q2 
0.68, p<0.001) or VAP from brain injured patients who had spent a similar amount of time on 
intensive care (R2Y 0.97, Q2 0.89, p=0.014) by combining clinical, metabolic and inflammatory data 
into a single model and selecting only the most important variables.  
Sequential sampling of all of the enrolled patients allowed some interesting findings regarding the 
metabolic and inflammatory changes over time. Patients with brain injuries were seen to have a 
reduction in glucose and mannitol with an increase in phenylalanine and glycoproteins over the 
course of their ICU stay combined with a shift in the dominance of fatty acids at the first time point 
towards the metabolites of arachidonic acid, in the form of 5,6-DHET, 8,9-DHET and 14,15-DHET and 
16(R)-HETE, 12(R)-HETE, 15(S)-HETE and 11(R)-HETE. Cytokine levels seemed generally to be at 
higher concentrations at the beginning of the ICU stay and fall over time with the exception of IL-13, 
IL-4, IL-1β, TNFα and IP-10 levels which increased.  
This study was limited by the relatively small numbers of patients included, especially when VAP was 
being considered. However, it would have been difficult in the time available to recruit many more 
patients from a single centre. Another limitation was the lack of a gold standard test by which to 
make a diagnosis of pneumonia or VAP. In attempt to address this we used a diagnosis based on CPIS 
scoring to allow a homogenous patient group with a limited amount of diagnostic bias from clinical 
opinion. Unfortunately two features of the CPIS were not routinely measured in our institution 
leading to some scores that were borderline. Patients with such scores were assessed by an 
independent assessor who was blinded to all other analysis and, where possible, these were used as 
a small validation group or to explore disease models in more detail. The use of broncheoalveolar 
lavage as a diagnostic tool was considered for this study, however, the fact that it is invasive, not 
routine practice in the critical care unit where the study was performed and not feasible to repeat 
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on a daily basis made CPIS scoring a more attractive daily screen for infection. The lack of a gold 
standard test meant that some of the patients identified as cases and controls may have been 
misclassified in the original groups prior to sample analysis adding bias to the multivariate models. 
Thus it was possible that the multivariate models could have had a better classification accuracy 
than the data used to define the groups. This study has only been able to separate those with 
pneumonia or VAP from controls with brain injuries, we have not been able to make any attempts to 
differentiate pneumonia from other types of infection or patients with acute lung injury, both 
frequent clinical problems. 
Future work based on this study would involve replicating these findings in a larger cohort of 
patients, including a larger validation set and another patient group with infection of a non-
pulmonary origin to establish if these techniques have the ability to distinguish pneumonia from 
other causes of sepsis. Further analytical work would include more detailed exploration of the serum 
metabolome with the use of MS methods to detect metabolites not seen with NMR and the 
application of lipidomic and proteomic methods to further identify the lipids and acetylated 
glycoproteins that appear important in identifying pneumonia patients. In order for these 
techniques to become useful clinical tests some adaption may need to be made to the modalities 
used for sample processing as, for example, NMR is not routinely available in the clinical setting. 
Once a robust panel of biomarkers is established it may be necessary to find other, more accessible, 
analytical platforms by which to measure them. 
In summary this study has added to the field by demonstrating the potential of serum metabolic and 
inflammatory profiles to aid the diagnosis of pneumonia and VAP in intensive care patients 
especially when combined with clinical data. 
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Appendix II a. Personal Consultee Assent Form 
Mechanisms of Monocyte Priming & Tolerance 
 
Ethics committee: North London REC 3 
 
REC reference: 10/H0709/77 
 
Name of Principal Investigator: Dr Anthony Gordon 
 
ASSENT FORM FOR PERSONAL CONSULTEES 
 
Please initial box 
 
1. I confirm that I have read and understood the Personal Consultee Information Sheet dated August 
2011 version 1.7 for the above study and have had the opportunity to ask questions which have been 
answered fully.            
 
2. I understand that I am giving this assent based on what I believe would be my 
relative/friend/partner’s wishes. In my opinion they would wish to participate.    
 
3. I understand that my relative/friend/partner’s participation is voluntary and I am free to change my 
advice about their wish to participate and to withdraw assent at any time, without giving any reason 
and without their medical care or legal rights being affected.       
 
4. I understand that sections of any of my relative/friend/partner’s medical notes may be looked at by 
responsible individuals from Imperial College/Imperial College Healthcare NHS Trust or from 
regulatory authorities where it is relevant to my taking part in this research. 
 
I assent to these individuals accessing my relative/friend/partner’s records that are relevant to this 
research.            
 
5. I assent to the use of my relative/friend/partner’s samples for future ethically approved research 
projects and for their blood to be used for DNA testing in inflammation research. I understand that this 
information will be kept confidential at all times.                    
6. The compensation arrangements have been discussed with me.      
7. I assent to my relative/friend/partner taking part in the above study.      
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8. I realise that my relative/friend/partner’s consent will override my assent when they are able to give 
informed consent.           
 
9. I assent to data being stored in anonymous form for up to 10 years & used in future, ethically 
approved, projects           
 
 
 
 
________________________  I am the patient’s ________________________________ 
Name of patient    (please write your relationship to the patient e.g. wife / brother etc.) 
 
 
 
_______________________   ________________   ________________ 
Name of personal consultee   Signature    Date 
 
 
 
________________________  ________________  ________________ 
Name of researcher taking assent Signature    Date   
 
 
1 copy for subject; 1 copy for Principal Investigator; 1copy to be kept with hospital notes 
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Appendix II b. Professional Consultee Assent Form 
 
 
 
Mechanisms of Monocyte Priming & Tolerance 
 
 
Name of Principal Investigator:  Dr Anthony Gordon 
 
Ethics committee: North London REC 3 
REC reference: 10/H0709/77 
 
PROFESSIONAL CONSULTEE ASSENT FORM 
 
 
Regarding patient _____________________________________________ 
 
 
This form should be completed by a doctor who is unconnected with the research study only in 
situations where the patient is temporarily unable to provide informed consent for themselves and if 
there is no relative / friend / partner willing and capable to act as the nominated personal consultee. 
The doctor primarily responsible for the medical treatment of the patient, or a person nominated by 
the relevant health care provider, can act as a professional consultee for the patient provided that 
they are not connected with the conduct of this study. 
 
I, Dr / Mr / Ms / Prof______________________________ as the clinician treating this patient 
declare by signing this form that I have read the Professional Consultee Information Sheet version -
___ dated ___________ and have no objection for this patient to be entered into this research 
study. I also understand that should the patient regain consciousness they will be fully informed of 
the decision to enter them into this research study and consent will be sought from them for their 
continued participation. I agree that the patient’s consent will override my assent when the patient is 
able to give consent. 
 
 
 
 
_______________________  ________________  ________________ 
Name of Professional Consultee Signature    Date 
 
 
 
 
 
________________________  ________________  ________________ 
Name of researcher taking assent Signature    Date 
 
 
 
1 copy for ProCon; 1 copy for Principal Investigator; 1copy to be kept with hospital notes 
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Appendix II c. Retrospective Consent Form  
 
Mechanisms of Monocyte Priming & Tolerance 
 
Name of Principal Investigator: Dr Anthony Gordon 
 
Ethics committee: North London REC 3 
REC reference: 10/H0709/77 
 
PATIENT REGAINING CAPACITY CONSENT FORM 
Please initial each box 
 
1. I confirm that I have read and understand the Patient Regaining Capacity Information Sheet 
dated August 2011 version 1.7 for the above study and have had the opportunity to ask questions 
which have been answered fully.       
 
2. I understand that my continued participation is voluntary and I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected.   
 
3. I understand that sections of any of my medical notes may have been looked at by responsible 
individuals from Imperial College London/Imperial College Healthcare NHS Trust or from 
regulatory authorities where it is relevant to my taking part in this research. 
 
I give permission for these individuals to access/continue to access records that are relevant to 
this research.            
 
4. I agree to the use of my samples for future ethically approved research projects and for my 
blood to be used for DNA testing in inflammation research. I understand that this information will 
be kept confidential at all times.         
5. The compensation arrangements have been discussed with me.    
6. I agree to my continued participation in the above study.     

7. I agree that data can be stored in anonymous form for up to 10 years & used in future, ethically 
approved projects.          

____________________ ________________________                 ________________ 
Name of Subject   Signature     Date 
____________________ _________________________  ________________ 
Name of Person  Signature     Date 
taking consent  
1 copy for subject; 1 copy for Principal Investigator; 1copy to be kept with hospital note 
Monocyte Priming & Tolerance     Patient consent v1.7 August 2011 
328 
 
 
 
Appendix III Bedside Clinical Data Collection Sheet 
Date: 
Sample Code: 
Serum 
Taken 
Time on 
Ice 
Time 
off Ice 
Time 
Centrifuge 
Time 
Out 
Time 
Cryotube 
Time 
-80 
RTube 
On 
RTube 
Off 
Time 
Cryotube 
Time 
-80 
           
Urine 
Taken 
Time  
Centrifuge 
Time 
Out 
Time 
Cryotube 
Time 
-80 
 
     
 
  
 Data for 24h prior to 8:00am 
 Before Collection During Collection After Collection Min Max 
Ventilation Mode      
PEEP      
FiO2      
RR set      
RR measured      
Insp TV      
Exp TV      
PS/PC      
Exp MV      
PPeak      
PPlat      
Pmean      
I:E      
HR      
SBP      
MAP      
DBP      
Sats      
GCS - - -   
Temp - - -   
CVP - - -   
U/O      
U/O Total      
Total IV Fluid input      
Total Oral Input      
PaO2      
FiO2      
PaCO2      
pH      
HCO3      
BE      
Lactate      
Glucose      
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Total Secretions:  Secretion Character  Clinical Examination Findings: 
Feed: 
Clinical opinion of VAP: 
Significant Events inc timing: 
Significant Procedures inc Timing: 
Drug Started Dose Frequ Last Dose Stopped 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
Fluid Start Stop Rate Total volume in 
24h 
     
     
     
     
 
Blood Product Start Stop Rate Total Volume in 
24h 
     
     
 
